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Abstract 
Although contemporary treatment cures most children with ALL, with survival rates in 
the region of 90%, treatment outcomes in certain cytogenetic subgroups remain poor. 
Patients with such abnormalities have a greatly increased risk of relapse and re-treatment 
responses are poor. Understanding the mechanisms of resistance in these patients is 
therefore a priority in the search for improvements in chemotherapy.  
The translocation t(17;19)(q22;p13) is a rare cytogenetic abnormality, which occurs in 
less than 1% of childhood ALL and is associated with a very poor prognosis and 
chemotherapy resistance. The translocation results in the fusion of E2A on chromosome 
17 with HLF on chromosome 19. It has been commonly assumed that, following relapse, 
ALL cells will divide more rapidly than at presentation. To test this hypothesis, 
competitive transplantation studies were performed using paired presentation and relapse 
samples from a case of t(17;19)-positive ALL in a NSG xenograft mouse model. 
Surprisingly mice engrafted with the presentation cells survived significantly shorter 
(p<0.05, logrank test) than those with relapse cells, indicating the aggressiveness and 
rapid proliferation of presentation cells, while the survival curves of mice engrafted with 
various proportions of presentation and relapse cells had intermediate levels of survival. 
Administration of dexamethasone prolonged the survival of mice engrafted with the 
presentation cells and those with various proportions of cells, with no effect on survival of 
mice with relapse cells. Flow cytometry analysis showed that a high percentage (70%-
95%) of human leukaemic cells engrafted in bone marrow and spleen across all groups 
tested. RT-PCR amplification identified this t(17;19) case to be a Type 1 E2A/HLF 
fusion.  
In order to determine the genes responsible for chemo-insensitivity, whole genome SNP 
array analysis was performed on the matched presentation and relapse samples which 
demonstrated deletion of glucocorticoid receptor (NR3C1) gene in relapse cells which is 
not seen in presentation cells, confirmed by fluorescence in situ hybridisation. This 
deletion was used to identify the relapse cells (R) in mice engrafted with mixtures of 
presentation and relapse cells. FISH analysis showed the percentages of presentation cells 
(P) were higher than the ratios of the cell initially transplanted. In concordance, real-time 
PCR analysis showed high levels of NR3C1 in all mix cells ratios. These results indicated 
that presentation cells proliferate more rapidly and outgrow relapse cells in competitive 
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clonal repopulation experiments. Dexamethasone treatment reduced the percentages of 
presentation cells in all mix populations with high significance (p<0.01, t-test) in the 
30%-P+70%-R ratio. Levels of NR3C1 in all mix cell populations were significantly 
depleted (p<0.05, t-test) by dexamethasone. 
To be able to physically track the proliferation of leukemic cells populations in vivo and 
to follow progression of the disease, two lentiviruses pSLIEW (expressing firefly 
luciferase and green fluorescent protein) and pSRLICW (expressing Renilla luciferase 
and mCherry fluorescent protein) were generated. pSRLICW was just successfully 
generated but has not yet been tested. Lentivirus pSLIEW functionality was validated by 
transducing various leukaemic cell lines. By assessing the percentage of green 
fluorescence (gfp) cells, transduction efficiencies in SEM and RS4;11 (ALL cell lines) 
were 45% and 5% respectively, whereas transduction efficiencies in Kasumi-1 and 
SKNO-1 (AML cell lines) were 72% and 98% respectively, higher than the ALL cell 
lines. Transduced SEM and Kasumi-1 lines were sorted for higher gfp populations for 
xenograft purposes. Real time bioluminescence imaging on mice xenografted with sorted 
transduced SEM cells showed rapid progression of the disease in the systemic while 
Kasumi-1 cells xenografted in mice produced localised tumours and progressed much 
slower. These lentiviral-transduced cell lines xenografts have proven the in vivo 
monitoring capability by real time luminescence imaging. 
The information gained from this project study provides novel insights into the 
mechanisms of relapse in childhood ALL. The growth characteristics of the leukaemic 
blasts should be considered in assigning patients to different therapeutic options. 
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CHAPTER 1  
INTRODUCTION 
1.1  General Introduction  
Haematopoiesis is a highly orchestrated process producing mature blood cells in the bone 
marrow. It is a route by which blood cells are produced in a hierarchical line from a 
common ancestor, the hematopoietic stem cell (HSC) (Figure 1.1). HSCs have the ability 
to self-renew to maintain the undifferentiated stem cell pool, whilst producing progenitor 
cells – common myeloid progenitor and common lymphoid progenitor. The progenitors 
are cells restricted to differentiate into specific cell types and the subsequent 
differentiated cells show increasing proliferation potential and continuously providing 
blood cells to the cellular component. Disruption of a normal haematopoiesis can lead to 
uncontrolled proliferation and abnormal differentiation of blood cells. As such, mutation 
of cells or stem cells during haematopoiesis gives rise to abnormal regulation of cell 
growth as seen in many haematological disorders. Leukaemias are one of the results of 
such abnormalities. 
1.2  Leukaemia  
Leukaemia is a disease of the blood characterized by an increased proliferation of 
abnormal white blood cells (leukocytes) or their precursors. The disease can arise from 
affected stem cells as well as affected mature cells of lymphoid or myeloid lineages 
(Figure 1.2). As such, leukaemias are classified according to the types of hematological 
cells that form the malignant clone and by the maturity of the affected cells. Malignant 
clones formed from the immature undifferentiated cells are termed acute leukaemia (acute 
lymphoblastic leukaemia, ALL, and acute myeloid leukaemia, AML). Acute leukaemias 
present an excessive abnormal proliferation of immature leukocytes that rapidly 
accumulate in the bone marrow, spilling into the bloodstream leading to rapid onset of 
clinical symptoms and death, if untreated (Cancer Research UK, 2006). Conversely, in 
chronic leukaemia transformation occurs in a more mature cell (chronic lymphocytic 
leukaemia, CLL) or in the whole spectrum of myeloid precursors (chronic myeloid 
leukaemia, CML). Chronic leukaemias generally progress much more slowly with slower 
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accumulation of more mature blood cells over a long period of time, typically taking 
months or years to progress to symptomatic stages. In general, leukaemia can be viewed 
as a new form of an abnormal hematopoietic cell initiated by an aberrant and poor 
regulation process of leukaemic stem cells (LSC) (Passegué, Jamieson et al. 2003).   
 
 
 
 
Figure 1.1  The hematopoietic hierarchy. Simple diagram showing development of a small pool of 
hematopoietic stem cell (HSC) into different mature blood cells of distinct lineages, in a hierarchical 
manner. (source: Stem Cell Network).  
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Figure 1.2  Simplified scheme of the origin of the major types of leukemia. Acute and chronic 
leukaemias arise from affected lymphoid and myeloid stem cells form the acute lymphoid leukaemia 
(ALL), chronic lymphoid leukaemia (CLL), acute myeloid leukaemia (AML) and chronic myeloid 
leukaemia (CML).  (source: Cancer Research UK, 2006).  
 
1.2.1 Leukaemic Stem Cell 
Leukaemia generally can be viewed as a new form of abnormal haematopoietic cell 
initiated by leukaemic stem cells (LSCs) that undergo an aberrant and a poor regulation 
process which is analogous to that of HSCs (Passegué, Jamieson et al. 2003). Like other 
tumours, leukaemia arises from the clonal expansion of a single cell, and is sustained by a 
leukaemic stem cell (Warner, Wang et al. 2004).  
In the concept of cancer, in principle, the notion of cancer biology that is widely 
acceptable is that most tumours arise from transformation of single cells due to genetic 
alteration (Hanahan and Weinberg 2000). Additionally, the relationship between tumour 
cell and stem cells is that cancer cells might contain some cancer stem cells (CSCs), 
which are rare cells with indefinite self-renewal potential that drive the formation and 
growth of the tumours (Bonnet 2005).  
The cancer stem cell is defined as a cell within ‘a tumor that possesses the capacity to 
self-renew and to cause the heterogenous lineages of cancer cells that comprise the 
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tumour’ (Clarke, Dick et al. 2006). In the general cancer stem cell (CSC) concept, CSCs 
are genetically identical to the rest of the malignant clone. However, this subset of CSCs 
or cancer-initiating cells is distinct from the bulk of the tumour and is responsible for 
long-term maintenance of tumour growth (Dick 2008). Due to their distinct property of 
stem cell-like character and functional similarities to that of normal stem cells, these 
definitive biological properties make the CSCs survive standard treatment (Dick 2008), 
show high resistance to chemotherapy (Essers and Trumpp 2010) and identify them as the 
prime candidates for initiation of relapse (Bomken, Fiser et al. 2010).  
This concept of CSCs is supported by syngeneic murine assays for leukaemic stem cells. 
The first evidence proposing leukaemia-initiating cells (LICs) was when transplantation 
of primary AML cells into SCID mice showed that the LICs are rare malignant stem cells 
capable of initiating and sustaining growth of the leukaemic clone in serial 
transplantation, similar to the original disease. This rare malignant stem cell, which has 
the ability to engraft and repopulate in mice owing to the self-renew potential and the 
capacity to differentiate, was only found within the immature CD34+CD38- fraction but 
not the CD34+CD38+ subpopulation (Lapidot, Sirard 1994; Bonnet and Dick 1997). 
Subsequently, these findings show that AML is organized as a hierarchy of distinct, 
functionally heterogeneous classes of cells that is sustained by a small number of LSC 
(Bonnet 2005).  
In childhood pre-B-cell ALL, the nature and frequencies of stem cells and leukaemia-
initiating cells have been controversial and not easy to define. In proposing the LICs in 
ALL, NOD/SCID mice transplanted with B-cell ALL have shown that only primitive 
blasts with a CD34+CD38- immunophenotype were able to initiate overt ALL in mice 
(Cobaleda, Gutierrez-Sianca, et al. 2000). It has also been proposed that candidate 
leukaemic stem cell populations in ALL were represented by CD34+CD38lowCD19+ 
(Cox, Diamanti et al 2009), CD34+CD38+CD19+ and CD34+CD38-CD19+ leukaemic 
blasts (Kong, Yoshida et al. 2008) that were able to reinitiate and sustain leukaemic 
growth in NOD/SCID mice. A limiting dilution study has shown that preB-ALL blasts 
sorted into fractions: CD34+CD19-, CD34+CD19+ and CD34-CD19+, re-established the 
complete immunophenotype of the original leukaemia and were able to self-renew in 
NSG mice, thus showing that all populations contain leukaemic-initiating cells (Le 
Viseur, Hotfilder et al. 2008). Additionally, in lymphoblastic leukaemia, genetic diversity 
occurs in functionally defined leukaemia-initiating cells and many primary diagnostic 
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samples contain multiple genetically distinct leukaemia-initiating subclones (Notta, 
Mullighan et al. 2011). In general, it could be concluded that in ALL, the putative stem 
cells responsible for initiating and maintaining B-cell ALLs are not a fixed cell identity 
but are subject to evolution (Testa 2011). 
Tumour heterogeneity can be shown morphologically as well as functionally, which can 
be explained by two models. The stochastic model proposes that all cells within a 
malignancy have the potential to act as cancer stem cells. Formation of tumours is 
initiated by intrinsic and extrinsic factors. The hierarchy model predicts that analogous to 
the normal tissue hierarchy, a malignancy is organized in a hierarchical manner with 
distinct cancer stem cells, which drive and maintain the malignancy (Dick 2008; Bomken, 
Fiser et al. 2010). Both the stochastic and hierarchy model support the functional LSCs in 
the formation and maintenance of leukaemia. To rule out which of the model fits the 
theory, John Dick proposed a functional LSC assay (perhaps by xenograft model) with 
isolated cell fractions followed by clonal analysis. If it is possible to fraction cells with 
LSCs activity from those that do not, the hierarchy model fits this theory. If the LSCs 
cannot be prospectively isolated in any fraction because all malignant cells have the same 
potential, then this theory fits the stochastic model. Thus, whereas AML fits the hierarchy 
model, ALL fits the stochastic model given credit to the discussion above. 
1.3  Acute Lymphoblastic Leukaemia  
Acute leukaemia is described as a fast progression of malignant disorder of white blood 
cells characterized by the clonal proliferation and successive division of progenitor cells 
with arrested maturation. The acute lymphoblastic leukaemia (ALL) is the main type of 
leukaemia in children which is also the most common childhood cancer overall. The 
majority of ALL cases are of B-cell origin, but it can also arise from T-cell precursors.  
In ALL, abnormal gene expression occurring at an early differentiation stage arrests 
lymphoblast development. This is often a result of chromosomal translocations. The 
leukaemogenic event may occur in committed lymphoid cells of B-cell or T-cell lineages 
or in early lymphoid precursors. Defective lymphoid precursors proliferate and 
accumulate immature blast cells in the bone marrow, interfering with the production of 
normal blood cells. Over expression of the malignant clones in the marrow lead to blasts 
spilling into the peripheral circulation and organ infiltration.  
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1.3.1 Incidence of Childhood ALL  
Acute leukaemia accounts for one third of all childhood cancers with approximately 450 
new cases diagnosed a year in the United Kingdom (Greaves 2002) and about one child in 
2000 develops leukaemia before the age of 15 (Dickinson 2005). ALL represents the 
biggest percentage of leukaemic cases which comprises 85% of childhood acute 
leukaemias in which it affects 59 of every 1 million children under the age of 5. Age-
specific incidence patterns demonstrate a characteristic increase in children aged 2 to 5. 
Although ALL can affect all age groups, the peak incidence at age 4. In the United States 
almost 4000 cases of acute lymphoblastic leukaemia are diagnosed annually. 
Approximately two thirds of the cases are in children and adolescents, making ALL the 
most common cancer in these age groups (Pui and Evans 2006). In childhood ALL, males 
are more often affected than females, and an excess incidence occurs among whites than 
blacks (Greaves 1999; Pui 1999). Bigger babies have slightly increased risk of developing 
leukaemia (Hjalgrim, Rostgaard et al. 2004). 
1.3.2 Aetiology and Epidemiology  
There is no conclusive evidence linking environmental factors with the cause of ALL. 
Like many cancers, we only know potential triggers. It has been suggested that 
epidemiologically, paediatric leukaemia and common ALL in particular is more prevalent 
in more socio-economically advanced societies. Potentially offensive exposures to 
environmental factors such as pesticides, electromagnetic fields, ionizing radiation, 
vitamin K and chemically or genetically modified food may predispose a child to develop 
the disease (Greaves 2002).  
There are several known risk factors of childhood leukaemia such as sex, age, race, 
exposure to ionizing radiation, and certain congenital diseases, such as Down syndrome, 
Li Fanconi’s anemia, ataxia-telangiectasia and neurofibromatosis, which account for only 
10% of the childhood leukaemia cases. Several lines of evidence suggest that childhood 
leukaemia may be more due to environmental rather than genetic factors, although genes 
may play modifying roles. The genetic abnormality is acquired rather than inherited, 
although certain inherited conditions such as Trisomy 21 predispose to ALL. Human and 
animal studies showed that the development of childhood leukaemia is a two-step process 
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that requires prenatal initiating events plus postnatal promoting events (Stiller 2004; 
Chang 2008).  
A series of studies by Greaves and colleagues have demonstrated that some leukaemias 
originated in utero based on Guthrie cards test on children diagnosed with ALL at age 
below 2 (Greaves 1999). It is also suggested that children with identical twins who were 
diagnosed with the illness before age 6, have a 20% to 25% chance of developing ALL, 
whilst siblings or non-identical twins of leukaemic children have a risk of developing this 
illness only two to four times the average (Reynolds 1998; Greaves 1999).  
Greaves also noted that ALL cases are much higher in industrialized countries than in 
developing countries and hypothesized that the chance of developing common ALL 
increases with better hygiene. This could be a pathological response to delayed exposure 
to some common infectious agents (Greaves 1999). Furthermore, pregnant women who 
are infected with any kind of virus could have passed the virus to the foetus and might be 
vulnerable to genetic damage (Smith 1997). Increased exposure to viruses or infectious 
organisms in high population areas also might have triggered the leukaemia particularly 
in genetically susceptible children (McNally and Eden 2004). Additionally, Kinlen found 
an increased incidence in childhood leukaemia in an extreme population mixing with new 
towns, commuter belts, major construction sites, country areas used for wartime 
evacuation or for military camps (Kinlen 2000). 
1.3.3 Prognostic Factors 
Predicting the prognosis of patients presenting with ALL is important for stratification 
into risk groups so that treatment can be tailored accordingly. In this way, patients which 
are likely to respond to standard chemotherapy are spared undue toxicity while a more 
intensified therapy is given to high-risk patients. Various factors have been found to have 
prognostic significance (Table 1.1) (Hoffbrand, Moss et al. 2006), however the most 
commonly used are presenting WBC, age and sex although haemoglobin level also have 
been reported to be important factor as well (Ng, Lin et al. 2000).  
The white blood count (WBC) at presentation is one of the most reliable prognostic 
indicators of patient outcome. Patients with a high white blood cell count (>50 x 10
9
/L) at 
diagnosis have a higher risk of treatment failure than patients with lower counts. Hence, 
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these patients receive a high risk treatment protocol. Another reliable prognostic indicator 
in ALL is the age of patients at presentation. This is partly because certain age groups 
have a high frequency of specific genetic abnormalities in the leukaemic blasts. In infant 
less than 12 months, 70-80% of cases present with rearrangements of the mixed lineage 
leukaemia (MLL) gene. These patients often also have a high WBC count, poor initial 
treatment response and absence of common ALL antigen (CD10) (Hilden, Dinndorf et al. 
2006). Patient aged less than 10 years old with high risk cytogenetic features such as 
hypodiploidy, Philadelphia chromosome positive t(9;22)(q34;q11) or t(4;11)(q21;q23) are 
treated with the most intensive treatment. Patients with slow response to treatment as 
indicated by minimal residual disease (MRD) or assessed by the rate of clearance of 
leukemic cells from bone marrow, are most likely to be at high risk of treatment failure.  
With these prognostic variables taken into account, patients can be identified who require 
more intensive therapy. At the same time the treatment is reduced to lessen the treatment 
toxicity as well as reducing short and long term side effects in patients less likely to 
relapse.  
 
 Good Poor  
WBC Low High (>50x10
9
/ L) 
Sex Girls Boys 
Immunophenotype B-ALL T-ALL (in children) 
Age Child Adult (infant <2 years) 
Cytogenetics Hyperdiploidy (>50 
chromosomes),                     
TEL-AML fusion 
Ph+ t(9;22),  
MLL rearrangement 
Time to clear blast from blood <1 week >1 week 
Time to remission <4 week >4 week 
CNS disease at presentation Absent Present 
Minimal residual disease Negative at 1 – 3 months Still positive at 3 – 6 months 
 
Table 1.1  Prognosis in acute lymphoblastic leukaemia. Ph+, Philadelphia positive; WBC, white blood 
cell count. (Hoffbrand, Moss et al. 2006). 
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1.3.4 Clinical Characteristics 
Children with ALL normally present with various forms of clinical presentations 
depending on the degree of severity of the disease. Many of the signs and symptoms of 
ALL result from the lack of normal and healthy blood cell production because of the 
malignant immature lymphoblast overcrowding the bone marrow cavity. Common signs 
and symptoms of ALL include paleness and lethargy caused by anaemia, pain in the 
bones or joints caused by overproduction of blast cells in the marrow, excessive and 
unexplained bruising, bleeding and/or petechiae due to low platelet levels. Patients may 
also present with painless lymphadenopathy, frequent infections and fevers or night 
sweats. A much more extensive condition due to extramedullary spread of patients with 
leukaemia include abdominal discomfort and swelling caused by splenomegaly or 
hepatomegaly which in turn leads to weight loss and/or loss of appetite due to the feeling 
of abdominal fullness.  
Brain infiltration in acute leukaemia may present with headaches, vomiting, confusion, 
loss of muscle control and seizures. Other parts of the body may also be affected such as 
the digestive tract, kidneys, lungs, heart or testes. 
1.3.5 Laboratory Features 
Patients with leukaemia generally have abnormal leukocytes with a very low absolute 
neutrophil count. More than 50% of patients present with leukocytes count >10x10
9
/L and 
15% of patients come with >50x10
9
/L leucocytes count. An increased WBC is commonly 
associated with anaemia. Almost 90% of patients have a haemoglobin <11x10
9
g/dL with 
half of this group presenting with a haemoglobin <7x10
9
g/dL. In 75% of leukaemia cases, 
blood tests show thrombocytopenia with a platelet count <1x10
5
/mm
3
. 
1.3.6 Cell Identification 
There are various subtypes of diseases in ALL which can be differentiated according to 
cell morphology, immunophenotype and genotyping analysis. Since the French American 
British (FAB) classification of ALL only describes the morphological aspects of the ALL 
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subtypes, to improve classification of biologically relevant ALL subsets and its 
prognostic value, other methods are applied.  
In general, to achieve the treatment goal of eradicating leukaemia, immunophenotyping of 
leukaemic lymphoblasts is essential to establish the correct diagnosis and define cell 
lineage. Genotyping the leukaemic lymphoblasts with highly specific and sensitive 
techniques such as RT-PCR, fluorescence in-situ hybridization, cytogenetics and single 
nucleotide polymorphism array analysis are used to detect specific fusion transcript, gain 
or loss of cellular DNA content, or specific chromosomes with prognostic or therapeutic 
relevance (Pui, Robinson et al. 2008).  
1.3.6.1 Cell Morphology 
In 1976, a French, American and British (FAB) cooperative group proposed a 
morphological classification of acute leukaemia guidelines. This system is used to 
classify leukemic cells into three categories, L1, L2, and L3, based on the predominant 
morphology of leukaemic lymphoblasts and cytological features of the cells. The 
classification and details of the morphology for each type of leukaemic lymphoblast is 
summarized in Table 1.2 (Bain 1999). In general, type L1 is more frequent in childhood 
ALL whereas L2 is more frequent in adults. L3, however, is considered as a leukaemic 
form of Burkitt’s lymphoma (Munker, Hiller et al. 2000; Szczepanski, van der Velden et 
al. 2003). 
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Cytological Features L1 L2 L3 
Cell size Small cells predominate Large, heterogeneous  Large, homogenous 
Nuclear chromatin Homogenous in any one 
case, maybe condensed in 
some cells 
Variable, heterogenous in 
any one case 
Finely stippled, 
homogenous 
Nuclear shape Mainly regular Irregular; clefting and 
indentation common 
Regular; oval or round 
Nucleolus Not visible or small and 
inconspicuous 
Usually visible, often large Usually prominent 
Amount of cytoplasm Scanty Variable, often abundant Moderately abundant 
Cytoplasmic 
basophilia 
Slight to moderate Variable Very strong 
Cytoplasmic 
vacuolation 
Variable Variable Often prominent 
  
Table 1.2  Morphological features of ALL subtype. (adapted from Bain, 1999). 
1.3.6.2 Immunophenotype 
Leukaemic cells display characteristic patterns of surface antigen expression (CD 
antigens), which facilitate their identification and accurate classification. These markers 
play an important role in instituting appropriate treatment plans. During lymphocyte 
development, different antigens are expressed according to the stage of differentiation as 
well as cell type. Expression of specific antigens on leukaemic cell reflects the stage of 
differentiation at which the cell became malignant. Therefore, different subtypes of 
leukaemic cells can be identified based on these antigens.  
Leukaemias of B-cell origin can be classified into four subtypes based on their surface 
marker. These are early pre-B cell, pre-B cell, transitional pre-B cell and mature B cell 
leukaemias. However, there has been a new proposed system for classifying B-cell ALL 
as described in Table 1.3 below (Szczepanski, van der Velden et al. 2003). Early 
precursor B-ALL is the most common subtype of which the phenotypes of the 
lymphoblast correspond to those of B-cell progenitors. Almost 70% of children with ALL 
are diagnosed with early pre-B cell ALL (EGIL B-I). Of these, only 20% of the patients 
have a better prognosis than those with pre-B cell ALL (EGIL B-III). Mature B-cell 
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leukaemia is treated differently to leukaemias arising from early progenitor blast cells. 
Patients with this subtype only receive short-term intensive chemotherapy. 
 
Markers  
Early Pre-B-ALL 
(EGIL B-I)  
 Common ALL 
(EGIL B-II) 
Pre-B-ALL 
(EGIL B-III) 
Transitional-pre-
B-ALL 
(no EGIL code) 
TdT ++ ++ ++ ++ 
CD10 - ++ ++ ++ 
CD19 ++ ++ ++ ++ 
CD20 - + + + 
CD22 ++ ++ ++ ++ 
CyCD79 ++ ++ ++ ++ 
CyIgµ - - ++ ++ 
SmVpre-B/λ5 - - - ++ 
SmIg-CD79 - - - + 
CD34 + + + + 
HLA-DR ++ ++ ++ ++ 
 
Table 1.3 Immunological classification of childhood ALL. EGIL, European Group for the 
Immunological Characterization of Leukaemias. (adapted from Szczepanski, van der Velden et al. 2003). 
1.3.6.3 Cytogenetics 
ALL can be classified according to cytogenetics or chromosomal abnormalities within the 
leukaemic blasts. The abnormalities can be in form of chromosomal copy number (ploidy 
and aneuploidy) or chromosomal structure as in translocations. Cytogenetic abnormalities 
are now known to be important prognostic indicators of treatment outcome.  
High hyperdiploidy (>50 chromosomes) is present in 30% cases of children with B-
precursor ALL. This abnormality is associated with a favourable prognosis (Harrison and 
Foroni 2002) which is often coupled with a number of other positive prognostic factors 
such as low WBC at diagnosis and a favourable age (1-9 years). In contrast, hypodiploidy 
(<45 chromosomes) is associated with a high risk of treatment failure (Heerema, 
Nachman et al. 1999).   
14 
 
Abnormalities in the chromosome structure, commonly translocation, have an impact on 
the prognosis as well as ploidy. Translocation with poor prognosis such as t(9;22) 
(q34;q11), t(4;11)(q21;q23) and t(17;19)(q22;p13) (are discussed in more detail in section 
3.1.1) are associated with high WBC at diagnosis and of age >10 and <1 years. In contrast 
t(12;21)(p13;q22) is associated with an excellent prognosis, independent of other 
prognostic factors. This translocation has a five-year event-free survival rate approaching 
90% (Armstrong and Look 2005). Numerous other translocation have been identified, 
however the cases are not as significant as these four types.     
1.3.7 Treatment 
Leukaemias have traditionally been classified and treated on the basis of phenotypic 
characteristics such as morphology and cell surface markers and more recently, 
cytogenetic aberrations (Ravandi and Estrov 2006). Most leukaemias arise from acquired 
aberrations (changes) in the genes of growing blood cells. Because these errors occur 
randomly and unpredictably, there is currently no effective way to prevent most types of 
leukaemia. Nevertheless, treatment of acute leukaemias has progressed from earlier 
uniform strategies devised for large groups of patients to more refined protocols tailored 
for discrete subgroups with the risk of relapse (Look 1997). With current treatment 
regimens of combination chemotherapy used in ALL cases, the overall response has 
achieved an approximately 80% long-term event-free survival rate (Pui, Robinson et al. 
2008), although this figure disguises success rates that vary from 10% to 90% with the 
different biological subtypes of the disease (Greaves 2002). Nonetheless, this success is 
led by careful stratification of patients at diagnosis in order to optimize risk-directed 
therapy with multi-agent chemotherapeutic drug regimens (Stankovic and Marston 2008). 
It has also been suggested that the success of treatment of childhood ALL is linked to the 
transformation of a B-cell progenitor prone to undergoing apoptosis (Greaves 1993) and 
B-cell precursor ALL (BCP-ALL) is commonly sensitive to chemotherapy (Pui, Robinson 
et al. 2008). 
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1.3.7.1 Treatment of Childhood ALL  
The treatment used for patients diagnosed with ALL is administered in several phases 
with combinations of drugs. The treatment protocol is divided into chemotherapeutic 
blocks which include a first phase of remission induction therapy, followed by a second 
phase of consolidation therapy and the last phase is continuation/maintenance therapy. 
Outline of the principle of therapy in managing children with leukaemia is as shown in 
Figure 1.3 (Hoffbrand, Moss et al. 2006). 
 
 
 
Figure 1.3  Principle of therapy in acute leukaemia. SCT – stem cell transplant; chemo±TBI – 
chemotherapy + total-body irradiation. (Hoffbrand, Moss et al. 2006). 
 
The initial aim of remission/induction therapy in children with ALL is to induce 
remission with elimination of 99% leukaemic cells and restoration of normal 
haematopoiesis. The standard induction protocol involves a combination of vincristine, 
glucocorticoid (prednisolone or dexamethasone) and asparaginase which results in 
complete remission in over 95% of low risk cases (Eden, Harrison et al. 2000). On 
completion of induction chemotherapy there is usually no evidence of leukaemia found 
on physical examination or examination of the bone marrow or peripheral blood.  
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Intensive chemotherapy given during the consolidation period of therapy shortly after 
induction of remission improves the outcome of patients with an otherwise poor 
prognosis. Drugs used in this phase include etoposide, cytarabine, cyclophosphamide and 
anthracyclines and treatment lasts for several months.  
Maintenance therapy follows intensified therapy to effectively prevent relapse from 
development of resistant clones. The protocol used includes a combination of 
mercaptopurine and methotrexate. Standard CNS prophylaxis by craniospinal irradiation 
is usually given to patients over the course of maintenance therapy to prevent relapse, 
particularly patients with CNS disease at diagnosis. 
The Medical Research Council (MRC) UK has carried out trials on children with ALL 
since 1980 to improve treatment for the disease (Table 1.4). Series of clinical trials aimed 
at finding the best therapy had tested drugs that not only treat the cancer but also treat the 
symptoms and side-effects. Progress has been made as a result of many gradual 
improvements in treatment achieved through these trials. This success has led to 
improvement in survival of children with ALL that four in five children with ALL now 
recover from the disease compared to three decades ago. For certain subgroup of patients, 
more intensive studies and trials are required to improve treatment plan for the survival of 
these children. 
 
  
  
Trial  Induction  Intensification  CNS Therapy Continuing Randomisation 
 
VIII 
(1980-1984) 
Vincristine 
Prednisolone 
Asparaginase 
+/- Daunorubicin 
 
None Intrathecal MTX 
Cranial irradiation 
 
6-MP 
Oral MTX 
Vincristine 
Prednisolone  
A: ± Daunorubicin during 
induction 
B: 2 or 3 years continuing 
therapy 
 
X 
(1985-1990) 
Vincristine 
Prednisolone 
Asparaginase 
Daunorubicin 
Daunorubicin 
Cytocine arabinoside 
Etoposide 
Vincristine 
Prednisolone 
6-TG 
 
Intrathecal MTX 
Cranial irradiation 
 
6-MP 
Oral MTX 
Vincristine 
Prednisolone 
A: no intensification 
B: week 5 intensification 
C: week 20 intensification 
D: both intensifications 
 
XI 
(1990-1992) 
Vincristine 
Prednisolone 
Asparaginase 
Daunorubicin 
Daunorubicin 
Cytocine arabinoside 
Etoposide 
Vincristine 
Prednisolone 
6-TG 
WBC <50 x 10
9
/L : 
Intrathecal MTX ± high 
dose MTX 
WBC >50 x 10
9
/L : 
High dose MTX or 
Cranial irradiation 
6-MP 
Oral MTX 
Vincristine 
Prednisolone 
A: week 20 intensification 
B: intrathecal MTX, high 
dose MTX or cranial 
irradiation  
 
XI (92) 
(1992-1997) 
Vincristine 
Prednisolone 
Asparaginase 
 
Daunorubicin 
Cytocine arabinoside 
Etoposide 
Vincristine 
Prednisolone 
6-TG 
WBC <50 x 10
9
/L : 
Intrathecal MTX ± high 
dose MTX 
WBC >50 x 10
9
/L : 
High dose MTX or 
Cranial irradiation 
6-MP 
Oral MTX 
Vincristine 
Prednisolone 
A: intrathecal MTX, high 
dose MTX or cranial 
irradiation 
B: ± week 35 intensification 
 
97 
(1997-2003) 
Vincristine 
Prednisolone or 
Dexamethasone 
Asparaginase 
Methotrexate 
Daunorubicin 
Cytocine arabinoside 
Etoposide 
Vincristine 
Prednisolone 
6-TG 
WBC <50 x 10
9
/L : 
Intrathecal MTX ± high 
dose MTX 
WBC >50 x 10
9
/L : 
High dose MTX or 
Cranial irradiation 
6-MP or 6-TG 
Oral MTX 
Vincristine 
Prednisolone 
A: Prednisolone or 
Dexamethasone 
B: 6-MP or 6-TG 
C: ± week 35 intensification 
 
            Table 1.4  The MRC childhood ALL trials carried out since 1980. MTX = Methotrexate, 6-MP = 6-Mercaptopurine, 6-TG = 6-Thioguanine.  
1
7
 
  
1.3.7.2 Treatment of Relapse 
Treatment resistance and relapse in ALL remains a significant clinical problem despite 
the high cure rate percentage. Complete remission is defined by less than 5% lymphoblast 
cells in the marrow, the absence of leukaemic blast cells in the blood and cerebrospinal 
fluid (CSF), normal peripheral blood count and the absence of localized disease. Relapse 
is defined as the recurrence of more than 25% blast cells in the marrow or presence of 
localized leukaemic infiltrates at any site after completion of induction therapy (reviewed 
in Ng, Lin et al. 2000).  
The vast majority of relapses occur due to the failure of therapeutic drugs to completely 
eradicate the original leukaemic clone and its subsequent re-expansion. It has been 
reported that over 70% of relapses happen within 3 years of initial diagnosis (Chessells, 
Veys et al. 2003). Intensive exposure to antileukaemic drugs is thought to be the most 
likely cause for a patient to subsequently develop chemoresistance (Klumper, Pieters et 
al. 1995) or alternatively, chemoresistance may be caused by treatment-related selection 
of primary drug-resistant subclones originally present at initial diagnosis (Stankovic and 
Marston 2008).  
The leukaemic stem cell (LSC) is likely to be the most crucial target in the treatment of 
leukaemias. However, like normal HSC, LSCs are quiescent cells and this resting status 
protects them from the commonly used cell cycle-specific chemotherapeutic agents used 
in leukaemia treatment (Essers and Trumpp 2010). This characteristic contributes to 
treatment failure. Furthermore, these cells may undergo mutation and epigenetic changes 
which leads to drug resistance and relapse (Ravandi and Estrov 2006).  
Options for the treatment of relapse patients include repeated course of systemic and 
intrathecal chemotherapy with or without radiation therapy. Bone marrow or stem cell 
transplantation is considered another option if relapse treatment is still a failure. Clinical 
trials of new drugs or combination chemotherapy regimens are significantly important for 
improving the therapy management of children with relapse in ALL. 
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1.3.7.3 Chemotherapeutic Agents  
Chemotherapeutic agents are chemical agents with cytotoxic or cytostatic effects used for 
treating cancerous cells, generally by directly killing or arresting cells with high 
proliferation rate. In haematological malignancies, specific therapy is aimed at reducing 
the malignant cell burden by the use of drugs or radiotherapy. A wide variety of 
therapeutic drugs are used in the management of children with ALL. Several drugs are 
often combined together in regimens that minimize the potential for resistance to occur 
against a single agent. The common multiagent chemotherapeutic regimens used include 
DNA damaging agents, alkylating agents, mitotic inhibitors, antimetabolites, 
corticosteroids and also cytotoxic antibiotic drugs. Although combinations of 
chemotherapeutic drugs are very effective in eradicating leukaemic cells in ALL, they are 
associated with significant side effects. Common side effects of chemotherapy are nausea 
and emesis (acute), and hair loss (chronic) (JLS Foundation Children with Leukemia; 
Cancer Health Center WebMD 2010). The mechanism of action and adverse effects of 
some of the commonly used therapeutic agents in ALL are detailed below. Chemical 
structures of the drugs used are as shown in Figures 1.4 and 1.5. 
 
Cytarabine (Ara C) is a pyrimidine analogue which acts as a cytotoxic antimetabolite. The 
drug incorporates into DNA where it inhibits DNA polymerase and subsequently blocks 
replication in the S phase, arresting cells from mitotic stage (Ogbomo, Michaelis et al. 
2008). Long term effects of cytarabine treatment include secondary malignancies and 
infertility.  
6-Thioguanine (6-TG) is an antimetabolite drug that exerts its cytotoxic effect by 
incorporation into RNA and DNA and triggers cell cycle arrest. It interferes with the 
purine and pyrimidine synthesis and epigenetic gene regulation by perturbing cytosine 
methylation. Serious but uncommon side effects include veno-occlusive liver disease and 
secondary malignancies (King and Perry 2001; Lancaster, Patel et al. 2001).     
6-Mercaptopurine (6-MP) is an efficient cytostatic anti-metabolite drug that interrupts the 
DNA synthesis phase of cell cycle, stopping development and division of cancer cells. It 
inhibits purine nucleotide synthesis and metabolism by interfering with nucleotide 
interconversion and glycoprotein synthesis. Possible side effects of 6-MP are diseases 
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such as acute non-lymphocytic leukaemias and lymphomas (Maekawa, Nagaoka et al. 
1990; King and Perry 2001; Lancaster, Patel et al. 2001). 
Cyclophosphamide, an alkylating agent from the nitrogen mustards group, alkylates DNA 
at N-7 on the guanine base. This purines affinity drug initially impairs fundamental 
metabolic processes such as replication and transcription, resulting in a block at G2 and 
death of the cell by apoptosis particularly in rapid-dividing cancer cells (Hoffbrand, Moss 
et al. 2006).  Cyclophosphamide can affect frequently dividing cells such as those in the 
testes and ovaries leading to infertility. Since an alkylating antineoplastic agent is also 
carcinogenic, long term side effects of cyclophosphamide treatment include a risk of 
treatment induced cancer.  
Vincristine is one of the earliest antineoplastic drugs used as treatment in patients with 
leukaemia. A vinca alkaloid from Catharanthus roseus plant (Johnson, Armstrong et al. 
1963), vincristine binds to specific site on tubulin inhibiting assembly into microtubules, 
hence arresting mitotic process in cell division. It is administered intravenously, often in 
combination with other antineoplastic drugs (Qweider, Gilsbach et al. 2007). Long term 
side effects of vincristine treatment include peripheral neuropathy, hyponatremia, and hair 
loss.  
Daunorubicin is a cytotoxic antibiotic drug that intercalates into DNA and binds strongly 
to topoisomerase, impairing DNA helical shape and DNA replication of cancer cells. Side 
effect includes tissue necrosis to the extent of damage to the nervous system.  
Methotrexate is in a class of antimetabolites that inhibit metabolism of folic acid and 
slowing the growth of cancer cells. Side effects of the drugs are hepatotoxicity and 
cytopenia.  
Etoposide inhibits topoisomerase II from re-ligating unwound DNA strands following 
replication. Long term use of etoposide induces secondary AML. 
Prednisolone, a synthetic glucocorticoid, is an anti-inflammatory and immunosuppressive 
drug that binds irreversibly with cytosolic glucocorticoid receptors found in almost all 
cells. The drug/receptor complex induced apoptosis in neoplastic lymphoid cells (Rang, 
Dale et al. 2010). Long term side effects of prednisolone treatment include cataract, 
osteoporosis, Cushing’s syndrome, diabetes mellitus, and insomnia. 
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Dexamethasone is a glucocorticoid drug that has a potent lymphocytotoxic activity. The 
drug provides better penetration into the CNS but has a higher incidence of side effects 
including psychological disturbance and avascular necrosis.     
Asparaginase is an important drug in the treatment of childhood ALL. Leukaemic cells 
require a high amount of asparagine but lack the ability to synthesize the amino acid, thus 
the malignant cells depend on circulating asparagine. Asparaginase however, catalyses 
the conversion of L-asparagine into aspartic acid and ammonia, thus depriving the 
leukaemic cells of the substance and subsequently killing the cells. Common side effects 
of asparaginase include anaphylaxis, pancreatitis and coagulopathy (Appel, van Kessel-
Bakvis et al. 2007).    
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Figure 1.4  Chemical structures of chemotherapeutic agents used in treatment of acute leukaemia. 
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1.4  Glucocorticoids  
Steroid hormones are divided into five groups by the receptor to which they bind: 
glucocorticoids, mineralocorticoids, androgens, estrogens and progestins. In general, they 
are pregnenolone derivates which is basically synthesized from cholesterol molecule. The 
endogenous glucocorticoid is cortisol, a biocompound produced in the adrenal gland. Its 
main function is to maintain normal homeostasis. Secretion of cortisol is regulated by the 
hypothalamus-pituitary-adrenal (HPA) axis. In response to stress and low level of 
circulating glucocorticoid, hypothalamus releases corticotrophin-releasing hormone 
(CRH) which triggers adrenocorticotropic hormone (ACTH) secretion by pituitary and in 
turn stimulates adrenal to produce glucocorticoids (Vegiopoulos and Herzig 2007). 
Cortisol has biologically pleiotropic role including regulation of fat, protein and 
carbohydrate metabolism, and activates anti-stress and anti-inflammatory pathways. 
Abnormality in the regulation of HPA axis leads to irregular patterns of cortisol levels as 
observed in Cushing’s syndrome, Addison’s disease, clinical depression and 
psychological stress.   
Synthetic analogues of cortisol which are widely used in therapy of haematological 
malignancies are the prednisolone and dexamethasone (Figure1.5).  
1.4.1 Glucocorticoid Receptors 
Steroid receptors are located in the cytosol and the nucleus of the target cells. The 
receptors located in the cytosol are activated and moved to the cell nucleus upon binding 
of intracellular hormone or synthetic steroids entering the target cells. Steroids may also 
directly enter the nucleus and activate the steroid receptors in the nucleus by binding to 
them. The most studied steroid receptors are members of the nuclear receptor subfamily 3 
(NR3). There are three groups of NR3: group A and B are mainly subdivided into the 
estrogen and estrogen-related receptors whereas group C are 3-ketosteroid receptor. 
Group C of the NR3 consists of four members which are: (1) glucocorticoid receptor 
(GR; NR3C1), (2) mineralocorticoid receptor (MR; NR3C2), (3) progesterone receptor 
(PR; NR3C3), and (4) androgen receptor (AR; NR3C4).       
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Figure 1.5  Chemical structure of the endogenous glucocorticoid, cortisol, and synthetic glucocorticoids, 
dexamethasone and prednisolone. 
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Glucocorticoids (GCs) generally are a class of steroid hormones (endogenous or synthetic 
derivatives) that bind to the glucocorticoid receptor (GR; NR3C1). GCs enter the cell 
passively and form a dimerization of GC/GR complexes, which subsequently translocate 
to the nucleus (Lambrou, Vlahopoulos et al. 2009) and activate or repress specific genes. 
It is known that GR is expressed in virtually all cell types, but both GR mRNA and 
protein levels vary considerably between tissues (Turner, Schote et al. 2007).  
1.4.2 Structure  
GC induces apoptosis in lymphoid malignancies and this action is mediated by GR 
protein, a ligand-induced transcription factor of the nuclear receptor family of 
transcription factors. GC-bound GR dimerizes, translocates to the nucleus and functions 
as transcription factor by binding to glucocorticoid response element (GRE) sequences 
(Geng, Pedersen et al. 2005). 
The human GR gene encodes a protein with a molecular weight of 85 – 97 kDa and 
covers a region of more than 80 kb within chromosome 5, specifically located at 5q31. 
The GR gene contains eight coding regions (exons 2 – 9) and heterogenous non-coding 
first exon (Turner and Muller 2005) consist solely of 5’-untranslated sequence (Encio and 
Detera-Wadleigh 1991). Additionally, the 3’untranslated region of exon 9 is also a non-
coding sequence (Charmandari, Kino et al. 2004). The GR gene in the eight coding region 
consists of three functional domains (Tissing, Meijerink et al. 2003) (Figure 1.4): (1) an 
N-terminal modulatory domain, (2) DNA-binding domain, and (3) a C-terminal ligand-
binding domain. Within these domains are shorter structural motifs involved in nuclear 
localization, receptor dimerization and protein-protein interaction (Giguere, Hollenberg et 
al. 1986). 
The N-terminal domain is encoded by exon 2 and contains a transactivation domain, AF1. 
This segment is required for the transcriptional activation of GR target genes (Hollenberg 
and Evans 1988) and involved in protein-protein interaction with various cofactors (Yudt 
and Cidlowski 2001; Geng, Pedersen et al. 2005). The N-terminal domain covers half the 
total length of the GR. 
The internal DNA-binding domain (DBD) is a highly conserved 66 amino acid core 
consisting of two putative zinc fingers motifs separately encoded by exons 3 and 4 (Encio 
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and Detera-Wadleigh 1991). The first zinc finger encodes domains essential for the 
binding of the transcription factors, NFB and AF-1, through which GR exerts its 
transrepression function. The DBD is essential for DNA binding to the GRE sequence 
located within the promoter regions of target genes (Yudt and Cidlowski 2001). Receptor 
dimerization and GRE-mediated transactivation functions through the encoded second 
zinc finger domain. DBD also contains the first nuclear localization signal (NLS1). 
The ligand-binding domain (LBD) located in the carboxyl terminus of the receptor 
specifically binds glucocorticoids and contains a second activation function (AF-2) and 
nuclear localization signal (NLS2). This domain also contains sequences important for 
interaction with heat shock proteins (hsps) and nuclear transcription factors, nuclear 
translocation and receptor dimerization (Charmandari, Kino et al. 2004). A total of five 
exons combined to form the LBD.   
Two native human GR protein have been described, a 777 amino acids hGRα and a 746 
amino acid hGRβ (Wright, Zilliacus et al. 1993). Each hGR is encoded by nine exons 
with the first 727 amino acid in eight exons aligned identically, whereas the ninth exons 
are heterologous and the sequence diverge beyond this position (Encio and Detera-
Wadleigh 1991).   In contradistinction to hGRα, hGRβ resides primarily in the nucleus of 
cells, and due to its defective LBD, does not bind glucocorticoids (Charmandari, Kino et 
al. 2004). hGRβ has an intact DBD identical to hGRα, and competes with hGRα in 
binding to GREs (Geng, Pedersen et al 2005).  
   
 
  
 
 
 
 
Figure 1.6  Schematic overview of the glucocorticoid receptor (GR) gene. The GR gene localized on chromosome 5 consists of 9 exons which can be divided into 3 
functional domains, N terminal domain, DNA-binding domain and Ligand-binding domain. (Tissing, Meijerink et al. 2003). 
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1.4.3 Mechanism of Glucocorticoid Action 
In the absence of ligand, the intracellular GR resides mostly in the cytoplasm as part of a 
large multiprotein complex which consists of the receptor polypeptide, two molecules of 
hsp90, hsp70, immunophilins and other proteins (Cheung and Smith 2000). GCs enter the 
cell through passive diffusion facilitated by their small size and lipophilic nature. Upon 
binding to the GR, the receptor undergoes an allosteric change which results in 
dissociation from hsp90 and other protein, unmasking/activation of the NLSs and 
phosphorylation at five serine sites (Charmandari, Kino et al. 2004). Additionally, the 
conformational change reveals domains which are necessary for nuclear translocation, 
dimerization, DNA binding and transactivation. The phosphorylated ligand-bound GC 
translocates into the nucleus and binds as homodimer to GREs in the promoter region of 
target genes. The bound GC interaction with basal machinery induces or represses the 
expression of target genes (Bamberger, Schulte et al. 1996). By physically interacting 
with other transcription factors such as activator protein AP1 and nuclear factor (NK) κB, 
the receptor can independently modulate gene expression of GREs (Jonat, Rahmsdorf et 
al. 1990; Scheinman, Gualberto et al. 1995). Additionally, through the AF1 and AF2 of 
the receptor in combination with coactivators which recruit the basal transcription 
machinery, regulates the GR transcriptional activity. The coactivators include p160 such 
as the steroid receptor coactivator 1 (SRC1) and the glucocorticoid receptor-interacting 
protein 1 (GRIP1), the p300/CREB binding protein cointegrators, and the vitamin D 
receptor-interacting protein/thyroid hormone-associated protein complex (Hittleman, 
Burakov et al. 1999; Auboeuf, Honig et al. 2002).    
Endogenous steroid hormones that act with the GR are progesterone and DHEA which 
have antagonist effects on the GR. Some examples of synthetic steroids are 
Dexamethasone, as an agonist of the receptor whereas Mifepristone (RU486) and 
Cyproterone, act as antagonists, of the receptor.  
1.4.4 Glucocorticoids in Therapy of ALL 
Glucocorticoids were the first drugs to be used successfully in the treatment of ALL. The 
synthetic analogues of cortisol, prednisolone and dexamethasone (Figure 1.4), are used 
extensively as routine chemotherapeutic agents in various hematologic malignancies 
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including multiple myeloma, non-Hodgkin’s lymphoma, chronic lymphoblastic 
leukaemia and ALL. This is due to their cytolytic actions in lymphoid and leukaemic 
cells, especially in childhood ALL (Galili 1983; Distelhorst 2002). GC drugs induce 
apoptosis and lysis of lymphoblast cells in those cases, however, the mechanisms are still 
poorly understood (Greenstein, Ghias et al. 2002). Since the late 1940s, prednisolone and 
dexamethasone have formed an integral part of treatment of childhood ALL. Although 
prednisolone has been the most commonly used glucocorticoid in treatment protocol, 
conventional glucocorticoid activity measurement showed dexamethasone is 6.5 times 
superior to prednisolone. In vitro experiment on defining sensitivity of patient blasts to 
glucocorticoid suggested that dexamethasone are 16-fold more potent than prednisolone 
(Kasper, Veerman et al. 1996). Dexamethasone also has a better penetration to the central 
nervous system (CNS) and more enhanced lymphoblastic cytotoxicity which results in 
lower bone marrow relapse rate, lower CNS relapse rate and the advantage in event-free 
survival recorded in children receiving the drug as in Figure 1.4 (Gaynon and Carrel 
1999; Bostrom, Sensel et al. 2003). Recent MRC trial protocol ALL97 has reported that 
the use of dexamethasone significantly improved event-free survival and decreased the 
risk of relapse in all risk groups and is now standard therapy for childhood ALL.       
       
 
Figure 1.7  Isolated central nervous system (CNS) relapse patients randomised for steroid treatment. 
The 6-year risk of isolated CNS relapse in patients randomized to receive dexamethasone and prednisolone 
(Bostrom, Sensel et al. 2003). 
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1.5  E2A/HLF t(17;19)(q22;p13) 
Of the known genetic events leading to leukaemia, translocations involving the fusion of 
transcription factors or activated signalling kinases are among the most common causes in 
childhood leukaemia (Wiemels 2008). In approximately one-half of cases of childhood 
ALL, chromosomal translocations are detected cytogenetically.  
The t(17;19)(q22;p13) chromosomal translocation in early B-lineage ALL results in  
creation of E2A-HLF fusion gene that links the paired transactivation domains of E2A 
(E12/E47) to the basic region/leucine zipper DNA-binding and dimerization domain of 
hepatic leukaemic factor (HLF). The fusion produces an oncogenic fusion protein with 
structural and functional properties of a chimeric transcription factor (Inaba, Roberts et al. 
1992; Hunger, Devaraj et al. 1994). The transforming activity of E2A-HLF requires at 
least one of the two transactivation domains of E2A, together with DNA-binding region 
and the leucine zipper dimerization domain of the HLF (Yoshihara, Inaba et al. 1995; 
Inukai, Inaba et al. 1998).  
A more detailed explanation of the disease is given in Chapter 3 section 3.2.  
1.6  Mouse Models for Leukaemia 
The use of immunodeficient mice in studying the in vivo repopulation of normal 
hematopoietic cells as well as cells from patients with leukaemia has been reported for 
four decades.  In the first attempts to establish mouse models for leukaemia, it was 
reported that nude mice injected subcutaneously with myeloid or lymphoid cell lines or 
primary cells developed myelosarcomas and solid vascularised tumours instead of 
leukaemias, although cells in the tumour were similar to those seen in the patients in long-
term culture (Lozzio, Machado et al. 1976). 
In 1983, severe combined immunodeficient (SCID) mice were described (Bosma, Custer 
et al. 1983). Homozygous SCID mice have few, if any, lymphocytes; therefore they are 
hypogammaglobulinaemic (Malynn, Blackwell et al. 1988) and deficient for functional B 
and T lymphocytes (Bosma and Carroll 1991). In addition these mice also have defects in 
activating components of the complement system, making them suitable recipients for in 
vivo experimental study since they cannot reject tumours and transplants.  
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The first successful engraftment of human stem cells in SCID mice was published in 1988 
(McCune, Namikawa et al. 1988). Normal human hematopoietic cells and human tumours 
can be engrafted into SCID mice and these mice are better recipients than nude mice for 
the transplantation of human leukaemic cells (Kamel-Reid and Dick 1988). It was shown 
that human ALL cell line transplanted into SCID mice proliferated in the hematopoietic 
tissues and that the distribution and invasion of the organs followed a similar pattern to 
the disease in children (Kamel-Reid, Letarte et al. 1989).  
Further experiments had treated SCID mice transplanted intravenously with human 
leukaemic cells with cytokine and growth factors to improve engraftment. These cells 
homed and proliferate extensively in the bone marrow, disseminate with a pattern similar 
to that seen in original patients and presenting cells morphologically identical to the 
patients leukaemic cells (Dick, Lapidot et al. 1991; Lapidot, Sirard et al. 1994). It has 
been shown that the prognosis of patients can be correlated with the growth rate of 
engrafted cells in these mice (Kamel-Reid, Letarte et al. 1991). More recently, a test 
model was published in which patient ALL and AML blast cells were used in 
subcutaneous (s.c.) injection into SCID mice. The growth of subcutaneous tumours 
compared to the clinical data demonstrated that the more aggressive the subcutaneous 
SCID tumours, the poorer the clinical outcome in patients (Yan, Wieman et al. 2009). 
Although human peripheral blood mononuclear cells, foetal hematopoietic tissues and 
hematopoietic stem cells were able to engraft in SCID mice, the number of engrafted cells 
was low and, in the case of experiments using normal haematopoietic cells failed to 
generate a functional human immune system (Greiner, Hesselton et al. 1998). 
The SCID mouse strain was later crossed with the NOD (non-obese diabetic) mouse 
strain, which can better support the in vivo repopulation assay of human hematopoietic 
and leukaemic stem cells. The NOD mice were originally used as a model for type I 
diabetes where destruction of the pancreas involved B and T lymphocytes. Additionally, 
these mice have an impaired immune system with depleted natural killer (NK) cells and 
defective complement system (Shultz, Schweitzer et al. 1995). By crossing these NOD 
and SCID strains, mice lacking B- and T- cells and reduced functional NK cells were 
generated. These mice have been shown to be superior to the SCID strain in the 
modelling of lymphoid malignancy (Hudson, Li et al. 1998).  
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Studies on lymphoid leukaemia utilizing NOD/SCID mice have demonstrated the 
engraftment of children ALL blasts obtained at diagnosis or relapse in the mice and 
highlighted the similarities of the xenograft assays to the clinical disease (Lock, Liem et 
al. 2002; Liem, Papa et al. 2004).  NOD/SCID mice conditioned with total body 
irradiation were reported to rapidly home and accumulate human scid repopulating cells 
in the bone marrow and spleen of the mice (Kollet, Spiegel et al. 2001). It was reported 
that intrahepatic injection of cells from adults with ALL into unirradiated newborn 
NOD/SCID mice led to successful engraftment after 6-18 week and the levels of bone 
marrow engraftment were linked to those in peripheral blood (Cheung, Fung et al. 2010).  
ALL blasts with CD133 expression together with primitive phenotypes were found to be 
important in the engraftment in NOD/SCID mice as these cells showed long term in vivo 
proliferation (Cox, Diamanti et al. 2009).     
Despite these successful engraftments of normal or leukaemic cells in mice, the 
disadvantage of using NOD/SCID mice in lymphoid xenograft was the high incidence of 
thymic lymphomas in some cases and a short lifespan of the mice with an average 8.5 
months (Chiu, Ivakine et al. 2002).     
The NOD/SCID mouse strain was further improved by homozygous mutation of the 
interleukin-2 receptor gamma chain locus (IL-2R-chain; IL-2R-null; Il2rg; NSG) where 
engraftment of human hematopoietic stem cells and peripheral-blood mononuclear cells 
in this immunodeficient strain is greater than the previously described humanized mouse 
strains (Shultz, Ishikawa et al. 2007). Importantly the lifespan of the NSG mice is 
extended to 15 months, making the strain a more ideal selection as a xenograft model for 
a long term study of haematological malignancy engraftment (Ishikawa, Yasukawa et al. 
2005). In addition, the implementation of orthotopic technique by intrafemoral injection 
of bone marrow or leukaemic cells into their natural microenvironment can improve 
engraftment in the implanted mice. This technique is now widely used in the study of 
haematopoietic cells in xenograft models.   
In a very recent published finding utilising NSG mice, Schmitz et al. (2011) reported de 
novo resistant very high risk (VHR) ALL cells reconstitute leukaemia earlier in mice 
compared to standard risk ALL cells. The VHR-ALL cells were able to maintain high 
engraftment levels in the bone marrow and spleen of xenografted mice after six serial 
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transplantations but not the standard risk-ALL cases. This finding demonstrated the 
ability of NSG mice to conserve repopulating capacity (Schmitz, Breithaupt et al. 2011). 
It has been reported that intrafemoral injection of flow sorted ALL cells into non-
irradiated NSG mice increased the bone marrow assay sensitivity by tenfold compared to 
intravenous injection (Mazurier, Doedens et al. 2003). Additionally, Le Viseur et al. 
(2008) have demonstrated that in limiting dilutions experiments, leukaemic blasts, which 
were sorted into specific committed lymphoid lineage with different markers, were able to 
transfer leukaemia in NSG mice in at least four sequential transplantations (Le Viseur, 
Hotfilder et al. 2008). Notta et al. reported that injection of human HSCs into NSG mice 
showed higher engraftment in female mice and concluded that self-renewal, proliferation 
and survival of the engrafted cells were influenced by gender associated factors (Notta, 
Doulatov et al. 2010). 
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1.7 Aims of Study 
 
Aim 1: 
To evaluate the kinetic, self-renewal and clonal evolution capacity of a t(17;19) E2A-
HLF-positive matched paired patient samples in in vivo model.  
A matched paired L707 presentation and relapse patient materials will be xenografted into 
NSG mice to evaluate and compare the proliferation and expansion capacity between the 
blast cells. Combination of both presentation and relaspe cells in different propotions will 
be carried out as well evaluating which cells have the advantage of repopulating and 
expanding in the absence and presence of glucococrticoid drugs. This experiment will 
determine if the engraftment of the matched paired materials is able to recapitulate the 
human disease condition, which organ is infiltrated and whether the engraftment is 
continuously reproducible in subsequent transplantation.  
 
Aim 2: 
To generate lentiviral vectors harbouring different reporter gene sequences coupled with 
fluorescent protein sequences. 
The purpose of this section is to generate tracking markers that could be used to label 
target cells to facilitate the monitoring progression of the cells in vivo. HIV-based 
lentivirus will be utilized in the cloning of different luciferase reporter genes coupled with 
different fluorescent protein genes. These cloned lentiviruses will be transduced into cell 
lines to evaluate the transduction efficiency.   
 
Aim 3: 
To monitor progression of leukaemic cells xenografted in mice by luminecscence 
imaging. 
This section utilized the transduced cell lines in mouse model xenografts. The purpose of 
this study is to prove the monitoring capability in tracking the progression of cells using 
luminescence imaging and the ability to compare expansion of different cells in vivo. 
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CHAPTER 2    
MATERIALS AND METHODS 
2.1 General Materials 
2.1.1 Equipment  
ABI 7900HT Sequence detection system (Applied Biosystems, USA) 
Agarose gel electrophoresis unit BIO-Rad (Hemel-Hempsted, Herts., UK) 
Allegra X-12 benchtop centrifuge (Beckman Coulter, High Wycombe, UK) 
Centrifuge 5415C (Eppendorf, Hamburg, DE) 
Centrifuge 5417R refrigerated (Eppendorf, Hamburg, DE) 
Class II microbiological safety cabinet (BIOMAT-2 Medical Air Technology Ltd., 
Manchester UK) 
FACS Calibur Flow Cytometer (Becton Dickinson, Oxford, UK) 
FACS Canto II Flow Cytometer (Becton Dickinson, Oxford, UK) 
FACS Sorting (Becton Dickinson, Oxford, UK) 
Fluorescent microscope (Nikon Eclipse TE2000-U) with Camera (Digital Sight SD-
2MBWc, Amstelveen, Netherland) 
Gel Doc BIO-Rad (Hemel-Hempsted, Herts., UK) 
Luminescence Bioimager (Caliper Ltd, USA) 
Mistral 2000 centrifuge (Fisher Scientific, Loughborough, Leicestershire, UK) 
Mistral 3000 refrigerated centrifuge (Fisher Scientific, Loughborough, Leicestershire, 
UK) 
ND-1000 Spectrophotometer (Nanodrop Technologies Ltd., USA) 
Olympus CK30 Light microscope (Olympus Corperation, Japan) 
Spectramax 250 Multiwell plate reader (Molecular Devices, Crawley,UK)  
Thermomixer comfort (Eppendorf Thermoblock, UK) 
Tissue culture incubators (Heraeus Equipment Ltd., Essex, UK) 
Universal Hood II BIO-Rad (Hemel-Hempsted, Herts., UK) 
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2.1.2 Disposables and Labware  
All disposable and plasticware were purchased from Greiner Bio-one (Frickenhausen, 
Germany), Eppendorf (Hamburg, Germany) and Becton Dickinson (New York, USA) 
unless stated otherwise. 
Thickwall-style polyalloer conical tubes (Beckman Instruments Inc., High Wycombe, 
UK). 
Derlin PKGED’1 tubes adapters (Beckman Instruments Inc., High Wycombe, UK). 
2.1.3 Chemicals and Reagents 
All standard chemicals, reagents and buffers used in the experiments were either 
analytical or molecular grades and purchased from Sigma-Aldrich Chemical Company 
(Dorset, UK), Fischer Scientific (Leicestershire, UK) or BDH (Dorset, UK) unless 
otherwise stated. 
2.1.4 Buffers  
E.coli growth and transformation 
Luria-Bertani (LB) Medium (1 Liter) 
10 g Bacto-Trypton 
10 g Sodium Cloride 
5 g  Yeast Extract 
pH 7.4, Sterilized by autoclaving 
 
Luria-Bertani (LB) Agar (1 Liter) 
10 g Bacto-Trypton 
10 g Sodium Cloride 
5 g  Yeast Extract 
15 g Agar 
pH 7.4, Sterilized by autoclaving 
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SOC medium 
2 g Bacto®-tryptone 
0.5 g Bacto®-yeast extract 
1 ml of 1M NaCl 
0.25 ml of 1M KCl 
Add water to 90 ml 
Autoclaved and let cooled, then add;  
1 ml of 1M MgCl2 • 6H2O  
1 ml of 2M glucose 
Bring to 100ml with distilled water  
pH 7.0 
filter-sterilized with 0.2 µm syringe filter unit 
Electrophoresis buffers 
50x TAE buffer (stock solution) 
242 g Tris-base dissolved in 200 ml distilled water 
Add 57.1 ml glacial acetic acid 
Add 100 ml of 500 mM EDTA solution (pH8.0) 
Bring the final volume up to 1000 ml with distilled water 
1x TAE buffer (working solution) 
20 ml stock solution 50x TAE buffer 
Bring to 1000 ml with distilled water 
The Tris-acetate-EDTA (TAE) working solution contains 40 mM Tris, 20 mM acetic acid 
and 1 mM EDTA.  
0.5 M EDTA solution 
84.05 g Ethylenediaminetetraacetic acid (EDTA)  
Add 100 ml of distilled water 
Add 5 M NaOH until pH8.0 reaches and EDTA dissolved 
Bring to 500 ml volume with distilled water 
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Phosphate buffer  
1x PBS 
Phosphate buffered saline (PBS) was prepared by dissolving PBS tablet into appropriate 
volume of distilled water and was sterilized by autoclaving. 
2.1.5 Molecular Cloning  
2.1.5.1 Conventional Restriction Enzymes 
All restriction enzymes used as listed below were supplied by Fermentas. The standard 
activity of all the enzymes was 10u/µl. 
BamHI   PstI   
BglII    PvuI  
Bsp119 (BstBI)  SacI  
Cfr42I (SacII)   SalI 
EcoRI    ScaI 
GsuI    SgsI (AscI) 
MunI (MfeI)   XbaI 
NcoI    XhoI   
NheI   
2.1.5.2 Modifying Enzymes 
T4 DNA Polymerase I    5u/µl (Fermentas) 
T4 DNA Ligase     5u/µl (Fermentas) 
DNA Polymerase I Large (Klenow) Fragment 1u/µl (Promega) 
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2.1.6 Cell Analysis 
Antibodies for Flow cytometry analysis were purchased from Becton Dickinson 
Pharmingen. 
     Clone    Dilution used 
CD10-FITC    Hl10a    10 µl / 10
6
 cells 
CD19-PE    SJ25C1   10 µl / 10
6
 cells 
CD20-PerCP-Cy5.5   L27    10 µl / 10
6
 cells  
CD33-PE    P67.6    10 µl / 10
6
 cells 
CD34-APC    8G12    2.5 µl / 10
6
 cells 
CD45-APC    2D1    2.5 µl / 10
6
 cells 
CD45-PE-Cy7    30-F11    2.5 µl / 10
6
 cells 
TER119-APC    TER-119   2.5 µl / 10
6
 cells 
TER119-PE-Cy7   TER-119   2.5 µl / 10
6
 cells 
2.1.7 PCR and q-PCR 
RevertAid
TM
H Minus First Strand cDNA Synthesis Kit (Fermentas, York, UK). 
REDTaq
®
ReadyMix
TM
 PCR Reaction Mix (Sigma-Aldrich, Missouri, USA) 
Taqman MasterMix (Applied Biosystem, Warrington, Cheshire, UK) 
2.1.8 Kits 
The following kits were purchased from Qiagen (Crawley, West Sussex, UK) and assays 
from Promega Corporation (Madison, Wisconsin, USA). 
QIAamp DNA Blood Mini Kit 
QIAquick PCR Purification Kit 
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QIAqiuck Gel Extraction Kit 
Miniprep Plasmid Isolation Kit 
Maxiprep Endofree Plasmid Isolation Kit  
Luciferase Assay System 
2.1.9 Primers and Oligonucleotides 
All primers and probes were purchased from Sigma-Aldrich (Dorset, UK). 
Self-designed oligonucleotides (polylinker) 
SacI-XhoI PL sense    5’ – CGGATCCTTCGAAGCTATCTAGAGAATTCA 
GCTCCATGGAGATCTGATCCAATTGGTCGACCGT
AC – 3’ 
SacI-XhoI PL antisense    5’ –TCGAGTACGGTCGACCAATTGGATCAGATC 
TCCATGGAGCTGAATTCTCTAGATAGCTTCGAAG
GATCCGAGCT – 3’ 
Primers for RT-PCR 
E2A exon 12    5’-GACATGCACACGCTGCTGCC-3’ 
E2A exon 13    5’-GCCTCATGCACAACCACGCG-3’ 
HLF exon 4    5’-CCCGGATGGCGATCTGGTTC-3’ 
Primers and probe for Q-PCR 
NR3C1 forward   5’- AGGACGCCACCCCATTG-3’ 
NR3C1 reverse   5’- TGTCTGAAGGGTCCCAGTTTG-3’ 
NR3C1 probe    [6FAM]ACTCAAATGCACACTCACA[TAM] 
ATP10A forward   5’- AGCCCCATGGTGAGTGTACAG-3’ 
ATP10A reverse   5’- GTAGGATTAAATATAGACACCTTCCATGAG-3’ 
ATP10A probe   [6FAM]CCACGTCTCTTCCCCATTTTCACCATC[TAM]       
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2.1.10 Cell Lines 
SEM: a B-cell precursor leukaemia cell line, established in 1990 from peripheral blood of 
a 5-year old girl at relapse, carrying t(4;11) MLL-AF4 malignancy (Greil, Gramatzki et 
al. 1994).  
Kasumi-1: a FAB M2 classification AML cell line, established in 1989 from the 
peripheral blood of a 7-year old Japanese boy at second relapse, carrying t(8;21) AML1-
ETO fusion gene (Asou, Tashiro et al. 1991).    
SKNO-1: a maturated myeloblast cells isolated from bone marrow of a 22-year old 
Japanese woman bearing the t(8;21) traslocation with AML1-MTG8 fusion gene 
(Matozaki, Nakagawa et al. 1995).    
RS4;11: a B-cell precursor leukaemia line, established from bone marrow of a 32-year old 
woman at relapse, classified as ALL L2 subtype of t(4;11) malignancy with MLL-AF4 
fusion gene (Stong, Korsmeyer et al. 1985). 
PreB 697: a B-cell precursor leukaemia line, established in 1979 from the bone marrow of 
12-year old male at relapse of ALL (Findley, Cooper et al. 1982).   
REH: a B-cell precursor leukaemic cell line, established in 1975 from the peripheral 
blood of a 15-year old North African girl with ALL at first relapse (Rosenfeld, Goutner et 
al. 1977; Matsuo and Drexler 1998). 
HAL-01: a B-cell precursor leukaemia of ALL-L2 subtype cell line, established in 1990 
from the peripheral blood of a 17-year old woman diagnosed with ALL, carrying Type 1 
t(17;19)(q22;p13) with E2A/HLF fusion gene (Ohyashiki, Fujieda et al. 1991). This cell 
line has a morphological and cytochemical appearance of lymphoid cells, with a myeloid-
associated marker in patients’ cells but not in the cell line. 
293T: a cell line derived from human embryonal kidney cell line 293, expressing large T 
antigen, of fibroblast morphology and highly transfectable (del Rio, Clark et al. 1985). 
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2.1.11 Competent Cells Bacteria 
JM109 
JM109 are E.coli competent cells lacking recA which improves DNA yield in plasmid 
isolation. These competent cells are also deficient in β-gal and carry the genotype of: 
endA1, recA1, gyrA96, thi-1, hsdR17 (rk–, mk+), relA1, supE44, Δ (lac-proAB), F' 
[traD36, proAB+, lacI
q
, lacZ Δ M15]. The JM109 competent cell was purchased from 
Promega, Madison, USA. 
Stbl3 
The Stbl3 are E. coli strain designed for cloning direct repeats found in lentiviral 
expression vectors. These cells reduce the frequency of unwanted homologous 
recombinations of long terminal repeats (LTRs) found in lentiviral and other retroviral 
vectors. Stbl3 cells are highly stable bacterial cells which help in increasing the efficiency 
of lentiviral cloning. The cells carry the genotype of: F-mcrBmrr hsdS20 (rB
-
, mB
-
 ) 
recA13 supE44 ara-14 galK2 lacY1 proA2 rpsL20 (Strr) xyl-5 λ-leu mtl-1r. The Stbl3 
competent cell was purchased from Invitrogen, UK. 
Self-produced competent cells 
E.coli competent cells JM109 and Stbl3 were prepared in high volume from the stocks 
using a CaCl2 / PEG protocol. 
2.1.12 Mouse Strain 
All animal experimentation used the same strain of immunodeficient mice.  
NSG mice 
Also known as NOD/SCID gamma, NOD.Cg-Prkdc
scid
 Il2rg
tmIWjl
 immune deficient mice, 
NOD-SCID IL2Rgamma
null
 or NOD-SCID IL2Rg
null
 or NSG, this mouse strain was 
purchased from Jackson Laboratory, USA.  
Mice are deficient in mature B, T and NK cells and carry the true null interleukin-2 
receptor gamma mutation. These mutant mice have been shown to readily support 
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engraftment of human CD34
+
 HSC and represent a superior, long-lived model suitable for 
studies employing xenotrasplantation strategies. 
2.2 Methods 
2.2.1 Methods Chapter 3 
2.2.1.1 Cell lines and Maintenance of Cells 
All cell lines used in this study were previously tested with the Mycoalert Elisa Assay and 
confirmed as being Mycoplasma negative. Cell culture work was carried out under aseptic 
condition in class II microbial safety containment hoods. All surfaces and equipment, 
disposables and glassware were sterilized with 70% ethanol. Cells were grown in flasks 
(Corning) or multi-well plates (NUNC, Invitrogen). All cell lines used grew in 
suspension, unless otherwise mentioned, and were incubated at 37ᵒC in a humidified 
tissue incubators (IncuSafe, Sanyo) supplied with 5% CO2.  
Cell lines are supplied by DSMZ (German Collection of Microorganisms and Cell 
Cultures, Braunschweig, Germany) unless otherwise stated. All cell lines used in the 
experiments were routinely grown in their respective medium. SEM, Kasumi-1, RS4;11 
and HAL-01 were grown in RFh10, a RPMI 1640 media with Hepes modification 
(Gibco) supplemented with 10% fetal calf serum (FCS) and 200 µM L-glutamine. SKNO-
1 was cultured in RFh20G, a RPMI 1640 media with Hepes modification supplemented 
with 20% FCS, 200 µM L-glutamine and 7 ng/ml GM-CSF.  PreB 697 and REH were 
cultured in RF10, a RPMI 1640 supplemented with 10% FCS only. All cells were 
passaged depending on their doubling times at a cell density of 0.5 x 10
6
 cells/ml, as 
summarized in Table 2.1.  
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Cell line Morphology Medium Subculture  
Doubling 
time 
Source 
REH 
small, round, single cells in 
suspension 
RF10 
every 3-4 days; at 0.5 x 10
6
 
cells/ml; maintain at high 
density (>2 x 10
6
 cells/ml);  
50-70 hours 
DSMZ No.: 
ACC22 
697 pre-B 
round, single cells and 
clusters of cells in 
suspension 
RF10 
every 2-3 days; at ca. 1.0 x 
10
6
; maintain at 0.5-1.5 x 10
6
 
cells/ml 
30-40 hours 
DSMZ No.: 
ACC42 
HAL-01 
single, round cells in 
suspension, some cells are 
slightly adherent 
RFh10 
twice a week; at 1 x 10
6 
cells/ml; adherent cells can 
be detached by tapping the 
flask;  
48 hours 
DSMZ No.: 
ACC610 
Table 2.1  Summary of morphology and maintenance of REH, 697 pre-B and HAL-01 cell lines. 
2.2.1.2 Mycoplasma Testing 
All cell lines used in the studies maintained in cultures were routinely checked for 
mycoplasma contamination. Cultures contaminated with mycoplasma can affect cell 
metabolism, antigenicity and growth characteristics of the cells. Contaminated cell lines 
will invalidate any experimental data achieved from the cells. Mycoplasma infection was 
analysed using MycoAlert® (Lonza, UK). The MycoAlert® Assay is a selective 
biochemical test that exploits the activity of mycoplasmal enzymes. The presence of these 
enzymes is utilized in a rapid screening procedure allowing sensitive detection of 
mycoplasma contamination in a test sample. The viable mycoplasmas are lysed and the 
enzymes released react with the MycoAlert® Substrate by catalyzing the conversion of 
ADP to ATP. The level of ATP in the tested samples is measured before and after 
addition of MycoAlert® Substrate to obtain a ratio which is indicative of the presence or 
absence of mycoplasma.   
2.2.1.3 Counting of Viable Cells 
Cell counts were performed using an Improved Neubauer counting chamber (Fisher 
Scientific), a hematocytometer which was used to determine the number of cells per unit 
volume of a suspension. The coverglass of the counting chamber was placed over the 
counting surface prior to adding the cell suspension. To count viable cells, an aliquot of 
single cell suspension was mixed 1:1 with 0.4% Trypan blue solution. 10 µl of the 
mixture was applied to the edge of the coverglass which completely filled the counting 
area by capillary action. The cells within four large squares with grids (made up of 4x4 
squares each) were counted under light microscope (Olympus) and the numbers of cells 
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scored were averaged. The total number of cells per ml of solution was equal to the 
average number of cells x 2 (of dilution with Trypan blue solution) x 10
4
. 
2.2.1.4 Resurrecting Frozen Cell Stocks  
All cell line stocks were stored in liquid N2 at -180ᵒC. In order to defrost them, vials were 
warmed at 37ᵒC in a water bath. Cells were transferred to 20-ml universal tubes (Sterilin) 
and 5 ml of pre-warmed growth media was added to dilute the frozen medium containing 
dimethyl sulphoxide (DMSO). Cell suspensions were spun at 1500 rpm for 5 min in MSE 
2000 centrifuge (GMI). Supernatants were aspirated off, the cell pellets were resuspended 
in fresh growth medium and transferred into 25 cm
2
 plastic flasks (Corning). Cells were 
incubated at 37ᵒC in a humidified incubator supplied with 5% CO2.    
To recover frozen cryopreserved patients cells, the frozen vials of cells were thawed 
rapidly in a 37ºC waterbath and diluted in 5 ml of RF10 medium. Viable cells were 
counted by trypan blue exclusion method as mentioned in section 2.2.1.3. Cells were 
pelleted by centrifugation at 1500 rpm for 5 minutes. The medium was aspirated and cells 
were resuspended in RF10 medium at an appropriate volume for cell analysis or xenograft 
mouse model.   
2.2.1.5 Freezing Down Cells for Storage 
To freeze down cells for storage in liquid N2, suspension cells were grown in 75 cm
2
 or 
175 cm
2
 flasks at high density. Viable cells were counted according to section 2.2.1.3 and 
suspensions containing the desired number of cells were spun down to remove the growth 
medium. The cell pellet was resuspended in a relevant amount of freezing medium to be 
frozen down at a concentration of 5 to 6 million cells per vial. The freezing medium 
contained 90% FCS and 10% DMSO. Cell stocks were stored in -80ᵒC overnight or up to 
two weeks, in order to freeze the cells at a rate of approximately 1ºC per minute. Within 
1-14 days vials were transferred into liquid N2 for long term storage. 
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2.2.1.6 Harvesting of Cells 
Cells were harvested for DNA, RNA and protein studies or other cells experiments when 
in exponential growth. The cultured cell suspension was aliquoted into a 20-ml sterillin 
tube and centrifuged at 1500 rpm for 5 minutes at room temperature. The supernatant was 
aspirated and the cell pellet was washed with PBS, centrifuged and repelleted. Cells were 
finally resuspended in the appropriate volume of medium or PBS.   
2.2.1.7 Cytospins of Cells 
Fresh or frozen samples of leukaemic blast cells were prepared for cytospins by diluting 
the cells to a concentration of 10
6
 cells/ml in RF20 (RPMI 1640 medium containing L-
glutamine (Invitrogen) supplemented with 20% foetal calf serum). 100 µl of cell 
suspension was dropped into a cell concentrator chamber attached to a glass slide. The 
slides were centrifuged at 400 rpm for 3 minutes at room temperature in a Cytospin 2 
centrifuge (Shandon Southern Products Ltd., UK). The slides then were allowed to air-dry 
at room temperature. Slides were directly used for cell staining or were wrapped with 
cling film and stored in -20ºC freezer. To use the frozen slides for staining, slides were 
defrosted at room temperature for one hour prior to use.        
2.2.1.8 May-Grünwald-Giemsa Staining of Blast Cells 
The May-Grünwald-Giemsa stain is an eosin-methylene blue solution which was 
modified for easier viewing of haematological specimens under microscopy. This stain is 
also among the widely used solutions in histological staining of blood smears that allows 
the different types of cells and components within the cells to be distinguished from one 
and another by their colour and shapes. Lymphocytes are generally round cells with large 
round nucleus and within a considerable size range. The lymphocyte nuclei stain a deep 
red or violet colour, while the cytoplasm is either a dark blue ring or not visible due to 
large nuclei. 
Protocol   
1.5 ml of May-Grünwald stain (Fisher Scientific) was added onto the cytospinned cells on 
slides prepared as discussed in section 2.2.1.7 and incubated for 3 minutes at room 
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temperature. Then 1.5 ml of water was added to dilute the stain on the slides and was 
incubated for a further 5 minutes at room temperature. Approximately 10 drops of 
Giemsa (Sigma) were diluted in 10 ml of water. The diluted May-Grünwald stain was 
poured off the slides (into a sink with running water). The slides were flooded with the 
freshly prepared diluted Giemsa stain and were incubated for 15 minutes at room 
temperature. Following this step, the slides were rinsed in water and air-dried. Slides were 
mounted in DPX stain and were covered with coverslips.       
2.2.1.9 Cell Growth and Growth Curves 
Assessment of cell growth is required for cell lines intended for use in drug induction 
assays. Cells in culture follow a characteristic growth cycle of a lag phase, a period of 
exponential growth or log phase and finally reaching a plateau in which the growth of the 
cells was arrested with zero or reduced growth period. Different cell lines have different 
characteristic of these growth phases which allows determination of the doubling time of 
the cell line. The population doubling time is the time taken for the culture to increase 
two-fold in the middle of the log phase. This assessment facilitates routine subculture of 
cells lines and is used in determining drug exposure for cytotoxicity assays. 
Protocol  
Cell lines in well maintained routinely passaged cultures were used for cell growth 
assessment. Cells in exponential phase of the growth cycle were passaged in a 25 cm
2
 
flask at a concentration of 0.5 x 10
6
 cells/ml in 10 ml of fresh medium. Cell growth was 
determined by counting the cells daily for seven consecutive days using trypan blue 
exclusion method as described in Section 2.2.1.3. To maintain the cells growing in culture 
without too much change in medium for the growth assessment, cell suspension was 
aliquoted 20 µl daily for cell counting. Growth curves were analysed using simple Excel 
worksheet.   
2.2.1.10 Cell Growth and Cytotoxicity Assays 
Cytotoxicity assays measure drug-induced alterations on cell growth. The colorimetric 
assay based on WST-1 is suitable for the non-radioactive quantification of cell 
proliferation, cell viability and cytotoxicity. For this purpose, Cell Proliferation Reagent 
49 
 
WST-1 (Roche Applied Science, Germany) was used. Proliferation assays utilizing this 
kit are useful for analyzing the number of viable cells by the cleavage of tetrazolium salts 
added to the culture medium. This technique does not require washing or harvesting of 
cells. The tetrazolium salts are cleaved to formazan by cellular mitochondrial enzymes. 
Overall activity of mitochondrial dehydrogenases in the sample correlates with the 
number of viable cells. Increased enzyme activity leads to an increase in the amount of 
formazan dye formed, which directly correlates to the number of metabolically active 
cells in the culture. Quantification of the formazan dye produced is measured by 
multiwell plate reader spectrophotometer.    
Protocol  
Cell lines PreB 697 and REH were maintained in culture in RF10 (RPMI supplemented 
with 10% FCS) medium and HAL-01 was cultured in RFh10 (RPMI with hepes 
modification supplemented with 10%FCS and 200 µM L-glutamine) medium. Cells at the 
exponential phase of the growth cycle were collected in universal tubes and centrifuged at 
1500 rpm for 4 minutes. Supernatants were removed and cell pellets were resuspended in 
respective media. Cells were then seeded in 96-well plates at a density of 1 x 10
5
 cells in 
150 µl medium per well. For the t(17;19) patient presentation and relapse cells, one vial 
of each frozen sample of cells harvested from spleens of xenografted mice were used in 
this experiment. Cells were recovered from cryopreservation as in Section 2.2.1.4. Cell 
suspensions were seeded in 96-well plates at a density of 1 x 10
6
 cells/well in150 µl RF10 
medium. Each cell was aliquoted in triplicate for each treatment dilution. Fifty microliters 
of dexamethasone (Sigma, USA) at various concentrations of 1 nM, 10 nM, 100 nM, 1 
µM and 10 µM were added to each triplicate of cells, in addition to 20 µl WST-1 reagent. 
Cells were incubated in a humidified incubator at 37ºC supplied with 5% CO2 for 96 
hours prior to measuring the colorimetric of the dye produced using the multiwell plate 
reader Spectramax 250 (Molecular Devices, UK). Dye absorbances in the samples were 
measured at 450 nm and an additional absorbance value at 650 nm were measured for 
correction to medium colour. Data were analysed using PrismPad v4.0 software.    
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2.2.1.11 Extraction of Genomic DNA 
Genomic DNA was extracted from cell pellets using the QIAamp DNA Mini and Blood 
Mini Kit (Qiagen, Crawley, UK). The kit simplifies rapid isolation and purification of 
DNA from 200 l of whole human blood, 5 x 106 lymphocytes, or cells with a normal 
karyotype. The DNA was eluted with a fast spin column without phenol-chloroform 
extraction. The DNA binds specifically to the QIAamp silica gel membrane while 
contaminants pass through. PCR inhibitors such as divalent cations and proteins are 
completely removed in two efficient wash steps. The pure nucleic acid is eluted in water 
or buffer provided in the kit. The technique yields DNA sizes from 200 bp to 50 kb 
depending on the age and storage of the samples. DNA extraction was performed 
according to manufacturer’s protocol. The proprietary reagents included in this kit were 
QIAGEN
®
 Protease or proteinase K, Buffer AL, Buffer AW1, Buffer AW2 and Buffer 
AE. 
Protocol  
Approximately 5 x 10
6
 cells were pelleted as previously described. Cell sample was 
pelleted in a 1.5 ml microcentrifuge Eppendorf tube for the following processes. The 
washing solution was aspirated out and the cell pellet was resuspended in PBS to a final 
volume of 200 µl. A total of 20 µl of proteinase K solution (20 mg/ml) was added to the 
cell suspension followed by 200 µl of Buffer AL for cell lysing. The sample was mixed 
thoroughly in the suspension using pulse-vortexing for 15 seconds. The mixture was 
incubated at 56ºC for 10 minutes in a heat block to lyse the cells. Following this step, 200 
µl of 100% ethanol was added to the sample and mixed twice by pulse-vortexing for 15 
seconds. The sample was then centrifuged briefly to remove any drops from the inside of 
the lid and the mixture was transferred to a QIAamp spin column with attaching 2-ml 
collection tube. The column was centrifuged at 13,000 rpm for one minute at room 
temperature. The DNA remained in the column filter and the collection tube containing 
the filtrate was discarded and replaced with a clean collection tube. The QIAamp spin 
column was washed by adding 500 µl Buffer AW1 and centrifuged at 13,000 rpm for one 
minute at room temperature. The collection tube containing the filtrate was discarded and 
replaced with a clean collection tube provided. The column was washed again by adding 
500 µl of Buffer AW2 followed by centrifugation at 13,000 rpm for 3 minutes. The final 
step was to elute the DNA from the column. The column was placed in a clean 1.5 ml 
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Eppendorf tube and 50-200 µl pre-warmed Buffer AE or nuclease-free water was added 
to the column, depending on the size of the initial pellet or cell count. The column with 
elution buffer was incubated for 1 minute at room temperature before centrifugation at 
13000 rpm for 1 minute. To increase the DNA yield, column was incubated for 5 minutes 
at room temperature before centrifugation. The DNA was stored at 4ºC ready for use. The 
concentration and purity of DNA was estimated using the NanoDrop® ND-100 
spectrophotometer. 
2.2.1.12 Extraction of Total RNA 
Total RNA was extracted from cell pellets using the Qiagen RNeasy Mini kit (Qiagen, 
Crawley, UK). The method relies on the selective binding properties of a silica-based 
membrane. The kit utilizes buffer containing a highly denaturing guanidine-thiocyanate to 
immediately inactivate RNases that ensures purification of intact RNA from the lysed and 
homogenized biological samples. Addition of ethanol provided appropriate conditions of 
the silica-gel membrane in the spin column to bind RNA to the membrane when the 
contaminants were efficiently washed away. Water provided in the kit was used to elute 
the high quality RNA. The proprietary reagents included in this kit were RLT buffer 
containing guanidium thiocyanate, RW1 buffer, RPE buffer containing 80% ethanol and 
RNase-free water.  
Protocol  
Appropriate numbers of cells (usually > 10
6
 cells) were aliquoted into centrifuge tubes 
and spun down for 5 minutes at 300 x g. Supernatants were discarded completely 
removing all media. Cell pellets were washed once with PBS and spun down to remove 
the washing buffer. Cell pellets were loosened by flicking the tubes. 350 µl of Buffer 
RLT (1% of 2 Mercaptoethanol added) was added to the pellet and the mixture was 
vortexed to mix. The homogenized lysates were pipetted directly onto QIAshredder 
columns with 2-ml collection tubes (supplied in the kit), and centrifuged for 2 minutes at 
maximum speed to homogenize. One volume or 350 µl of 70% ethanol was added to the 
flow-through and mixed well by pipetting. Lysates were transferred to RNeasy spin 
columns with 2-ml collection tubes, and centrifuged for 15 seconds at 8000 x g (10,000 
rpm). 700 µl of Buffer RW1 was pipetted onto the RNeasy columns and centrifuged for 
15 seconds at 8000 x g to wash the columns. Columns were transferred into new 2-ml 
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collection tubes (supplied). 500 µl Buffer RPE was pipetted onto the column and 
centrifuged at 8000 x g to wash. This step was repeated twice. Flow-through was 
discarded and columns were centrifuged again for 2 minutes at maximum speed to dry the 
RNeasy membrane. RNeasy columns were transferred into 1.5-ml collection tubes 
(supplied). 50 µl of RNase-free water was pipetted directly onto the RNeasy membranes. 
The columns were centrifuged for 1 minute at 8000 x g to elute. RNAs were either kept in 
-80ºC for long-term storage or used directly to synthesize cDNA.       
2.2.1.13 Assessing DNA and RNA Concentration and Quality 
The concentration of DNA and RNA samples yielded were assessed using a ND-1000 
Spectrophotometer (Nanodrop Technologies, Labtech International, UK). The Nanodrop 
measures the concentration of DNA or RNA using only 1µl of sample. 
Spectrophotometric absorbance at 260 nm (A260) and 280 nm (A280) were measured 
against water blank. The ratio of A260:A260 was taken as a guideline of sample purity, 
with values between 1.8 and 2.0 indicating pure DNA or RNA. Lower ratio values 
indicated protein contamination.   
2.2.1.14 Synthesis of cDNA  
The total RNA isolated from the samples was first converted into cDNA by a reverse 
transcriptase step before it can be analyzed. RevertAid
TM
H Minus First Strand cDNA 
Synthesis Kit was used for this purpose. The cDNA synthesis kit was supplied with 
Random Hexamer Primers, 5x Reaction Buffer, Ribolock RNase Inhibitor, RevertAid H 
Minus Reverse Transcriptase and DEPC-treated water. The incubation steps for cDNA 
synthesis were performed using the Applied Biosystem GeneAmp PCR System 9700 
thermal cycler machine.  
Protocol 
To prepare the cDNA from RNA samples, 200 µl PCR tubes were used and the cDNA 
synthesis was performed according to manufacturer’s procedures. A volume of 20 µl 
reaction mix was prepared using reagents from the kit. Two microliters of RNA samples 
with concentrations between 250 ng to 1 µg was used in the initial step. One microliter of 
Random Hexamer primers and 9 µl of DEPC-treated water were mixed with the RNA in 
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the PCR tube. The first step reaction mixture was incubated at 70ᵒC for 5 minutes 
followed by a cooling-off step with a reduction of temperature to 4ᵒC for 10 minutes. 
During this time, a mixture of 4 µl 5x reaction buffer, 2 µl of 10 nM dNTPs, 1 µl RNase 
inhibitor and 1 µl of reverse transcriptase were added. The second step reaction mixture 
was run for a full cycle of incubation at 25C for 10 minutes, 42C for 60 minutes and 
70C for 10 minutes followed by cooling at 4C. The synthesized cDNA was kept at 4C 
for short term storage and at -20C for long term storage.    
2.2.1.15 RT-PCR 
Reverse transcription polymerase chain reaction (RT-PCR) is a technique used to amplify 
minute amount of specific DNA sequence. This technique utilizes DNA polymerase 
enzyme (often Taq polymerase) together with specific primers and single nucleotides to 
produce complementary copies of the template DNA. The reactions take place in different 
temperature conditions – heating to denature DNA strands, decreasing temperature to 
allow primers to anneal to DNA, optimum temperature to allow enzyme to extend the 
primers – with repeated cycles to amplify the amount of DNA. REDTaq® ReadyMixTM 
PCR Reaction Mix supplied by Sigma-Aldrich was used in this technique. The REDTaq 
ReadyMix is a ready-to-use mixture of Taq DNA polymerase, 99% pure 
deoxynucleotides, reaction buffer, and an inert red dye in a 2x concentrate. With the red 
dye already added in the ReadyMix, the PCR products can be loaded directly onto an 
agarose gel without having to add loading/tracking dye prior to electrophoresis.  
Protocol  
The cDNA prepared in Section 2.2.1.14 at a concentration of 50 ng/µl was used in this 
procedure. A volume of 50 µl reaction mixture was prepared in a 200 µl PCR tube. 
Primers used for RT-PCR are as shown in Section 2.1.9. E2A exon 12 and E2A exon 13 
are forward primers while the reverse primer is HLF exon 4. 25 µl REDTaq ReadyMix 
was mixed with 1 µl of 50 µM forward primer, 1 µl of 50 µM reverse primer, 1 µl 
template cDNA and 22 µl water. The mixture was mixed well, centrifuged to collect the 
components in the bottom of the tube and run for PCR in an optimized thermal condition. 
The reactions mix was run for initial denaturation at 94C for 5 minutes followed by 35 
cycles at denaturing temperature at 94C for 30 seconds, annealing temperature at 56C 
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for 30 seconds, and elongation step at 72C for 1 minute. The final step was elongation at 
72C for 15 minutes. 
2.2.1.16 Agarose Gel Electrophoresis 
To determine the bands of amplified genes, the PCR products were run on agarose gel by 
electrophoresis. 2% agarose gel was prepared in a conical flask by adding 2 g of Agarose 
(Sigma) into 100 ml 1x TAE buffer prepared as in Section 2.1.4. Gel was prepared in a 
mould with the desired number of wells. PCR products were pipetted into the wells and 
gel was run by electrophoresis in 1x TAE buffer for 60 minutes at 80V. Gel was later 
viewed for bands produced under UV light in a dark chamber using the GelDoc system.  
2.2.1.17 Real-time PCR 
Real-time quantitative PCR (qPCR) was developed to monitor DNA amplification as it 
occurred with data collected throughout the reaction. The specific DNA product from the 
target sequence is detected as it accumulates (Figure 2.1). The first PCR product is 
detected in the early exponential phase and the product doubles during every cycle in the 
Log-linear phase. The cycle threshold (Ct) is determined during this phase where the Ct is 
the number of cycles required to meet a predefined threshold. In this study the TaqMan
TM
 
(Applied Biosystems) was used.  This technique uses a probe with fluorogenic label 
which binds to the target sequence. The probe is tagged with a high energy reporter dye 
fluorescein (FAM) at the 5’ end, and a low energy quencher dye (TAMRA) at the 3’ end. 
When FAM is excited by the light source, instead of emitting fluorescence it transfer the 
energy to TAMRA through fluorescence resonance energy transfer (FRET).  
In this technique, the TaqMan Universal Master Mix was used in preparation together 
with NR3C1 forward and reverse primers and NR3C1 probes for the target gene which 
were designed using Primer Design program earlier by Marian Case from Julie Irving’s 
group. The control gene uses ATP10A forward and reverse primers and a probe, which 
were available from Applied Biosystems. Genomic DNA was isolated from blasts 
collected from highly engrafted spleen of mice in xenograft experiment.     
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Figure 2.1  Phases of the PCR amplification curve. The PCR amplification curve depends on the 
accumulation of fluorescent emission at each reaction cycle. Rn is the intensity of fluorescent emission of 
the reporter dye divided by the intensity of fluorescent emission of the passive dye. ΔRn represents the 
magnitude of signal generated during PCR. (Adapted from www.dorak.info/genetics/realtime) 
 
Protocol  
Reactions were carried out in 384-well plates. The total reaction volume for each well 
was 10 µl. Each reaction was performed in triplicate on each plate. The reagent mixture 
for each sample is as summarized below. Volumes of reagents have been optimised by 
Marian Case previously and the same concentrations were used as this in house protocol. 
            .  Volumes required per well (µl)  . 
Reagent   NR3C1  ATP10A  
Taqman MMix       5          5 
DNA 25 ng        1          1 
Forward primer     1.8       0.375   
Reverse primer     0.6         1.125     
Probe      0.45         0.4 
Water      1.15         2.1  
Total volume   10 µl        10 µl  
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Plates were spun at 1,500 rpm for 1 minute in a 4K15 centrifuge (Sigma) to remove air 
bubbles trapped in the well. The plates were run on a 7900 HT-RT-PCR system (Applied 
Biosystems) with the SDS software. The qPCR was run by commercial thermal cycling 
for activation of Taqman Mastermix at 50ºC for 2 minutes, initial denaturation at 95ºC for 
10 minutes, 40 cycles of 95% for 15 seconds and annealing and extension at 60ºC for 1 
minute. 
The results were analysed using the SDS 2.2 software (Applied Biosystems). 
Amplification plots were generated for each well with the plots for magnitude of signal 
(ΔRn) versus number of cycles. The unknown (target gene NR3C1) results were 
normalized against the control ATP10A results. The unknown values were calculated 
relative to the standard curve.  
2.2.1.18 Fluorescence In Situ Hybridization (FISH) 
Preparing cells for analysis 
Fluorescence in situ hybridization (FISH) was performed on cells from the highly 
engrafted spleens from xenografts of L707 presentation, relapse and mixed populations of 
the cells in the treated and non-treated groups. Thawed viable cells were made into cell 
suspension following methods used previously in sections 2.2.1.3 and 2.2.1.4. 10 ml of 
0.75 M KCl was mixed in the suspension and incubated for 15 minutes in a 37ºC 
incubator. The suspension was then centrifuged at 1,500 rpm for 7 minutes and 
supernatant was removed, pellet was resuspended by vortexing in 1 ml of fresh 
Methanol:Acetic acid (3:1) fixative added drop by drop to avoid cells clumping. A 
volume of 10 ml fixative was added and this was then centrifuged at 1,500 rpm for 7 
minutes. Supernatant was discarded and cell pellet was suspended in 1 ml of fixative. 
Approximately 3 µl of cells were pipetted and dropped onto slides with 2 – 3 drops per 
slide. Cells were left to air-dry prior to FISH probing. Cells in fixative were stored in –
20ºC for future use.  
Preparation of probes   
Probes for labelling the target gene and a control gene in an unaffected region, both on 
chromosome 5, were selected from lists of available probes from the Ensembl website 
(Figure 2.2). The BAC (Bacterial Artificial Chromosome) clones of the RP11-92B6, 
57 
 
RP11-790H4, RP11-614D16, RP11-320G11 (Chr5-32k-2P22) and RP11-1259L22  
probes were purchased from Roswell Park Cancer Institute (Buffalo, New York, USA). 
To prepare the probes for FISH analysis, initially Luria-Bertani (LB) agar plates and 
broth were prepared supplemented with 12.5 µg/ml Chloramphenicol. The supplied 
probes were cultured separately on the LB agar plates and were incubated overnight in a 
37ºC incubator. Following this, single colonies from each of the probe cultures were 
picked and precultured in 3-5 ml LB broth for 8 hours, prior to a large 200 ml overnight 
culture in LB broth, incubated at 37ºC in an orbital shaker with 300 rpm shaking. The 
following day, the cultures were spun down at 5,000 x g for 10 minutes at 4ºC to pellet 
the plasmid, and the supernatant was discarded.  
For purification of plasmid DNA, the Plasmid DNA Purification NucleoBond®Xtra Midi 
Kit (Macherey-Nagel GmbH & Co., Dūren, Germany) was used. By following the 
manufacturer’s instruction, the plasmid pellet was resuspended in 16 ml Buffer RES 
(RNase added). Then equal volume of Buffer LYS was added and mixed thoroughly 
followed by incubation at room temperature for 5 minutes. To neutralize the lysis, 16 ml 
of Buffer NEU was added to the suspension and mixed by swirling to form precipitates. 
The suspension was centrifuged at 5,000 rpm for 15 minutes at 4ºC and the supernatant 
was transferred into a filter-column pre-equilibrated earlier with Buffer EQU. Column 
filter was washed with 5 ml equilibration Buffer EQU followed by 8 ml of Buffer WASH. 
The bound DNA was eluted by adding 5 ml elution Buffer ELU and the eluate was 
collected in 50-ml falcon tube. 3.5 ml isopropanol was added to the eluate to precipitate 
plasmid DNA. The mixture was mixed by pulse vortexing, incubated for 2 minutes at 
room temperature and centrifuged at 12,000 rpm for 30 minutes at 4ºC. Supernatant was 
discarded and the DNA pellet was purified with 2 ml 70% ethanol and centrifuged at 
12,000 rpm for 5 minutes at room temperature. Ethanol was removed and the DNA pellet 
was dried at room temperature for 10 minutes before dissolving in 200 µl sterile distilled 
water. DNA was measured using Nanodrop for use in the next step. Probe DNA was kept 
at –20ºC for long-term storage.     
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Figure 2.2 Selection of probes for genes labelling in FISH. Ensemble web page was used to select 
suitable probes covering the deleted targeted gene, NR3C1 (A), a region in the q31.3, and control unaffected 
gene, (B), a region in the q35.1. Red boxes indicated selected probes. 
 
Nick Translation protocol 
In this protocol, probes for labelling target gene were labelled with spectrum green and 
probes for labelling control gene were tagged with spectrum red. These probes were 
prepared using Nick Translation Kit (Abbot Molecular Inc., Germany) which involves 
mixing of 10 µl dNTPs and 5 µl dTTP, 5 µl NT buffer, 2.5 µl dUTP spectrum red or 
green, 17.5 µl DNA of target gene probes and control gene probes and 10 µl NT enzyme. 
Following overnight incubation at 15ºC, labelled probes were mixed with 3 µl 0.5M 
EDTA, filtered through resin column, added 10 µl human cot-1 DNA, 6 µl of 3M sodium 
acetate and 160 µl ice cold ethanol and incubated. After incubation in –80ºC for 3 hours 
A 
B 
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and spun down, supernatant removed and pellet air dried, probes were resuspended in 14 
µl hybridization buffer and 6 µl nuclease-free water then stored in –20ºC until used. 
Performing FISH with labelled probes    
Fixed cells were dropped onto slides and heated on a hot plate at 60ºC for 5 minutes. 
Three probes labelling the target gene, RP11-92B6, RP11-790H4 and RP11-614D16, 
labelled with spectrum green, and control gene probes, RP11-320G11 (Chr5-32k-2P22) 
and RP11-1259L22, labelled with spectrum red, were mixed equal volume each. Of this, 
2 µl was used to hybridize each drop of cells and covered with round coverslip. Rubber 
glue was put around the coverslips and slides were incubated at 37ºC overnight. 
Following this, the rubber glue and coverslips were removed, slides were placed into a 
coplin jar with 0.4x SSC/0.3% NP-40 at 73ºC for 2 minutes then removed and placed into 
2x SSC/0.1% NP-40 at room temperature for 2 minutes. Slides were then air dried in 
darkness, then 3 µl DAPI was applied to each drop and covered with a coverslip. The 
hybridized cells were visualized under a fluorescent microscope and red (R) and green 
(G) signals were counted in each cell. For each drop of cells, 100 cells were scored for the 
presence of the signal patterns: either 2R2G, 2R1G or 2R0G.  
2.2.1.19 SNP6K Microarray Analysis 
For microarray analysis of L707 presentation and relapse blasts, one vial of cryopreserved 
blasts from engrafted spleen were processed as the previous protocol (section 2.2.1.4) for 
labelling with CD19 human antibodies in combination with CD45 and TER119 mouse 
antibodies for exclusion of murine cells. CD19 cells were sorted by FACS cell sorting and 
DNA was isolated as previously mentioned. DNAs were sent out for microarray analysis 
by Vikki Rand. Raw data received were analyzed using Genome Console software.     
2.2.1.20 Xenotransplantation of Leukaemic Cells  
Animal work was approved and covered by project licence PPL 60/3846. Non-obese 
diabetic/severe combined immunodeficient IL2Rgamma
null
 (NSG) mice were used in all 
animal studies unless otherwise mentioned. Animals were housed in the Comparative 
Biology Centre (CBC) of Newcastle University, where all experimentation with live 
animals was carried out.  
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Animal preparation and intrafemoral leukaemic cell transplantation  
To prepare the animals for implantation of leukaemic cells, mice were anaesthetized with 
an isoflurane/oxygen gas mix (25% isoflurane and 0.5 l O2 per minute) and 50 ng 
carprofen (Rimadyl, Pfizer) per 10 g body weight was injected subcutaneously as an 
analgesic. All leukaemic cell samples were injected into the right femur of NOD/scid 
mice. The femur was punctured with a 27G needle and sample volumes up to 30 μl were 
subsequently injected with a 0.5 ml (30G needle) insulin syringe.  
Primary cells – L707 presentation and relapse cells  
One vial each of frozen stocks of L707 presentation and relapse cells were thawed in a 
waterbath at a temperature of 37ºC. Cells were transferred to universals with 2 μl of 
medium and viable cells were counted using trypan blue exclusion method as described in 
Section 2.2.1.3. Medium was added to a 5 ml volume. Cell suspensions were centrifuged 
at 1500 rpm for 5 minutes and supernatant was removed. Cells were resuspended in an 
appropriate volume of medium for a 20 µl injection into each mouse with required cell 
numbers for xenotransplantation into NSG mice.  
Mix population  
For a competitive clonal repopulation study, mixtures of L707 presentation and relapse 
cells at different ratios were prepared. Frozen stocks of cells collected from the spleen of 
primary transplanted mice were used for this experiment. Each vial of presentation and 
relapse spleen cells were thawed at room temperature. Cells were transferred into 
universal tubes and 10 ml fresh medium RFh10 was added gently to the cell suspensions. 
Suspensions were centrifuged for 1500 rpm for 5 minutes. Supernatant was removed and 
pellet was resuspended in 5 ml medium. Cells were counted and calculated for different 
percentage mixture as shown in Table 2.2 below. Cell mix was prepared for experiments 
with 5 mice each and finally resuspended with medium for 20 μl transplants of 105 cells. 
Mixed cells in 1.5 ml centrifuge tubes were centrifuged for 1 minute at 3000 rpm. 
Supernatant was removed and cells were resuspended in fresh medium.  
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Percentage of cells 
Cells ratio 
Presentation Relapse 
100 0 10P:0R 
90 10 9P:1R 
70 30 7P:3R 
50 50 5P:5R 
30 70 3P:7R 
10 90 1P:9R 
0 100 0P:10R 
Table 2.2  Percentages for mixture of cells in different ratios for transplantations. 
 
2.2.1.21 Fluorescence-Activated Flow Cytometric Analysis of Retrieved Cells 
FACS analysis was performed using antibodies purchased from BD Pharmingen Research 
Products (San Diego, Calif.). Specific antibodies used for common human B-ALL cells 
were as follows: anti-CD10 (fluorescein isothiocyanate-conjugated), anti-CD19 
(phycoerythrin-conjugated), anti-CD20 (peridinin-chlorophyll protein-Cy5.5-conjugated) 
and anti-CD34 (allophycocyanin-conjugated). Mouse antibodies used to label mouse cells 
and mouse erythrocytes were anti-CD45 (phycoerythrin-Cy7-conjugated) and anti-
TER119 (phycoerythrin-Cy7-conjugated) respectively. 
One million cells from thawed stocks of tissue suspensions (refer to section 2.2.1.4) were 
aliquoted into FACS tubes. Cells were washed with PBS twice. Supernatants were 
removed and cells were resuspended in 100 µl PBS. Mixture of antibodies was added to 
each sample: 10 µl CD10, 10 µl CD19, 10 µl CD20, 2.5 µl CD34, 2.5 µl CD45 and 2.5 µl 
TER119. Mixtures were incubated for 20 minutes in the dark with occasional vortex for 
mixing. After 20 minutes, antibodies labeled-cells were washed twice with PBS and 
resuspended in 500 µl for analysis using FACS Canto II machine with the FACS-Diva 
v6.1.2 software. 
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2.2.1.22 Survival Analysis 
Survival curves of the mice engrafted with leukaemic blasts were analysed using Kaplan-
Meier method. Data used were number of days the xenografted animals survived before 
succumbing (endpoint) to the disease. Data were plotted as a percentage of mice 
surviving against number of days elapsed.  
2.2.2 Methods Chapter 4 
2.2.2.1 Restriction Digest of DNA Sequence 
Digestion of DNA sequence was performed to isolate specific target genes from vectors 
or plasmids in molecular cloning. Restriction enzymes used either produce a single cut or 
multiple cuts depending on restriction sites of the enzyme present in the vector. To 
linearize the vector or insert sequence, the same restriction enzymes were used to produce 
the same flanking overhang for the vector and insert. Digestion was performed by adding 
the appropriate buffer, restriction enzymes and DNA as recommended by Fermentas 
webpage. Digestion was performed at 37ºC for 1 hour and enzymes were inactivated by 
increasing the temperature to 80ºC for 20 minutes.    
2.2.2.2 Gel Electrophoresis 
Agarose gel electrophoresis was performed following the technique in Section 2.2.1.16. 
Agarose gel was prepared as 0.8% or 1% agarose in 1x TAE buffer depending on the size 
of vector. Whole volumes of the digested vector and insert were transfered into agarose 
gel wells and electrophoresis was run at 80V until clear cut separated bands were 
produced when viewed under UV light. The correct sizes of band for ligation were 
excised and put into 1.5 ml tubes separately.    
2.2.2.3 DNA Purification by Gel Extraction 
QIAquick Gel Extraction Kit (Qiagen) was used in this protocol. The kit was supplied 
with Buffer QG, buffer PE, Buffer EB, and QIAquick spin columns. To purify DNA of 
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fragments excised from agarose gel, the gel fragments were weighed in colourless 1.5 ml 
tube. 3 volumes of Buffer QG was added and gel slices were incubated at 50ºC for 10 
minutes with 600 unit shaking or until the gel had completely dissolved. For DNA 
fragments < 500 bp or > 4 kb, isopropanol was added at 1 gel volume to increase the yield 
of DNA. The mixtures were transferred into QIAquick spin columns and centrifuged for 1 
minute at 13,000 rpm to bind DNA to the membranes. Flow-through was discarded and 
750 µl of Buffer PE was added to the column to wash the bound DNA. Columns were 
centrifuged at 13,000 rpm for 1 minute and the flow-through was discarded. Columns 
were spun for an additional 1 minute to dry the ethanol from the washing buffer off the 
membrane. 50 µl of nuclease-free water was used to elute the DNA from the membrane. 
2.2.2.4 Ligation of DNA Sequence 
To clone a fragment into a plasmid vector, several ratios of vector:insert DNA were used. 
Normally the ratios used were 1:1, 1:3 and/or 3:1 depending on the type of vector. The 
formula used for calculation of DNA required was as follows. 
 
 
 
Protocol  
T4 DNA Ligase (Promega) was used in this ligation technique. Typically, ligation 
reactions use 100-200 ng of vector DNA. To insert a 500 bp insert into a 3 kb vector in a 
1:1 ratio, for a preparation of 10 µl ligation volume, reaction mixture assembled 1 µl of 
10x Ligase buffer, 1 µl of 100 ng vector DNA, 1 µl of 50 ng insert DNA, 1 µl of 1unit/µl 
T4 DNA Ligase and 6 µl of nuclease-free water. The ligation mix was incubated at 12ºC 
overnight. Some modifications were made in preparing the ligation mixture and 
incubation temperature and duration depending on the success of the following steps in 
cloning.    
ng of vector  x  kb size of insert 
kb size of vector 
molar ratio of 
insert/vector 
ng of insert x = 
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2.2.2.5 Transformation of Competent Cells 
For transformation into competent cells using heat shock technique, 10 μg of the 
lentivector clone DNA or 6-8 µl of ligation reaction mix was added to bacterial strain 
JM109 or Stbl2 with no preference. After 10 minutes incubation on ice, the cells was 
incubated in 42C water bath for 50-60 seconds and immediately immersed into ice for 2 
minutes. 900 µl SOC medium prepared as in Section 2.1.9 was added to the cells and 
incubated at 37C with vigorous shaking for 1 hour. The transformed competent cells 
were spread onto agar plates supplemented with 100 µg/ml Ampicillin. Agar was 
incubated overnight (16-20 hours) in 37C incubator.   
2.2.2.6 Expansion of Cloned Plasmids 
Single colonies of transformed clone were inoculated overnight (16-20 hours) in 5 ml of 
Luria-Bertani broth (refer to Section 2.1.9). The following day, 2 ml of the cultures were 
processed for isolation of DNA using Qiagen Miniprep Kit. The DNAs were digested 
with compatible restriction enzymes for confirmation of lentivector clones with inserted 
sequence. The remainder of the overnight culture from the confirmed lentivector clone 
was cultured in 200-250 ml Luria-Bertani broth for maxiprep preparation with endotoxin-
free Qiagen kit. 
2.2.2.7 Extraction of Plasmid DNA 
For large volumes of endotoxin-free plasmid DNA extraction from cultured broths, 
EndoFree Plasmid Maxi Kit (Qiagen) was used. Cultured broths were transferred into 
several 50-ml polypropylene tubes for easy handling. Bacterial cells were harvested by 
centrifugation at 6000 x g for 5 minutes at 4ºC. Bacterial pellets were resuspended in 10 
ml Buffer P1. 10 ml Buffer P2 was added and mixed gently by inverting tubes 4-6 times 
before incubating the blue viscous lysate at room temperature for 5 minutes. 10 ml of 
chilled Buffer P3 was added to the lysate and was mixed immediately by inverting the 
tube gently for 4-6 times to produce fluffy white precipitates containing genomic DNA, 
proteins and cell debris. Lysate was then poured into the barrel of a QIAfilter Cartridge 
with a screw cap nozzle and incubated for 10 minutes at room temperature. The plunger 
was inserted after the cartridge nozzle was uncapped and the lysate was filtered through 
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the cartridge into a 50-ml tube. Then 2.5ml Buffer ER was added to the filtered lysate and 
was mixed by inversion 10 times before incubating on ice for 30 minutes. During this 
time, a QIAGEN-tip 500 column was equilibrated by adding 10 ml Buffer QBT and 
allowing the column to empty by gravity flow. After incubation, the filtered lysate was 
applied to the QIAGEN-tip and allowed to flow through the resin by gravity. The 
QIAGEN-tip was washed twice with 30 ml of Buffer QC. 15 ml Buffer QN was added to 
elute DNA into a 30-ml endotoxin-free tube. 10.5 ml isopropanol was added to the eluate 
to precipitate DNA and centrifuged at 15,000 x g for 30 minutes at 4ºC. The supernatant 
was carefully decanted. The DNA pellet was washed with 5 ml endotoxin-free 70% 
ethanol and centrifuged at 15,000 x g for 10 minutes. The supernatant was carefully 
decanted and the pellet was dried for 5-10 minutes. The DNA was redissolved in a 
suitable volume of endotoxin-freeBuffer TE. This DNA is suitable to be used in cloning, 
direct transformation into competent cells, transfection and transduction if the DNA has a 
cloned lentivirus.   
2.2.2.8 Hybridization and Ligation of Oligonucleotides 
To generate a lentivirus vector harboring Renilla luciferase reporter gene and red 
fluorescence protein, a 10.2 kb lentivector pHR-SINcPPT-SIEW, a pRL-SV40 vector 
carrying a 947 bp Renilla luciferase gene, and a pcDNA3.1-mcherry(Zeo) vector with a 
724 bp red fluorescence protein (mcherry) sequence in the backbone were used. To 
simplify the transfer of genes of interest, a 76 bp oligonucleotide containing a series of 
restriction enzymes was designed as shown in Table 2.3 below.  
Sense and antisense of the oligonucleotides were hybridized at 95C for 30 seconds in a 
heat block and then left to cool off gradually to room temperature in the block. The 
reaction mixture was prepared in a total volume of 100 µl, with final concentrations of 
0.8x Buffer O (Fermentas), and 10 µM of each sense and antisense oligonucleotides 
prepared at the concentrations of 100 µM each. The annealed oligonucleotides were 
further diluted for ligation with the pBlueScript KS+ vector. 
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SacI – BamHI – Csp45I –N– XbaI – EcoRI –N– NcoI – BglII –N– MunI –N– SalI – XhoI 
Restriction enzymes (RE) RE Sequence 5’– 3’ 
SacI G A G C T C 
BamHI G G A T C C 
Csp45I T T C G A A 
XbaI T C T A G A 
EcoRI G A A T T C 
NcoI C C A T G G 
BglII A G A T C T 
MunI C A A T T G 
SalI G T C G A C 
XhoI C T C G A G 
Table 2.3  Designed oligonucleotides with series of enzymes. N represents random sequence of 4 
nucleotides serves as insertion sites.  
 
For ligating the hybridized oligos into pBlueScript KS+ vector, the vector was prepared 
by digestion with SacI and XhoI restriction enzymes for 1 hour at 37C in a final volume 
of 20 µl. Reaction mixture was prepared as recommended by Fermentas for double 
digestion. The digested mixture was then run for gel electrophoresis with 1% agarose gel 
in 1x TAE buffer (tris-acetate-EDTA) and the expected band was cut out and purified 
using Qiaquick Gel Extraction Kit (Qiagen) following the protocol provided.  
Ligation of annealed oligos and purified digested pBlueScript KS+ was prepared by 
mixing the reagents and DNAs as shown in Table 2.4 below. All reagents used were from 
Fermentas. Mixture was incubated for 3 hours at room temperature and 5 µl of ligation 
mix was used for transformation of JM109 competent cells. The protocol for 
transformation and subsequent steps were standardized and used as detailed in Section 
2.2.2.5. 
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Reaction mix Final concentration 
10x Ligase Buffer  1x 
10nM pBlueScript KS+ digested 2.5 nM 
200nM oligonucleotide hybrid 10 nM 
5U/µl T4 DNA Ligase 5U in 20 µl 
dH2O - 
Final volume 20 µl 
Table 2.4  Mixture of reaction reagents for ligation of oligonucleotides and pBlueScript vector. 
 
2.2.2.9 Blunt-ending  
Blunting of DNA ends involves fill-in 5’-overhangs or/and removal of 3’-overhangs. T4 
DNA Polymerase is a 104 kDa monomer enzyme and a template-dependent DNA 
polymerase in which it catalyzes 5’3’ synthesis from primed single-stranded DNA. The 
enzyme has 3’5’ exonuclease activity but lacks 5’3’ exonuclease activity. The T4 
DNA Polymerase consists of DNA polymerase enzyme supplied in 20 mM potassium 
phosphate (pH7.5), 200 mM KCl, 2 mM DTT and 50% (v/v) glycerol, and 5x Reaction 
Buffer with a composition of 335 mM Tris-HCl (pH 8.8 at 25ºC), 33 mM MgCl2, 5mM 
DTT and 84 mM (NH4) SO4.  
Protocol  
Five micrograms of DNA was linearized with appropriate restriction enzymes and 
compatible buffers in a 20 µl volume. The DNA was digested at 37ºC for 1 hour followed 
by heating up to 80ºC for 20 minutes to stop the reaction enzymes. The linearized DNA 
with overhang ends was blunt-ended by mixing 1 µg of the DNA with 4 µl of 5x reaction 
buffer, 1 µl of dNTP mix with 2 mM of each dNTP and 0.2 µl T4 DNA Polymerase. The 
reaction mixture was prepared in 20 µl volume with addition of nuclease-free water and 
incubated at 11ºC for 20 minutes. The reaction enzyme was inactivated by heating at 75ºC 
for 10 minutes. The blunt-ended DNA was ready for use for ligation in the cloning 
procedure. 
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2.2.2.10 Klenow Fill-in 
Klenow fill-in technique utilizes the DNA Polymerase I Large (Klenow) Fragment 
(Promega) which consists of a single polypeptide chain (68 kDa) that lacks the 5’ 3’ 
exonuclease activity of intact E.coli DNA polymerase I. However, the fragment retains its 
5’ 3’ polymerase, 3’ 5’ exonuclease and strand displacement activities. The 5’ 3’ 
polymerase activity of Klenow Fragment can be used in many applications, which 
include: (a) to fill-in 5’-protruding ends with unlabelled or labelled dNTPs; (b) to 
sequence single- or double-stranded DNA templates; (c) for in vitro mutagenesis 
experiments using synthetic oligonucleotides; (d) for cDNA second strand synthesis; (e) 
to generate single-stranded DNA probes. The 3’ 5’ exonuclease activity is used in 
experiments that require to generate blunt ends from a 3’-overhang. Klenow Fragment is 
active in many restriction enzyme buffers which is useful in which the fill-in reaction can 
be performed directly in the restriction buffer. In the cloning of pSLIEW lentivector, 
Chapter 4 utilizes the applications of Klenow Fragment for filling 5’-protruding ends in 
the presence of dNTPs in the reaction.  
The Klenow Fragment kit consists of Klenow Fragment supplied in 50 mM Tris-HCl (pH 
7.5), 1 mM DTT, 0.1 mM EDTA and 50% (v/v) glycerol, and Klenow 10x Buffer with a 
composition of 500 mM Tris-HCl (pH 7.2) 100 mM MgSO4 and 1 mM DTT.  
Protocol 
Approximately 1 – 4 µg of DNA was digested with appropriate enzymes and buffers to 
generate 5’-overhang. The digestion was prepared in 20 µl volume and incubated at 37ºC 
for 1 hour. Restriction enzymes were inactivated at 65ºC or 80ºC depending on the 
enzyme following manufacturer’s recommendation for 20 minutes. Klenow fill-in 
technique was performed directly in the digestion buffer. One unit of Klenow Fragment 
was used per microgram of DNA in optimal reaction conditions of 50 mM Tris-HCl (pH 
7.2), 10 mM MgSO4, 0.1 mM DTT, 40 µM of each dNTP and 20 µg/ml acetylated BSA. 
The reaction was incubated at room temperature for 10 minutes followed by heating the 
reaction at 75ºC for 10 minutes to stop the enzyme reaction. 
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2.2.2.11 Cell Culture Preparation 
293T cells are embryonic kidney cells of fibroblast morphology and are highly 
transfectable with lentivirus system. These cells are also known as a lentivector producer 
cell line. For transfection purposes, early passages (not more than passage 20) of 293T 
cells are preferable for higher yield of provirus concentration. 293T are adherent cells 
cultured in DMEM media supplemented with 10% FCS. 
To passage the cells cultured in 75 mm
2
 flask, the culture medium was removed and PBS 
was added to the adherent cells to wash the remaining medium off the culture. The 
washing buffer was aspirated, 2 ml of 1x Trypsin was added and the culture flask was 
tapped vigorously to detach the cells from the surface.  Approximately 5 ml culture 
medium was added to neutralize the trypsin reaction. The detached 293T cells were 
mixed in the flask by pipetting up and down to give a single cell suspension. Viable cells 
were counted by trypan blue exclusion method as detailed in Section 2.2.1.3 to prepare a 
culture with appropriate cell counts for transfection purposes. 
2.2.2.12 Transfection of 293T Cells 
293T cells were precultured in a 90 mm culture dish at 2 x 10
6 
cells in 10 ml medium one 
day prior to transfection with lentivirus. Transfection procedures using lentiviral work 
was performed in the Level 2 Biosafety culture hood. Lentivirus was prepared by mixing 
20 μg of lentivectors (pSLIEW or pSRLICW) with 5 μg of envelope plasmid (pMD2.G) 
and 15 μg of packaging plasmid (pCMVdelta8.91) into Hepes buffered water made up to 
250 μl. The mixture was added to an equal volume of 0.5 M CaCl2. The solution was then 
added by dropping slowly into 500 μl of 2x HeBS (0.28 M NaCl, 0.05 M Hepes, 1.5 mM 
NaHPO4) with continuous bubble blowing with pipette in the other hand. The mixed 
solution was allowed to stand for 30 minutes at room temperature in the culture hood for 
CaPO4 precipitates to form. After exactly 30 minutes, the final mixture was added 
dropwise to precultured 293T cells and was incubated overnight in 37C with 5%CO2 
humidified incubator. The following day the culture medium was removed and cells were 
washed once with PBS gently before adding fresh medium and returning to incubator for 
another 3 days.     
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2.2.2.13 Concentration of Lentivirus 
On the third day of 293T cell transfection in Section 2.2.2.12, medium with free lentivirus 
was collected from the culture into a 20-ml Sterilin tube and was centrifuged at 3000 rpm 
for 15 minutes at 4C to pellet the debris. Supernatant was filtered through 0.45 µm 
Acrodisc Syringe Filter to removed remaining debris. The filtrate containing lentivirus 
was concentrated in polyallomer Konical tubes in an ultracentrifuge with swinging 
bucket, at 26,000 rpm for 2 hours. Supernatant was removed and the pellet was 
resuspended in 3 ml medium containing cells to be infected.  
2.2.2.14 Transduction of ALL and AML Cell Lines 
Cells to be transduced (SEM, RS4;11, Kasumi-1 or SKNO-1) were precultured a day 
prior to use. Cells were seeded at 2.0 x 10
6
 cells per well in 6-well plates in 2 ml culture 
medium. 1 ml of concentrated lentivirus was added into each precultured cells and 
polybrene was added for a final concentration of 8 µg/ml. The plates were covered with 
parafilm and the cells were spinoculated at 1500 x g for 2 hours in 32C condition. After 
spinoculation, the culture plates were incubated in CO2-incubator and for an additional 24 
hours. The following day, cells were collected, centrifuged and washed with medium 
once to remove unbound lentivirus and polybrene. Cells were resuspended with fresh 
media and cultured in new 6-well pates for 3-4 days before analyzing for expression 
signals with flow cytometry.  
2.2.2.15 Evaluation of Transduced Cells by Flow Cytometry 
500 µl of cultured-transduced cells were aliquoted into FACS tubes. Cells were washed 
once with PBS and resuspended in 1 ml PBS. Cells were tested using green channel for 
measuring the transduced and non-transduced cells in FACScan Caliber BD.  
2.2.2.16 Sorting of gfp Cells 
Aliquots of 10
7
 transduced cells were spun at 1500 rpm for 5 minutes. Medium was 
removed and cell pellet was washed with PBS and spun again. Cell pellets were 
resuspended in 3 ml of PBS for sorting of gfp+ cells using green channel in 
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FACSVantage cell sorter. Gfp+ cells were sorted into 1 ml medium supplemented with 
2% penicillin/streptomycin. Sorted cells were spun at 1200 rpm for 3 minutes and 
resuspended into 200 µl media with 1% penicillin/streptomycin. Cell suspensions were 
transferred into one well each of 24-well plate and left to recover from sorting. 
Proliferated cells were later transferred into appropriate well or plates. 
2.2.2.17 Luciferase Assay  
Luciferase assay was performed using the Luciferase Assay System (Promega). 
Approximately 10
5
 of transduced cells were aliquoted into 1.5 ml tubes. Cells were spun 
at 13,000 rpm for 1 minute and supernatant was discarded. The cell pellets were washed 
with 500 µl PBS spun again. Supernatant was removed and cells were mixed with 50 µl 
1x Reporter Lysis Buffer. Cells were then incubated at 37ºC for 10 minutes followed by 
freezing down at –80ºC for 20 minutes. The frozen cells were then thawed and 
resuspended well before aliquoting 10 µl into opaque lumi-plate (Wallac). 50 µl of 
substrate reagent was added prior to running plate in Scintillation/Luminometer Counter 
for luminescence count.     
2.2.3 Methods Chapter 5 
2.2.3.1 Growth Curve Study 
Cells were grown in flasks (Corning) or multi-well plates (NUNC, Invitrogen). All cell 
lines used grew in suspension and were incubated at 37ᵒC in a humidified incubators 
(IncuSafe, Sanyo) supplied with 5% CO2. All cell lines used in the experiments were 
routinely grown in their respective medium. SEM and Kasumi-1 were grown in RFh10, a 
RPMI 1640 media with Hepes modification (Gibco) supplemented with 10% fetal calf 
serum (FCS) and 200 µM L-glutamine. SKNO-1 was cultured in RFh20G, a RPMI 1640 
media with Hepes modification supplemented with 20% FCS, 200 µM L-glutamine and 7 
ng/ml GM-CSF. Cells were maintained and subcultured as described in Section 2.2.1.1.  
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Cell line Morphology Medium Subculture  
Doubling 
time 
Source 
SEM 
round to polygonal single 
rather small cells in 
suspension, some cells 
slightly adherent  
RFh10 
every 2-3 days at 0.5 x 10
6
 
cells/ml;  
30 hours 
DSMZ No.: 
ACC546 
Kasumi-1 
 
round cells growing singly 
or in small clumps in 
suspension 
RFh10 
every 3-4 days; at 0.5 x 10
6
 
cells/ml  
48-72 hours 
DSMZ No.: 
ACC220 
SKNO-1 
round cells growing singly 
and in clumps in 
suspension 
RFh20G 
every 3-4 days; at 0.5 x 10
6
 
cells/ml; maintain at about 
0.5-1.0 x 10
6
 cells/ml 
48-72 hours  
Table 2.5  Summary of morphology and maintenance of SEM, Kasumi-1 and SKNO-1 cell lines. 
2.2.3.2 Animal Handling 
Animals were handled according to the approved animal project licence. The immune 
deficient mice were kept in sterile conditions in a specialised room in CBC. Handling of 
animals was carried out in a laminar flow hood using aseptic techniques to avoid 
infections in these mice. Sterile food and water were provided ad libitum. Mice were 
regularly checked for any sign of distress or pain throughout the experiments. Painful 
procedures were handled under anaesthetic condition accompanied by analgesic 
(Carprofen) injection. Suffering animals were humanely killed. 
2.2.3.3 Intraperitoneal Injection (i.p) 
To administer i.p injection, the mouse was held by scruffing the loose skin at the nape of 
the neck and restraining the tail and the leg. A 26G needle was used to inject 150 µl of 30 
mg/ml Rediject D-luciferin (XenoLight, Caliper, USA) into the lower quadrant (left or 
right) of the abdomen. It was acertain that the needle was within the peritoneal cavity 
before slowly injecting the luciferin, ensuring not to penetrate any internal organ. If there 
was a shot of blood coming through the needle, this indicated that the needle had entered 
an organ.        
2.2.3.4 Intrafemoral Injection (i.f) 
For i.f injection, the mouse fur surrounding the knee was shave and sterilized with 
ethanol. The knee was bent and held firmly. The femur was punctured on the upper part 
of the kneecap towards the femoral cavity with a 27G needle and the needle was removed 
without shifting the position of the puncture. Cells were transplanted by inserting a 0.5 ml 
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(30G needle) insulin syringe into the same puncture and volumes of up to 20 μl of desired 
cell concentrations were subsequently injected in to the femoral cavity. 
2.2.3.5 Transplantation of Transduced Leukaemic Cells 
Lentiviral infected cell lines, the SEM, Kasumi-1 and SKNO-1 cells, were stably 
maintained in culture for the procedure. Cells were prepared for transplantation into three 
mice each with 10
6
 cells in every 20 µl injection.  
Animals were anaesthetized and injected intraperitoneally with 150 μl/30 g body weight 
of 30 mg/ml D-luciferin (Caliper Life Sciences, USA) before putting the animals in the 
dark chamber for imaging. After imaging, animals were returned to the cage and 
monitored for regaining consciousness before returning the cage to the racks. Animals 
implanted with lentivirus labeled-cells were imaged weekly for the detection of 
luminescence emitted by transduced cells. 
2.2.3.6 Bioluminescence Imaging 
All imaging was done using IVIS

 Spectrum Imaging System 100 Series (Caliper Life 
Sciences, USA). Images acquired were processed by Living Image

 Software (Caliper 
Life Sciences, USA). For bioluminescence imaging, the imaging system requires a 
photographic image and bioluminescence image. In principle, the photographic image is 
taken in a grayscale mode whereas the luminescence image is in pseudocolor mode. In the 
overlay display mode, the pseudocolor luminescent image is displayed on the associated 
grayscale photographic image. The Living image software automatically coregisters the 
images to generate an overlay image. The luminescence image displayed in pseudocolor 
represents intensity of luminescence emission. A longer exposure time of the subject 
taken in darkness is required to capture low levels bioluminescence emission. When cells 
occur in tissue, photon emission from the tissue surface is called surface radiance 
(photons/sec/cm
2
/sr). The in vivo IVIS Imaging System consists of cooled CCD (charge-
coupled device) camera mounted on a light-tight specimen chamber (dark box), a camera 
controller, a camera cooling system and a Windows computer system for data acquisition 
analysis.  
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Prior to imaging for luciferase activity, transplanted mice are injected intraperitoneally 
with 150 mg/kg of 30 mg/ml Xenolight Rediject D-Luciferin (Caliper LifeSciences Inc., 
Massachusetts, US). Luciferin distributes quickly and easily throughout the animal and 
does not affect the animals deleteriously (no evidence of toxicological or immunological 
effects).  
2.2.3.7 Processing Tissue and Specimen 
Tissue specimens collected from terminated animals in the experiment include spleen, 
liver, kidney and tumour. The specimens are cut into 4-5 mm
3
 pieces then passed through 
a 70 mesh tissue filter and washed with media into a 50-ml tube. Cell suspension was 
transferred into sterilin tube and centrifuged at 1,500 rpm for 5 minutes. Supernatant was 
removed and cells were suspended in freezing medium containing 90% FCS and 10% 
DMSO and aliquoted at 1 ml per cryovial. Cells were cryopreserved in liquid nitrogen for 
future use. Prior to centrifugation, cell suspensions were aliquoted at 100 µl into FACS 
tube for flow cytometry analysis.  
2.2.3.8 Flow Cytometry Analysis of Retrieved Cells 
FACS analysis was performed by labelling cells with specific antibodies for different cell 
lines. SEM cells were labelled with CD133-APC, Kasumi-1 cells with CD34-APC and 
SKNO-1 with CD38-APC in combination with mouse antibodies CD45 and TER119 
conjugated with PE-Cy7 to exclude murine cells. Cells aliquoted from organs as 
described in Section 2.2.3.7 were washed with PBS twice. Cells were spun at 1,500 rpm 
for 5 minutes and the supernatant was removed. Cells were resuspended in 100 µl PBS. 
Mixture of appropriate antibodies was added to specific cells and was incubated for 20 
minutes in the dark with occasional vortex for mixing. After 20 minutes, antibody 
labeled-cells were washed twice with PBS and resuspended in 500 µl for analysis using 
FACS Canto II machine with the software FACS-Diva v6.1.2. 
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CHAPTER 3  
COMPETITIVE CLONAL REPOPULATION OF t(17;19) CELLS 
3.1 Introduction 
Non-random, somatically acquired chromosomal translocations are detected 
cytogenetically in approximately one-half of cases of childhood ALL. One of the major 
classes of these chromosomal translocations is those that create fusion genes and chimeric 
proteins that have structural and functional properties (Raimondi 1993; Hunger, Devaraj 
et al. 1994) such as those that encode transcription factors (Look 1997). Various types of 
chromosome translocation in ALL have been widely studied. One of such cases is the 
childhood ALL translocation t(17;19).    
3.1.1 Translocation t(17;19)(q22;p13)  
The translocation t(17;19) is a recurring chromosomal translocation that is rarely found 
(0.5-1%) in a subset of childhood B-lineage ALL (Ramanujachar 2009). This 
translocation results in an in-frame fusion of the 5’-region, amino-terminal transcriptional 
activation domains 1 and 2 of E2A gene on chromosome 19, and the 3’-region, the 
carboxyl-terminal DNA-binding and protein dimerization domains of leucine zipper and 
basic protein of HLF gene on chromosome 17. The fusion product, E2A-HLF chimeric 
protein, is associated with a poor prognosis (Hunger, Devaraj, et al 1994), and is 
responsible for the pathogenesis of t(17;19)-ALL in that it inhibits lymphoid precursor 
cells from going into apoptosis (Hunger, Devaraj, et al 1994; Takahashi, Goto, et al. 
2001). In addition, the chimeric oncoprotein in its homodimeric form can bind directly to 
promoter/enhancer elements of downstream target genes and abnormally alter the 
expression for the growth, differentiation or survival of early B-cell progenitors and 
contribute to leukemogenesis (Inukai, Inaba et al. 1997).  
To elucidate the mechanism by which E2A-HLF escapes the normal development 
pathway, Inaba et al. has shown that dominant-negative inhibition of E2A-HLF in 
transformed lymphocyte progenitors induces apoptosis (Inaba, Inukai et al. 1996). This 
suggested the E2A-HLF fusion protein increases the number of immature B-lymphocytes 
by preventing their death (Look 1997). Moreover, E2A-HLF blocks apoptosis in mouse 
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pro-B cells deprived of growth factor and inhibits p53-mediated apoptosis triggered by 
ionizing radiation (Inukai, Inaba et al. 1998). Additionally, the block of apoptosis 
imposed by E2A-HLF in pro-B lymphocytes depends critically on the transactivating 
regions of E2A (Dang, Inukai et al 2001) supported by functional transcription factor 
within HLF that promotes survival of the mutated cells (Ikushima, Inukai et al. 1997; 
Altura, Inukai et al. 1998).  
3.1.1.1 E2A 
E2A is an immunoglobulin enhancer binding protein which is also known as transcription 
factor 3 (TCF3). This gene is located on the short arm of chromosome 19 at band p13. 
The E2A gene is comprised of transcriptional activation domains 1 and 2 (AD1 and AD2) 
and basic helix loop helix (bHLH) coding region (Figure 3.1). Basically, the E2A gene is 
a member of the bHLH family. This gene encodes two alternatively spliced bHLH 
transcription factors, the E12 and E47 which is expressed in most cell types.  These 
transcription factors act together in promoting the maturation of B-lymphocytes (Bain, 
Robanus-Maandag et al. 1994; Bain, Robanus-Maandag et al. 1997; Dang, Inukai et al. 
2001). The transactivation domains AD1 and AD2 activate programmed cell death in 
normal cells.  
In human leukaemias, E2A gene is found in two translocations. The t(1;19) which 
generates the E2A-PBX1 chimera, and the t(17;19) that generates the E2A-HLF chimera. 
Both translocations consist of the AD1 and AD2 transactivation domains of E2A fused to 
their respective translocated sites. Therefore, these fusion genes are considered as variants 
of each other (Inukai, Inaba et al. 1998; Dang, Inukai et al. 2001).   
 
 
 
Figure 3.1  Schematic presentation of E2A gene which encodes the basic helix loop helix (bHLH) 
transcription factors E12 and E47 and contains transactivation domains (AD1 and AD2).   
 
E2A       bHLH       AD1   AD2 
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3.1.1.2 HLF 
Hepatic leukaemia factor, also known as HLF, is a human gene normally expressed in 
liver and kidney but not lymphoid cells. This gene is located on the long arm of 
chromosome 17 at locus q22. The HLF gene encodes a member of the proline and acidic 
amino acid-rich (PAR) protein family, a subset of the bZIP transcription factors and 
contains a transcriptional activation domain (TAD) (Figure 3.2). The encoded protein 
forms homodimers or heterodimers with other PAR family members and binds sequence-
specific promoter elements to activate transcription. The bZIP proteins are a major family 
of transcription factors characterized by a highly charged basic region which is 
responsible for DNA binding. An adjacent leucine zipper, the amphipatic α-helical 
domain, mediates protein dimerization (Inukai, Inaba et al. 1998). Chromosomal 
translocations fusing portions of this gene with the E2A gene cause a subset of childhood 
B-lineage acute lymphoid leukaemias. Alternatively spliced transcript variants have been 
described, but their biological validity has not been determined.  
  
 
 
Figure 3.2  Schematic presentation of HLF gene consists of basic leucine zipper (bZIP) transcription factor 
which normally expressed in hepatocytes and, at lower level, in lung and renal cells but not in 
hematopoietic cells, prolin / acidic amino acid rich domain (PAR) and a transactivation domains (TAD). 
 
3.1.1.3 Fusion Gene of E2A-HLF 
As previously mentioned, E2A-HLF is rare occurring in less than 1% of all childhood B-
ALL. It is associated with a poor prognosis and patients with t(17;19) abnormality are 
stratified as very high risk of early refractory relapse (Vora 2006). With the cytology of 
pro-B lymphocytes ALL and a precursor-B cell immunophenotype, the E2A-HLF fusion 
gene anomaly is characterized by expression of the surface markers CD10, CD19, TdT 
and HLA-DR. The morphology presents usually as a balanced translocation 
t(17;19)(q22;p13), however, in some unbalanced cases, the der(19)t(17;19) is observed. 
The E2A-HLF gene encodes 574 amino acids (Inaba, Roberts et al. 1992). 
     TAD PAR   bZIP HLF 
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The hybrid gene involved a fusion between the amino terminal activation domains 1and 2 
of E2A to the carboxyl-terminal leucine zipper and basic domain of HLF (Figure 3.3). 
The fusion gene encodes a chimeric transcription factor E2A-HLF with altered binding 
affinity. In leukaemic cell transformation, the chimera functions as an antiapoptotic 
transcription factor. The E2A-HLF oncoprotein disrupts signalling pathways that are 
normally responsible for cell death, allowing the cells to accumulate as transformed 
lymphoblasts (Inukai, Inaba 1998).   
 
 
 
 
 
 
Figure 3.3  Schematic presentation of hybrid gene E2A-HLF created by fusion of transactivation domains 
(AD1 and AD2) of E2A from chromosome 19 (black dotted line) to the leucine zipper and basic domain 
(bZIP) of HLF from chromosome 17 (blue dotted line). Red arrow indicated breakpoint on chromosome 19 
(E2A) and chromosome 17 (HLF) which generated the E2A-HLF chimera. 
 
Breakpoints in fusion genes generally occur in non-coding introns of each gene. 
Alternative mRNA splicing joins the exons of the two genes together in the same reading 
frame, in which this fusion are translated into functional chimera (Hunger, Devaraj et al. 
1994).       
Two types of E2A-HLF has been described: whereas type 1 fusion is produced by a link 
between exon 13 of E2A and exon 4 of HLF with insertion of a cryptic exon known as 
joining region which maintain the open reading frame, type 2 fusion is generated by a link 
between exon 12 of E2A and exon 4 of HLF in the same reading frame (Figure 3.4) 
(Takahashi, Goto et al. 2001; Inukai, Hirose et al. 2007). The type 1 and type 2 E2A-HLF 
fusion proteins showed similar DNA binding activities but with a slight difference in the 
transcriptional activation properties analysed in in vitro assay (Hunger, Brown et al. 
1994). This was thought may explain the distinct clinical differences between patients 
with these two types of t(17;19)-ALL (Takahashi, Goto et al. 2001). Additionally the type 
     TAD PAR   bZIP HLF 
E2A       bHLH       AD1   AD2 
E2A-HLF   bZIP         AD1   AD2 
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1 E2A-HLF rearrangement is associated with disseminated intravascular coagulation 
(DIC) and type 2 rearrangements are associated with hypercalcemia (Yeung, Kempski 
2006).    
 
 
 
Figure 3.4  Schematic presentations of Type 1 and Type 2 of E2A-HLF fusion gene. Type 1 is 
generated by fusion between exon 13 of E2A and exon 4 HLF with insertion of joining region. Type 2 is 
generated by fusion between exon 12 of E2A and exon 4 of HLF. (Adopted from Inukai, Hirose et al. 
2007).  
 
 
3.1.2 NR3C1 Gene 
The NR3C1 (nuclear receptor subfamily 3, group C, member 1) gene, or commonly 
known as glucocorticoid gene, encodes protein for glucocorticoid receptor (GR). This GR 
protein has two functions: (1) as a transcription factor that binds to glucocorticoid 
response elements (GRE) in the promoters of glucocorticoid responsive genes to 
modulate their transcription, and (2) as a regulator of other transcription factors (Rhen 
and Cidlowski 2005; Lu, Wardell et al. 2006).  
As previously mentioned, the GR is typically found in the cytoplasm until it binds with 
ligand glucocorticoids (GCs), which induce transport of the GR into the nucleus. This 
protein can also be found in heteromeric cytoplasmic complexes along with heat shock 
proteins and immunophilins. It is involved in inflammatory responses, cellular 
proliferation, and differentiation in target tissues. Mutations in this gene are a cause of 
generalized glucocorticoid resistance. 
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3.1.3 Dexamethasone Treatment in Mouse Model of Childhood 
Leukaemia 
A few studies have developed childhood ALL in vivo by xenograft in mice models and 
retrieved the engrafted cell for dexamethasone sensitivity assays in vitro (Bachmann, 
Gorman et al. 2005; Igarashi, Medina et al. 2005; Bachmann, Gorman et al. 2007). 
Although these studies could guide the in vitro growth inhibition assay, in this chapter, 
the in vivo blasts sensitivity to drug treatment requires other similar experimental 
evidence.   
A number of studies have reported on established xenograft of childhood ALL in mouse 
models and assessment of their in vivo sensitivity to dexamethasone (Liem, Papa et al. 
2004; Kang, Kang et al. 2007; Bhadri, Cowley et al. 2010; Bonapace, Bornhauser et al. 
2010).  
In Liem et al. study, tertiary inoculation of four cases of ALL blasts in NOD/SCID mice 
was treated with 15 mg/kg dexamethasone for 5 days a week for 4 weeks, when the 
engraftment reached 1% in peripheral blood. As a result, dexamethasone prolonged 
survival of mice in all four tested ALL blasts, although with different responsive capacity 
(Liem, Papa et al. 2004). Another study by Kang et al. used a combination of drugs, 
vincristine (0.15 mg/kg), dexamethasone (5 mg/kg) and L-asparaginase (1000 IU/kg) in 
secondary inoculation of patient ALL blasts at diagnosis and relapse in NOD/SCID mice. 
Treatment was given for four consecutive weeks on a 5 days per week basis. Combined 
with a small molecule (ABT-737) that inhibits antiapoptotic Bcl-2 family protein 
overexpressed in leukaemia, VXL treatment greatly delayed the progression of both 
diagnosis and relapse blasts in mice (Kang, Kang et al. 2007).   
Bhadri et al. xenografted NOD/SCID mice with ALL blasts from a child with B-cell 
precursor ALL and injected dexamethasone at 15 mg/kg when engraftment reached more 
than 50% to investigate GC-induced gene expression. Thereafter they harvested blasts 
from spleen in serial durations within 0 to 48 hours and reported that at the 8 hour 
timepoint, gene set enrichment analysis showed significant upregulation of genes in the 
catabolic pathways and down regulation of genes in the pathways associated with cell 
proliferation (Bhadri, Cowley et al. 2010). In the same year, Bonapace et al. in their 
studies transplanted NSG mice with primary ALL blasts recovered from first 
xenotransplantation. Similar to the study by Kang et al., a significant delay in leukemia 
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progression was achieved when Bonapace et al. injected 5mg/kg dexamethasone into the 
secondary xenografted mice for 5 days per week for 3 consecutive weeks, in combination 
with a small molecule obatoclax that inhibits antiapoptosis Bcl-2 family protein 
(Bonapace, Bornhauser et al. 2010).  
In this chapter, we selected NSG mice as a model for leukemia cell engraftment, which 
has been in practice in our group and for the reasons explained in chapter 5 (Section 
5.1.1). NSG mice lack B, T and NK cells which give the advantage of xenotranplantion of 
human leukaemic cells without rejection or decreased engraftment compared to 
NOD/SCID mice. In addition, in one study the investigators engrafted HSC in 
NOD/SCID and NSG mice to compare the reconstitution capacity of the stem cells in 
both models. They reported that both NOD/SCID and NSG models adequately supported 
human HSC reconstitution and in vivo-selection in the primary recipient mice, but the 
NSG mice were far superior to the NOD/SCID model for secondary reconstitution (Cai, 
Wang et al. 2010). For glucocorticoid treatment, dexamethasone administration in mice 
was given following the work of Liem et al. who reported on survival of ALL-cell 
engrafted-mice. As part of the study within this chapter evaluates the survival of 
engrafted mice, the mice will be given 15 mg/kg dexamethasone for 4 consecutive weeks 
on a 5 day a week basis.       
3.1.4 Case Study 
In this chapter, the experiments performed were based on a single case with a matched 
pair of diagnosis (presentation) and relapse cells from the same patient. The 16 year old 
female patient was diagnosed with B-cell progenitor (BCP) ALL. Cytogenetic analysis 
confirmed that the patient presented with a t(17;19) with white blood count of 39.1x10
9
 
cells/L. Cytogenetic analysis also confirmed that the patient had der(19)t(17;19), an 
unbalanced form of the translocation. The presentation karyotype of the patient was 
46,XX,der(19)t(17;19)(q2?;p13)[12]/46,idem,fra(10)(q25)[17]/46,XX[1].ishder(19)t(17;19)(19ptel-,wcp17+,wcp19+,19qtel+) 
and the relapse karyotype was 46,XX,der(19)t(17;19)(q2?;p13)[5]. The patient was treated on 
regimen B of ALL2003 and achieved MRD (minimal residual disease) after 28 days. 
However, she suffered from relapse within 5 months from first diagnosis and despite 
treatment given (R3 and then FLAG) it was not possible to reinduce remission. The 
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patient developed encephalopathy and deceased post-intracranial bleed after 2 months of 
relapse.     
This chapter details the xenograft of paired presentation and relapse blasts from this 
patient in NSG mice and evaluates the clonal expansion and progression of the disease by 
single as well as combinations of the blasts in various proportions. Dexamethasone was 
used to measure the effects on clonal expansion. 
3.2 Results 
3.2.1 Dexamethasone response in cell 
3.2.1.1 Growth curves for cell lines 
Growth curves of the cell lines were generated to determine the growth characteristic of 
the cells in vitro and to determine the optimal growth duration for the subsequent drug 
toxicity assays.  
HAL-01, REH and PreB 697cell lines were cultured in their respective medium as 
described in Material and Methods Section 2.2.1.10, with initial seeding density of 0.5 x 
10
6
 cells/ml. Cell growth was counted daily for 7 consecutive days using trypan blue 
exclusion method as described in the Section 2.2.1.3, without changing of medium 
throughout the experiment. The characteristic growth curves obtained for the cell lines is 
shown in Figure 3.5, with each cell lines showing a lag, exponential and plateau phases.  
All three cell lines showed a normal growth curves with a short lag phases followed by a 
long exponential phases and cells started to reach plateau phases after 96 hours (4 days) in 
culture. This was chosen as the optimal time for drug exposure in the following 
dexamethasone cytotoxicity assays.  
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Figure 3.5  Growth curves of HAL-01, REH and PreB 697 cell lines. HAL-01 cell was grown in RPMI 
1640 with Hepes modification medium supplemented with 10% FBS (v/v) and 2 mM L-glutamine (v/v). 
REH and PreB 697 cells were grown in RPMI 1640 medium supplemented with 10% FBS (v/v). Cells were 
seeded at 0.5 x 10
6
 cells/ml at the start of experiment and cell growth was counted daily for 7 consecutive 
days using Neubauer hematocytometer counting chamber with trypan blue exclusion method as describe in 
Materials and Methods. The data presented are mean ± s.e.m of three independent experiments. 
 
3.2.1.2 Growth inhibition by dexamethasone 
To determine the glucocorticoid-sensitivity in the cell lines and the L707 presentation and 
relapse cells of t(17;19) studied in this chapter, dexamethasone cytotoxicity was carried 
out as described in Materials and Methods Section 2.2.1.10. Briefly, cells in exponential 
phase of the growth cycle were harvested and the viability of the cells prior to the assay 
was determined using trypan blue exclusion method as mentioned earlier (Section 
2.2.1.3). In this experiment, cells were seeded in flat-bottomed 96-well plates in 
triplicates. For all cell lines, cells were seeded at a density of 1 x 10
5
 cells/well while the 
seeding density for patient presentation and relapse cells from xenotransplantation were 1 
x 10
6
 cells/well. These seeding densities of cell lines and ‘primary’ patient cells were 
determined by Julie Irving’s group earlier (Lindsay Nicholson 2008). All cell lines and 
the L707 cells were exposed to an increasing concentration of dexamethasone or a vehicle 
control (0.05% ethanol) for 96 hours as described in Section 2.2.1.9. The cells viability 
was measured using Cell Proliferation Assay WST-1 and data was calculated as a 
percentage of vehicle control-treated cells.     
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Figure 3.6  Growth inhibition by dexamethasone. The effect of dexamethasone on cell viability was 
assessed using Cell Proliferation Assay WST-1. The viable number of cells at each concentration of 
dexamethasone was calculated relative to vehicle control-treated cells. Data were presented as mean of at 
least two independent experiments.   
 
The PreB 697 cell line is known to express high glucocorticoid receptor (Geng and 
Vedeckis 2011) while REH and HAL-01 cell lines have impaired express of the receptor 
(Bachmann, Gorman et al. 2007). Therefore, as expected, the PreB 697 cell line was 
highly sensitive to dexamethasone treatment in which REH and HAL-01 cell lines were 
resistant and had no response to (Figure 3.6). For the L707, presentation cells expressing 
glucocorticoid receptor were sensitive to dexamethasone treatment however, with less 
effective than the PreB 697 cell line whereas relapse with deletion on glucocorticoid 
receptor gene (explained in this chapter section 3.3.4) had no effect on the treatment.    
3.2.2 Engraftment of t(17;19) in mice  
3.2.2.1 Primary and secondary xenotransplantation of L707 into NSG mice  
In order to understand the clonal expansions and kinetics of patients with t(17;19) 
malignancy in vivo, studies using xenograft mice model is the best way to elucidate this 
phenomenon. Mouse work experimentation was covered partially by grant no. 
LREC06/Q0906/79 and was under approved of R&D Project No.07/H0906/109, funded 
by Leukaemia and Lymphoma Research Fund and sponsored by The Newcastle upon 
Tyne Hospitals NHS Foundation Trust. Animals were housed and worked on in the 
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Comparative Biology Centre (CBC) of Faculty of Medical Sciences, Newcastle 
University.   
Frozen cryopreserved stocks of match paired primary materials from the patient were 
obtained from Newcastle Haematology Biobank. The bone marrow samples were 
assigned as L707 presentation and relapse blasts. Viable cells were assessed by trypan 
blue exclusion method to determined number of cells to be transplanted in mice. The 
L707 presentation and relapse cell were pelleted and resuspended in appropriate volume 
of RF10 medium. Cells were implanted directly into the femur of 8–10 weeks old female 
NSG mice by intrafemoral injection (Figure 3.7). This orthotopic injection has been 
implemented in our group (Josef Vormoor’s and Olaf Heidenreich’s) because of the much 
improved engraftment since the cells are transplanted into their natural environment in the 
bone marrow. All transplantation work in this study was performed by Mike Batey and 
Klaus Rehe. Preparation of cells and animals for transplantation were as detailed in 
Materials and Methods Sections 2.2.1.20       
 
 
 
Primary transplantation 
From the cryopreserved bone marrow stocks supplied, viable patient primary material 
available were 6 x 10
5
 presentation blasts and 4.5 x 10
6
 relapse blasts. For primary 
transplantation, with available viable L707 blast cells, 20 µl of 2 x 10
5
 presentation cells 
and 20 µl of 1.5 x 10
6
 relapse cells were transplanted into 3 mice each to expand the cells 
excessively for modulation in future. The mice were monitored daily for progression of 
the disease. Unexpectedly, mice engrafted with presentation cells succumbed to the 
 Figure 3.7  Route of leukemic cell transplantation.  
       Intrafemoral injection (i.f) into a mouse femur.  
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disease earlier than those with relapse cells, despite the low number of cells initially 
transplanted. Mice xenotransplanted with presentation cells showed severe manifestation 
of the disease after 6 to 7 weeks, where all three mice in this group were lethargic and had 
total loss mobility of their hind limbs. They were humanely killed at day 43, 44 and 51. 
At week 8, mice implanted with relapse cells were severely engrafted when animals 
looked pale and were lethargic. All relapse mice had significant enlargement in the right 
legs, at site of implantation. However, other than difficulty moving the right leg due to 
this enlargement, mice engrafted with relapse cells did not show lost mobility of their leg 
compared to that displayed by mice engrafted with presentation cells. All 3 mice were 
killed at day 59 post xenograft. All animals were killed after consultations and as adviced 
by CBC Animal Care personel. Bone marrows from the femurs of all mice were flushed 
out and organs grossly showing infiltration were collected.  
In both groups, the spleens of all the engrafted mice were noticeably enlarged, 
approximately 4-5 times from the normal size with weight ranging between 400 mg to 
600 mg. The normal spleen was collected from non-transplanted mouse, weighing 
approximately 100-120 mg.  In the relapse cell engrafted group, surprisingly mice showed 
infiltration of the ovaries, which was not seen in presentation cell engrafted mice. These 
organs appear whitish and rubber-like hard and with the size 5-6 times larger than the 
normal size. The ovaries and other possibly infiltrated organs including kidneys with 
white spots and gastric lining which appeared whitish in both groups (but not all mice), 
and the leg tumours in relapse mice were also collected for analysis. Organs were 
processed for immunophenotyping and cell suspensions aliquots were cryopreserved for 
future use.  
 
Secondary transplantation 
The subsequent secondary transplantation of the presentation and relapse L707 cells were 
also done by randomly selecting frozen stocks of bone marrow sample from primary 
engraftment. For both presentation and relapse L707 cells, three mice of each group were 
xenotransplanted with the same number of cells, 5 x 10
5
 blast cells each. After 6 weeks 
post xenograft, mice with presentation cells were severely engrafted, showing similar 
conditions with the ones in primary xenotransplantation, with lethargy and loss mobility 
of hind limb. Mice in relapse group were engrafted and killed after 8 weeks and also 
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displayed similar conditions with the mice in primary implant except without leg tumour. 
This showed that the leg tumour seen in the primary relapse was due to excess cells 
implanted into the femur which was thought to overspill into the femoral cavity to the 
surrounding vicinity and overgrown as tumour. Bone marrow and spleens of these mice 
were collected for analysis and cryopreserved. Mice engrafted with relapse cells also had 
enlarged ovaries (not seen in presentation mice), which were collected as well. Other 
organs were not collected due to random infiltration of the blasts cells.  
Another subsequent secondary transplantation was carried out using randomly selected 
cryopreserved spleen suspensions from primary engraftment. In this secondary 
transplantation, various combination ratios of presentation and relapse L707 cells were 
carried out to study the competitive repopulation of the clones, which is explained later in 
Section 3.3.5.   
3.2.2.2 Morphology of engrafted cells 
Blasts cells retrieved from bone marrow and spleen of primary engraftment were stained 
for morphological analysis as detailed in Materials and Methods Section 2.2.1.8, for 
comparisons with the patient primary biopsies (Figure 3.8). Initial patient presentation 
and relapse biopsies were stained and scored by Lynne Minto from Julie Irving’s group. 
The biopsies showed high population of blast cells identified as large nucleus and ring of 
cytoplasm in which patient presentation biopsy was accounted for 99% blasts cells 
(Figure 3.8A) and relapse biopsy indicated 97% of blast cells (Figure 3.8B). For blast 
cells retrieved from xenograft bone marrow, however cytospin failed to produce good 
quality of cells for staining after several repetitions. This was abandoned due to 
preserving limited primary xenograft materials for subsequent xenograft purposes. Figure 
3.8 C and D showed high population of match blast cells retrieved from engrafted spleens 
with similar morphologies to that of corresponding patient’s biopsies.  
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Figure 3.8  May-Grünwald-Giemsa stain of L707 blast cells. Patient bone marrow at presentation, A, 
with high blast cells accounted for 99%, and patient bone marrow at relapse, B, with blasts count of 97%. 
Presentation blasts in spleen of an engrafted mouse, C. Relapse blasts from spleen of an engrafted mouse, 
D. b = blast cell or group of blast cells; r = red blood cell in vicinity. 400x magnification. 
 
3.2.2.3 Infiltrated organs  
As mentioned in Section 3.3.2.1, the engrafted spleen and ovaries were enlarged 
compared to normal condition of the tissues. Figure 3.9 showed gross anatomy of the 
tissues mentioned. Whereas the normal spleen was small with healthy dark red colour, the 
enlarged spleen was 4 to 5 times larger measuring 25 mm x 8 mm and appeared paler and 
whitish indicating high infiltration of blast cells (figure 3.9 A and B respectively). The 
normal ovaries taken from control non-transplanted mice (Figure 3.9C) measuring 
approximately 2 mm x 2 mm were relatively smaller than the highly infiltrated ovaries 
which appeared white and measuring 7 mm x 9 mm (Figure 3.9D). Ovaries from the 
presentation mice were similar to those of control normal mice. Figure 3.9E showed 
uneven size of ovaries collected from mixed population studies. However, this 
phenomenon was only seen in three mice (8.6%) which was thought to be a random 
occurrence.  
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Figure 3.9  Infiltrated spleen and ovaries. Enlarged spleen and ovaries grossly noted in the blasts 
engrafted organs. (A) A normal spleen from a non-transplated mouse, and (B) an enlarged spleen which 
appears paler, which is similarly seen in both presentation and relapse engrafted mice. (C) Normal ovaries 
from a non-transplanted mouse, (D) evenly enlarged relapse ovaries and (E) uneven enlargement of ovaries 
collected from mouse engrafted with mixed population. 
 
3.2.2.4 Immunophenotyping of engrafted cells by flow cytometry 
Blasts cells retrieved from bone marrow, spleen and other infiltrated organs were labelled 
with conjugated human antibodies CD19-PE, CD10-FITC, CD20-PerCP-Cy5.5 and 
CD34-APC to determined immunophenotype of the blast cells. To distinguish and 
exclude mouse cells from human blasts, murine antibodies, CD45- and TER119-PE-Cy7, 
were added in combination with the human antibodies.  
Flow cytometry analysis of presentation blasts retrieved from bone marrow and spleen 
were as shown in Figure 3.10. Human blast cells were gated out from mouse cells in the 
histogram graph and to ensure only human cells were counted for, this cell population 
was further purified in the dot plot graph by setting the threshold and gate on blast 
population (Figure 3.10 A and C). Dot plot graphs in Figure 3.10 B and D showed high 
populations of blast cells populating the bone marrow and especially highly depositing in 
the spleen. These dot plots graphs indicated the presentation blasts as high CD10 and 
CD19 expression, low or non-CD20 and non-CD34 expressing blasts.   
 
A B 
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Figure 3.10  Flow cytometry analysis of engrafted L707 presentation blast cells. Histogram and dot plot 
graphs showed gating of the blast cells in bone marrow (A) and spleen (C). Dot plot graphs (B and D) 
showed blast cells were expressing CD10 and CD19, low or non-expressing CD20 and non expressing 
CD34. 
A 
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Figure 3.11 showed flow cytometry analysis of relapse blasts isolated from the bone 
marrow and spleen of an engrafted mouse. Similar gating was applied as those with the 
presentation cells. Relapse blasts showed similar pattern of phenotypic markers as those 
with presentation blasts. This indicated the relapse cells had no changes 
immunophenotypically from presentation cells. Figure 3.11 B and D showed high 
populations of blast cells populating the bone marrow and infiltrating spleen of a 
xenografted mouse. Detailed percentages of blasts analyzed by flow cytometry are as 
presented in Appendix 1. 
These flow cytometry analysis results were similarly seen in primary xenograft, 
subsequent secondary xenograft and secondary xenograft with mixed populations of the 
presentation and relapse cells. These flow analysis results distinguished the L707 blast 
cells with a typical CD19
+
CD10
+
CD20
-
CD34
-
 immunophenotype. In normal 
hematopoietic conditions, Rimsza et al. (2000) has stated that B-blast cells are CD34+, 
CD10+, CD19+ and CD20- (Rimsza et. al. 2000). 
As mentioned in Section 3.3.2.1 and shown in figure 3.9 (D and E), ovaries of the relapse 
blast xenografts were persistently infiltrated with blast cells resulting in enlarged tumoric 
tissue. Mice xenografted with the primary relapse cells were presented with leg tumour, 
thickened and whitish gastric lining and pale kidneys. Flow cytometry analysis of cells 
isolated from these tissues was as shown in Figure 3.12. Histogram A and B showed high 
population of blast cells in the leg tumour and the ovaries with more than 95% of the 
populations were relapse blast cells. This clarifies our thought that the xenografted cells 
overfilled the bone marrow cavity and filled the surrounding cavity that produce tumour. 
The ovaries and the tumour were frozen and stored as high percentage of blast cells. 
Histogram C and D showed analysis of cells from kidneys with low infiltration and 
stomach lining with 80% blast cells infiltration. However, gastric lining infiltration was a 
random occurrence since subsequent xenotransplanted mice showed no similar findings.  
All presentation cell xenotransplanted mice, as mentioned previously, had lost mobility of 
their hind limbs towards the end point. As this condition was thought to involve the CNS, 
the spinal cord distal to the brain stem of a mouse was removed. As expected, the spinal 
cord was affected by populating blast cells as shown in flow cytometry analysis in Figure 
3.13. The populations in red in the dot plot graphs showed the blasts cells from the brain 
stem.       
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Figure 3.11  Flow cytometry analysis of engrafted L707 relapse blast cells. Histogram and dot plot 
graphs showed gating of the blast cells in bone marrow (A) and spleen (C). Dot plot graphs (B and D) 
showed blast cells were expressing CD10 and CD19, low or non-expressing CD20 and non expressing 
CD34.  
A 
B 
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Figure 3.12  Flow cytometry analysis of infiltrated tissues in L707 relapse blasts engraftment. 
Analysis of relapse xenografted mice showed: High population of blast cells in leg tumour (A) and ovaries 
(B). Kidneys has low infiltration (C) and stomach lining has infiltration (D).  
 
 
 
Figure 3.13  Flow analysis of L707 presentation infiltration in spinal cord. The presence of presentation 
blast cells (in purple) in spinal cord could explain condition of lost mobility in these mice. 
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3.2.3 Identifying type of t(17;19) fusion by RT-PCR 
As Inukai et al. (2007) has reported, there are two types of E2A-HLF fusion in t(17;19) 
malignancy which involved either exon 13 of E2A fused to exon 4 of HLF (Type 1) or 
exon 12 of E2A fused to exon 4 of HLF (Type 2), as explained in the Introduction in this 
chapter. To identify the type of fusion the L707 bear, the techniques and protocol used by 
Inukai et al. were implemented.  
RT-PCR was performed on complementary DNA (cDNA) of RNA isolated from patient 
L707 primary presentation (P pt) and relapse (R pt) cells and cells retrieved from 
xenografted mice (P and R) using the primers that were homologous to sequences in E2A 
exon 12 and exon 13, and HLF exon 4 as detailed in Materials and Methods Sections 
2.2.1.12 to 2.2.1.16.     
Figure 3.14 showed agarose gel analysis on the amplified gene with fusion between exon 
13 and exon 4 (gel A) and fusion between exon 12 and exon 4 (gel B). Bands produced in 
gel A confirming that the L707 cells is a Type 1 t(17;19) malignancy. No band was 
produced in gel B with primers which was confirmed functional prior. HAL-01 cells (H) 
was used as a positive control since this cells was confirmed bearing the Type 1 fusion.  
Although the L707 was confirmed having the Type 1 E2A-HLF fusion, there were three 
bands produced by the L707 cells differed from that of HAL-01 with only a single band 
was amplified. This was thought to be due to the joining region present within the fusion 
(refer to Figure 3.4). To confirm the fusion, excised bands were sent for sequencing 
(Gene Service, Cambridge). However, due to time constraint and limited time, Vikki 
Rand is continuing this work onwards.  
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Figure 3.14  Representative analysis of RT-PCR amplification of E2A/HLF. Total RNA were isolated, 
cDNA were generated, PCR performed using primers of exons 4, 12 and 13. Primary presentation and 
relapse blasts from patient and corresponding mice engrafted cells were processed identifying 
L707/t(17;19) as Type 1. Primers from exon 13 or exon 12 of E2A and exon 4 of HLF were used. H, HAL-
01 cell line; Ppt, presentation cells from patient; Rpt, relapse cells from patient; P, xenografted presentation 
cells; R, xenografted relapse cells; C, control without DNA  
 
3.2.4 Genetic changes identification using Affymetrix SNP 
microarrays 
Affymetrix microarrays platform is used in determining the copy number alteration in 
human whole genome. The paired L707 blast cells used in this chapter were subjected to 
the analysis.     
DNA from paired primary presentation and relapse cells as well as the matching DNA 
from xenografts were isolated according to Materials and Methods Section 2.2.1.11. 
Presentation and relapse cells were labelled with human CD19 antibody sorted for CD19+ 
using FACS cell sorter (FACVantage). Figure 3.15 showed dot plot graphs of 
presentation cells (A) and relapse cells (B) sorted by the cell sorter FACS. Both cell 
populations were gated to exclude murine cells in the pre-sort graphs. Sorted cell were 
short run through FACS in post-sort graphs to confirm purity of sorted cells. DNA of the 
presentation and relapse cells were extracted and were sent for genotype analysis. This 
work was undertaken by Vikki Hall. 
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Figure 3.15  FACS sorting of CD19+ cells for microarray analysis. L707 presentation and relapse cells 
isolated from spleen from engrafted mice were processed and labelled with human anti-CD19 antibody in 
combination with murine anti-CD45 and anti-Ter119 as detailed in Materials and Methods. Dot plot graphs 
from FACS cell sorter shows pre-sort (left panel) and post sort (right panel) of presentation blast cells (A) 
and relapse blast cells (B). CD19-labelled blast cells were gated in the pre-sort to exclude mouse for sorting 
human blast cells population. Sorted cells were short run through FACS for confirmation of blast cells 
isolation.      
 
Whereas the primary samples from patients earlier (in 2005) were hybridized on 
Affymetrix Human Mapping 500K Array Set according to the manufacturer's protocols 
(performed by Geneservices, Cambridge, UK), the matching xenograft DNA samples 
were hybridized on microarrays from Affymetrix Genome-Wide Human SNP Array 6.0 
performed by Atlas Biolabs GmbH.  
To analyse the data, Andy Hall and Vikki Rand carried out the analysis and provided the 
region of interest for this study. Raw intensity data from primary materials were analyzed 
using Affymetrix Genotyping Console v4.0 for quality control and Partek Genomic Suite 
v6.5 (Partek Incorporated) to determine paired DNA copy number alterations, the 
xenograft raw data were analyzed using Partek Genomic Suite v6.5 for copy number and 
A 
B 
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segmentation analysis. Regions of the aberration were mapped according to the human 
reference sequence GRCh37. 
Figure 3.16 showed data processed using Affymetrix Genotyping Console v4.0 on 
chromosome 5. Results obtained showed a deletion occurred in this chromosome at 
5q31.3–q32 in relapse cells (green histogram) which was not present in presentation cells 
(blue histogram).  
Figure 3.17 showed comparison between dot plot data from array analysis on 
chromosome 5 between paired patient primary presentation and relapse blasts (A) and the 
matching xenografts data (B). The deleted region on relapse cells occurred from location 
141.9 Mb to 143.6 Mb on the chromosome (C) as determined from the analysis software. 
The deleted location were run through Ensembl Human Genome Archive (Ensembl 54: 
May 2009) website. Figure 3.17D showed the deleted region in chromosome 5 affected 
the NR3C1 (nuclear receptor subfamily 3 group C member 1) gene located in the middle 
of the region (blue box). NR3C1 is an intracellular glucocorticoid receptor gene, which 
plays a major role for binding steroids to the nucleus. Deletion of this particular steroid 
receptor gene is responsible for the immunochemo-resistance in relapse cells.       
 
 
Figure 3.16  Raw data processing software Affymetritrix Genotyping Console. Analysis on 
chromosome 5 displayed histogram of presentation cells (top, blue) and relapse cells (below, green) 
showing deletion on relapse cells. Red bar with arrows (below) mapped the downregulation of the region. 
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Figure 3.17  Relapse specific deletion on chromosome 5. (A) Array analysis on patient presentation and 
relapse cells. (B) Array analysis on presentation and relapse cells xenografted mice. Deleted region 
identified in relapse cells in A and B was mapped to chromosome 5 to identify the length of the region, C, 
and deleted region was searched in Ensembl website for chromosome 5 which displayed the deleted region 
encompassing NR3C1 gene (blue box), D. 
 
3.2.5 Evaluation of competitive repopulation of t(17;19) mix cells in 
vivo 
In this section, NSG mice were xenotransplanted with combination or mix L707 
presentation and relapse blast cells at different ratios to determine which clone has greater 
advantage in expanding and repopulating in vivo. All intrafemoral transplantation of blast 
cells was performed by Mike Batey and Klaus Rehe. Effect of dexamethasone treatment 
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on the repopulation of cells was also studied on the similar mixed populations of cells at 
similar ratios. The ratios of the mix cell populations were as shown in Table 3.1. For the 
dexamethasone treated study, ratios of 90% and 10% presentation cells were omitted. 
Five mice were used in each combination ratio. A 100% presentation (10P:0R) and 100% 
relapse (0P:10R) cells were also included in the mix population study as comparison. 
Each mouse was transplanted via intrafemoral injection with 1 x 10
5
 blast cells which 
were retrieved from primary xenograft of patient’s primary presentation and relapse 
leukaemic cells in NSG mice prior. After the cells were engrafted, animals with severe 
manifestation of the disease were humanely killed and bone marrow and spleen were 
collected to retrieve the engrafted leukaemic cells. 
 
 
Cells implant in mice 
(100,000
 
cells each) 
Ratio of cells 
100% P 10P:0R 
90% P + 10% R 9P:1R* 
70% P + 30% R 7P:3R 
50% P + 50% R 5P:5R 
30% P + 70% R 3P:7R 
10% P + 90% R 1P:9R* 
100% R 0P:10R 
 
Table 3.1  Ratios of combination cells transplanted into mice in mix population studies.  
P=presentation cells; R=relapse cells. * indicates ratio omitted in dex-treated groups. 
 
For the dexamethasone (Dex) treated groups, peripheral blood of randomly selected mice 
were collected on day12 post xenograft and were analysed for engraftment of blast cells. 
Figure 3.18 showed the flow cytometry analysis of peripheral blood of three mice. Figure 
3.18A showed a low engraftment of blast cells was detected in a mouse with 10P:0R 
(100% presentation cells). Therefore, it was decided for Dex treatment to commence on 
day 14. Treatment was administered via intraperitoneal injection on a five days a week 
basis for four weeks. At the end point of the mice where the xenografted mice in this 
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group were killed, none of the mice was presented with loss of hind leg mobility as seen 
in the xenografted mice in the non-treated group. However, all mice showed extreme 
lethargy, pale, immobolized and weight loss of almost 20% at the time of sacrificed. Mice 
were killed as advised by the CBC Animal Care personnel. The femur of almost all 
xenografted mice in Dex-treated group was noticeably fragile, making bone marrow 
collection difficult. This condition was not seen in the untreated group.    
 
 
Figure 3.18  Flow cytometry analysis of peripheral blood on day 12 post xenograft. Peripheral blood 
was isolated from random mice on day 12 to analyse for engraftment before starting dexamethasone 
treatment on day 14. Low engraftment of was detected in presentation cells (10P:0R) xenografted mice A.  
No engraftment was seen in mix population (5P:5R ) B, and relapse cells (0P:10R) xenografted mice C.    
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3.2.5.1 Survival analysis 
The survival of the mice following engraftment was estimated using Kaplan-Meier 
analysis. The starting point was the start of leukaemic cell inoculation in mice, which is 
the day 0 of intra femoral xenotransplantation of L707 cells, and the end point was the 
day the mice was killed depending on the severity of illness due to the disease, following 
guidelines from CBC. At the end point of each mouse in the mix cell populations study, 
percentages of survival after mix cells engraftment were analyzed. Figure 3.19 showed 
Kaplan-Meier curves of survival rates of mice engrafted with mix populations of L707 
without treatment. Mice engrafted with L707 relapse cells (0P:10R) survived significantly 
longer than those with presentation cells (10P:0R) (p=0.0034, log rank test) (A), while 
survival rate for mice with different ratios of the mix cells fall in between the two curves. 
Mice engrafted with ratios of 9P:1R and 1P:9R both survived significantly shorter than 
those with relapse cells (B) (p<0.05, p<0.05, log rank test). The survival rates of mice 
engrafted with blast cell ratio 7P:3R, 3P:7R and 5P:5R were moderately in between 
survival of mice with presentation cells and relapse cells only (C and D).       
In the Dex-treated experiment on mice xenografted with the mix cells at different ratios, 
Dex was administered at concentration of 15 mg/kg body weight and treatment was given 
for 4 weeks. Figure 3.20 showed Kaplan-Meier curves of survival rates of mice engrafted 
with mix populations of L707 with Dex treatment. As the relapse blast cells have deletion 
on the steroid receptor gene, as expected Dex-treatment has no significant effect on the 
survival rate of mice xenografted with 0P:10R (A) compared to those without treatment. 
Dex treatment successfully prolonged survival rates of mice engrafted with 10P:0R, 
towards those of 0P:10R (A). With Dex treatment given mice xenografted with all ratios 
of mix cell populations survived as long as the relapse 0P:10R (B and C). 
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Figure 3.19  Kaplan Meier analysis of survival in non-treated mice. A, Presentation cells xenografted 
mice and relapse cells xenografted mice. B, 90%P and 10%P cells mix populations with presentation and 
relapse cells xenografted mice. C, 70%P cells and 30%P cells mix populations with presentation and relapse 
xenografted mice. D, 50%P mix population with presentation and relapsed cells xenografted mice.    
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Figure 3.20  Kaplan Meier analysis showing survival of mice treated with dexamethasone. A, 
Presentation cells xenografted mice and relapse cells xenografted mice. B, 70%P cells and 30%P cells mix 
populations with presentation and relapse xenografted mice. C, 50%P mix population with presentation and 
relapsed cells xenografted mice.    
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3.2.5.2 Cytogenetic analysis of engrafted cells 
From the SNP microarray analysis result in Section 3.2.4 which identified deletion in the 
NR3C1 gene, the percentages of cells with this deletion present in the mixed cell 
engrafted mice could be determined using fluorescence in situ hybridization (FISH) 
technique. Probes covering the NR3C1 gene and a control non-affected gene on the far 
end of chromosome 5 at q35.3 were selected from the same Ensembl webpage as shown 
in Section 2.2.1.18. 
Cryopreserved cells were thawed and fixed with methanol/acetic acid (3:1). To perform 
FISH technique, cells dropped on slides were hybridized with target gene probes, RP11-
92B6, RP11-790H4 and RP11-614D16 labelled with spectrum green (G), and control 
unaffected gene probes, RP11-320G11 (Chr5-32k-2P22) and RP11-1259L22 probes 
labelled with spectrum red (R), as described in Materials and Methods Section 2.2.1.18.  
In this analysis, cells were scored based on the presence of the biallelic target gene. Cells 
with unaffected NR3C1 gene were identified by homozygous 2G2R, cells with 
heterozygous NR3C1 deletion by 1G2R or homozygous deletion of NR3C1 by 0G2R. For 
every sample analysed, 100 cells were scored. The cut-off values for the chance finding 
of a deletion were established to be 5% by Claire Schwab. The preparation of samples 
and scoring of cells were partially assisted by Claire Schwab and Heather Morrison from 
Leukaemia Research Cytogenetics Group, (NICR, Newcastle University).  
In Figure 3.21, fluorescent photographs A and B showed initial patient primary 
presentation and relapse cells respectively. Presentation cells with intact NR3C1 gene 
showed the presence of both green and red signals (2G2R). Patient relapse cells showed a 
population of bilateral loss (0G2R). There was also a presence of a single cell with 2G2R 
in the population seen in photograph B. Given the size of the cell, this was thought to be 
the origin LSC clone, residing dormant in the bone marrow niche, which was resistant to 
antiproliferative chemotherapy. 
Figure 3.21 C, D and E showed cells retrieved from presentation cells xenografted mouse, 
relapse cells xenografted mouse and a mix population xenografted mouse respectively. 
The presentation xenograft sample showed cells expressing 2G2R whereas relapse 
xenograft cells expressed only red signal as expected. Mix cells engrafted sample showed 
presence of both 2G2R and 0G2R.  
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Figure 3.21  Fluorescence microscopic representative of NR3C1 gene detection in blast cells. Target 
gene NR3C1were labelled with spectrum green and control gene were labelled with spectrum red. A, 
Primary presentation cells from patients. B, Primary relapse cells from patients. C, Presentation cells in 
xenograft mouse. D, Relapse cells in xenografted mouse. E, Mix population in xenografted mouse.    
 
To evaluate the effect of drug treatment on clonal evolution and expansion of patient 
presentation and relapse blasts in xenografted mice, cytogenetic analysis was performed 
on the blast cells retrieved from treated and untreated mice engrafted with mixed 
population of the blasts.  
 Figure 3.22 shows percentages of presentation cells present in the xenograft mice with 
and without Dex treatment. In the non-treated group (A), the graphs showed the 
percentage of presentation cells in the engrafted mice with mix populations of cells were 
higher than the initial ratios of the cells transplanted. In xenografts of 10P:0R and 
0P:10R, percentages of P cell 100% and 0% respectively. For the mix populations, 
percentage of P cells in 9P:1R, 7P:3R, 5P:5R, 3P:7R and 1P:9R were (99 ± 0.7)%, (74 ± 
8.2)%, (66.3 ± 17.5)%, (69.3 ± 19.4)% and (53.7 ± 8.6)% respectively. Detailed 
breakdown of cell scored is given in Appendix 2. This indicated that the presentation cells 
were expanding and repopulating faster than the relapse cells in vivo. In Dex-treated 
group (B), the percentage of presentation cells in xenografted mice were lower than the 
initial ratios of the presentation cells transplanted indicating that dexamethasone 
successfully suppressed the growth of presentation cells in the mix population. The 
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percentages of presentation cells in 10P:0R, 7P:3R, 5P:5R, 3P:7R and 0P:10R were (95.8 
± 4.3)%, (49.0 ± 23.2)%, (45.6 ± 17.9)%, (7.8 ± 1.7)% and 0% respectively. By 
comparison with the non-treated group, dexamethasone significantly reduced the 
percentage of presentation cells in mice xenografted with 3P:7R ratio of mix cells 
(p<0.01; t-test). Surprisingly, in the 10P:0R (100% presentation cells) group, one mouse 
was presented with 16% of cells expressing single green signal (2R1G). This could 
possibly indicate that these cells have loss of heterogeneity (LOH) condition, selected by 
dexamethasone.    
  
 
 
Figure 3.22  FISH analysis representing percentage of presentation cells engraftment in non-treated 
and dexamethasone-treated mice. A, Percentages of presentation cells in non-treated xenografted mice. B, 
Percentages of presentation cells in dexamethasone treated xenografted mice. * indicates significant value 
(p<0.01, t-test) compared to the corresponding non-treated mice in A. 
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3.2.5.3 Determination of NR3C1 levels in engrafted cells 
Complementary to the FISH analysis, real-time PCR was carried out to quantify NR3C1 
level in genomic DNA of cells retrieved from mice xenografted with mix cell 
populations. A Taqman real-time PCR method with primers and fluorogenic 
oligonucleotide probe was used in this analysis. Standard curve was built up from mixture 
of DNA of 10P:0R and 0P:10R from the non-treated group, prepared at the same ratios as 
the transplanted mix cell populations. CT values of target gene NR3C1 were normalized 
against CT values of a control ATP10A gene. To quantify the NR3C1 level, the ΔΔCT 
values of the untreated 10P:0R was used as an internal control and data were presented in 
2
-ΔΔCT
 as detailed in Materials and Methods Section 2.2.1.17. 
Figure 3.23 shows the levels of NR3C1 in the xenografted mice with Dex treatment and 
those without treatment. Standard curves in both graphs were indicated as blue lines. In 
the non-treated group (A), the NR3C1 gene copy levels in the engrafted cells were higher 
than the corresponding standard mixes. As an internal control, the NR3C1 level in 10P:0R 
was 1.0 and NR3C1 level in 0P:10R was undetectable. For the mix cell populations 
groups, the levels of NR3C1 in 9P:1R, 7P:3R, 5P:5R, 3P:7R and 1P:9R were 1.4 ± 0.07, 
1.15 ± 0.26, 1.28 ± 0.32, 0.81 ± 0.40 and 0.59 ± 0.17 respectively.  This indicated the 
presence of high numbers of presentation cells across all the mix cell engraftments. In 
contrast, in Dex-treated group (B), NR3C1 levels were lower than the standard curves 
indicating lower numbers of presentation cells. The level of NR3C1 measured were 0.72 
± 0.07 in 10P:0R, 0.35 ± 0.09 in 7P:3R, 0.29 ± 0.14 in 5P:5R, 0.02 ± 0.01 in 1P:9R and 
non-detectable in 0P:10R. By comparing these Dex-treated and non-treated groups, the 
NR3C1 gene copy numbers were significantly different with p<0.05 (t-test) in ratios of 
10P:0R, 7P:3R, 5P:5R and 3P:7R.    
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Figure 3.23  Real-time PCR analysis on NR3C1 level in non-treated and dexamethasone-treated 
xenograft. A, Analysis on the level of NR3C1gene in non-treated xenografted mice. B, Analysis on the 
level of NR3C1gene in dexamethasone treated mice. Blue lines indicate standard curves were generated by 
mixing DNA from 10P:0R and 0P:10R of non-treated group at the same ratios of initial engraftment of mix 
cell ratios. * indicates significant value (in all, p<0.05, t-test) compared to the corresponding non-treated 
mice in A.  
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3.2.6 Engraftment of t(17;19) – second case 
To compare the clonal expansion and kinetics between two t(17;19) cases, a second 
match paired presentation and relapse of t(17;19) samples were obtained from Dublin 
Hospital. This sample pair was assigned as L878. The frozen samples were processed and 
viable cells were counted by trypan blue exclusion method as described in Materials and 
Methods. The viable presentation cells counted were 1.2 x 10
5
 cells and unfortunately, for 
relapse sample there was hardly any cells seen in the provided vial. The vials were spun 
down and cells pellet were washed with RF10 medium and suspended with medium for 
xenograft in NSG mice. The relapse vial contained a very tiny cell pellet, despite this, the 
cell pellet was xenotransplanted as well. L878 presentation cells were transplanted into 
two mice and relapse cells was transplanted into one mouse to bulk-up the cells in vivo. 
However, after 7 months transplantation, the mice did not show any manifestation of the 
disease. Bone marrow puncture was performed to collect samples for analysis. Due to old 
age, the mice was killed 2 months later after transplanting bone marrow aspirates of 
presentation cells into three NSG mice for subsequent (secondary) engraftment.  Figure 
3.24 shows histograms from flow cytometry analysis of the bone marrow sample 
collected at 7 month and cells retrieved from spleens of the killed mice.   
Analysis on the bone marrow puncture showed there was low engraftments by the 
presentation cells in both xenografted mice (left panel, top and middle) whereas the 
relapse cells xenografted mouse did not show any engraftment in the bone marrow (left 
panel, bottom graph). However, histogram of the flow analysis on the spleen showed low, 
but detectable presentation and relapse cells deposited in the organ (right panel). The 
subsequent secondary xenograft work is still on going to this date. Because of the limited 
time left in the lab, this experiment was passed unto other colleague to continue and care 
for.     
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Figure 3.24  Flow cytometry analysis of engrafted L878 blasts cells. Histograms showed analysis of 
bone marrow puncture on the left panel and isolated spleen on the right. The top and middle histograms 
represented corresponding bone marrow and spleens results of  L878 presentation cells xenografted mice. 
Bottom histogram represented bone marrow and spleen results from the L878 relapse cells xenografted 
mouse.       
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3.3 Discussion 
The main aim of this chapter is to evaluate competitive clonal repopulation of the mix 
combinations of presentation and relapse cells in various proportions in xenograft mouse 
models to determine which clone has greater advantage of repopulating and expanding in 
vivo. A dexamethasone treatment was applied in another similar xenograft set up as a 
comparison for the advantage of repopulating and expanding cells.      
Only a single case of matched paired presentation and relapse cells of t(17;19)-positive 
pro-B ALL was studied in this chapter. Since the translocation t(17;19) occurs rarely in 
childhood ALL, similar cases of t(17;19) was rarely available and those that were 
available did not have matching pairs of samples. 
The principle of xenografting of leukaemic cells, either fresh or cryopreserved, into 
immunodeficient mice was to establish a continuous supply of samples from these 
patients without having to establish an in vitro culture. The presentation and relapse blast 
cells of L707 were by preference xenotransplanted into female mice since the paired 
samples were taken from female patient. Moreover, John Dick’s group has reported that 
female mice more efficiently engrafted human haematopoietic stem cells with 1.6- and 
1.7-fold higher engraftment in bone marrow and spleen, respectively, in comparison to 
males (Notta, Doulatov et al. 2010).  
High engraftment of the L707 blasts in the xenografted mice was demonstrated in the 
infiltration of the spleen, ovaries and occasionally other organs randomly. This study has 
shown that for L707 case, relapse cells persistently infiltrated the ovaries and presentation 
cells penetrated the CNS as seen in primary and subsequent secondary transplantation. 
This is supported by the similar morphology of blasts isolated from spleen and brain stem 
of the respective mice, and flow analysis of the engrafted cells.      
Immunophenotyping of primary and secondary engrafted L707 blast cells showed similar 
features of presentation and relapse blasts phenotype of CD10+CD19+CD20–CD34–. As 
Rimsza et al. (2000) reported, normal B-blast cells have a phenotype of CD10+19+20–
34+ (Rimsza, Larson et al. 2000). However, the t(17;19) HAL-01 cell lines were reported 
to have antigens of CD10+CD19+CD20+CD22+ (Ohyashiki, Fujieda et al. 1991) and 
another cell line, YCUB-2 with t(17;19) was reported to express CD10, CD19, CD20 but 
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not CD34 (Takahashi, Goto et al. 2001). This indicates that the L707 phenotypes of 
CD10+CD19+CD20-CD34- are typical for this particular ALL subtype.  
The L707 presentation and relapse blast cells were similarly identified as Type 1 t(17;19), 
however the band produced differed from those of HAL-01 which was used as a positive 
Type 1 t(17;19) control. Takahashi et al. reported the same three bands produced from 
RT-PCR of the YCUB-2 cells (Takahashi, Goto et al. 2001). The reason was possibly that 
the E2A gene was truncated in the middle of exon 13 and fused to HLF exon 4 with 
insertion in between which produced the upper two bands. The lower band was a direct 
fusion of the exon 12 E2A and exon 4 HLF (Takahashi, Goto et al. 2001) which gives the 
Type 2 t(17;19) as reported by Inukai et al. (Inukai, Hirose et al. 2007). Clearer evidence 
may be produced by sequencing the produced band, which is still in progress.     
The Affymetrix SNP microarray analysis of the whole genome identified that the relapse 
L707 blast cells had deletion on chromosome 5, which totally removed the NR3C1 gene 
from the affected region. This deletion was not seen in the L707 presentation blasts. The 
deletion results in resistance to glucocorticoid treatment, which was seen in the 
glucocorticoid inhibition study. The L707 relapse blasts were not affected by 
dexamethasone treatment while the L707 presentation cells were sensitive to the 
treatment. This phenomenon may explain why at relapse the patient was non-responsive 
to chemotherapy which may include glucocorticoid drugs. 
In competitive repopulation of the mixed L707 blast cells, survival curves showed mice 
xenografted with presentation cells had a shorter life span than those of relapse, indicating 
the ‘aggressiveness’ and faster evolution and kinetics of the presentation cells. This 
phenomenon has no possible evidence reported so far on such study. One possible reason 
might be that the clonal proliferation and expansion of the relapse cells were slightly 
impaired because the relapse cells unlike presentation cells, has gone through 
chemotherapies with drugs targeted directly to kill the cells. Cell proliferation capacity 
could have been affected making the relapse cells propagate much slower. Thus, tumour 
burden potential of relapse cells is much lower than presentation cells, which in turn 
prolonged the survival of mice engrafted with relapse cells. Xenografted mice with mixed 
cells in various ratios of the L707 presentation and relapse cells had an intermediate life 
span which was expected to be.  
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Treatment with dexamethasone prolonged and shifted the survival curve of the 
presentation cell xenografted mice and the mix cell population xenografted mice towards 
those of relapse xenografted mice, for which survival was similar to those without 
treatment. This indicated that dexamethasone successfully killed if not all, most of the 
presentation cells engrafted, without any effect on the GR-deleted relapse cells. However, 
dexamethasone treatment may have had a side effect on mice, given that the treated 
xenografted mice seemed to be moving slower and the femurs were visibly thinner and 
fragile, easily broken. Those conditions were not seen in the non-treated xenografted 
mice.            
Glucocorticoids are widely used not only as combination therapy to treat leukaemia but 
also in the clinic to treat a variety of diseases including inflammation, other cancer, and 
autoimmune disorders (Rhen and Cidlowski 2005). Responsiveness to glucocorticoid 
therapy, however, differs considerably among patients, and even within the same 
individual, different tissues have different glucocorticoid responsivenesses (Bronnegard 
1996). In addition, patients, particularly in the elderly treated chronically with 
glucocorticoids such as in the cases of rheumatoid arthritis, osteoarthritis, Crohn’s 
disease, ulcerative colitis, and asthma (Kino, De Martino et al. 2003) suffer side effects 
including metabolic syndrome, muscle wasting, and osteoporosis, which are frequently 
accompanied by fracture and fatality. Glucocorticoid-induced osteoporosis has been 
attributed to multiple mechanisms such as impaired intestinal calcium absorption, 
increased osteoclast activity, suppressed osteoblastic formation, and stimulated osteoblast 
apoptosis (O’Brien, Jia et al. 2004), since the glucocorticoids exert their cell-killing 
effects directly on bone cells (Weinstein 2001). These could possibly explain the 
condition seen in dexamethasone treated mice. 
Cytogenetic analysis on the xenografted mice revealed that without treatment, the 
presentation cells outgrown relapse cells which was seen in the mix population groups. 
Regardless of initial ratios of presentation cells in mix populations, the percentage of the 
cells engrafted were higher. Dexamethasone selectively reduced or suppressed the 
presence of presentation cells in the engrafted mice. In the treated group as well, although 
uncommon, one mouse from the presentation cells only group (100%P) was presented 
with 16% single green signal of the target gene (NR3C1). The other four mice showed 
100% of two red signals and two green signals. The presence of single signal could 
possibly be because the deletion of one allele of the chromosome 5 which indicate loss of 
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heterozygosity (LOH). In primary ALL cases, loss of heterozygosity (LOH) or mutations 
within the GR gene are rarely found (Irving, Bloodworth, et al. 2005; Tissing, Meijerink 
et al. 2003; Bachmann, Gorman et al. 2007) although a number of studies have described 
the association between endocrinological glucocorticoid resistance syndromes with 
genetic mutations within the GR or NR3C1 gene (Ruiz, Lind et al. 2001; Charmandari, 
Tsigos, et al. 2005). Therefore, from this finding, it appears that dexamethasone treatment 
has induced a heterozygous deletion in this patient and it could be suggested that the 
finding of homozygous deletion of relapse is exceptionally rare.  
The FISH cytogenetic analysis was complemented by the real-time q-PCR analysis of 
NR3C1 gene expression level. Without treatment, NR3C1 levels in mixed populations of 
engrafted mice were higher than the levels for standard mixes across all ratios, in contrast 
dexamethasone markedly reduced these levels. This indicated the presentation cells 
outgrown relapse cells which was suppressed by dexamethasone.  
In summary, NR3C1 deletion seen by copy number microarray was confirmed by 
cytogenetic and real-time PCR analysis at relapse. In competitive transplantation in vivo, 
cytogenetic and real time copy number analysis of different ratios showed that 
xenografted mice treated with dexamethasone demonstrated lower presentation cells than 
relapse cells in these experiments. These mice also exhibited shorter survival.  
In normal conditions, without dexamethasone treatment, the presentation cells had an 
advantage of outgrowing the relapse cells. In presence of drug treatment, this advantage 
was diminished.  
These competitive repopulation and clonal evolution in mixed populations studies would 
be much clearer if the presentation and relapse cells could be tracked using real-time 
bioimaging. To be able to this, these cells have to be labelled differently. Lentivirus 
vector system could be developed to facilitate this need.     
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CHAPTER 4  
LENTIVIRAL: CLONING, PRODUCTION AND TRANSDUCTION 
4.1 Introduction 
Viruses were first discovered and presented in 1892 by Dimitry Ivanovsky in which he 
stated that the infected tobacco leaf filtrate from the Chamberland filter used to filter 
bacteria could still infect new tobacco plants (Lustig and Levine 1992). In a similar study, 
this filterable infectious non-bacterial agent was later named virus by Martinus Beijerinck 
in 1898, in recognition of Ivanovsky’s work. Since these discoveries, to date over 5000 
viruses have been described in detailed. 
Viruses are non-living particles that do not require nutrients or energy and cannot 
replicate themselves. However, like living forms, they do carry genetic information in 
form of RNA or DNA. They need living hosts to replicate. Viruses can infect all genera 
of living organisms including animals, plants, bacteria and archaea. Viruses are the most 
abundant type of biological entity and they are found in almost every ecosystem.  
Virus particles, known as virions, consist of two or three parts: the RNA or DNA as 
mentioned above which contains genetic material, a protein coat that protects these 
genomes and, in some cases a lipid encapsulating the core of structural and catalytic 
protein once outside the host (Pedersen and Duch 2001). In addition, a virus also has 
signalling and enzymatic functions which are needed during multiplication in host cells. 
As the size of viruses ranges from 20 nm to 300 nm, they can only be seen under an 
electron microscope.   
There are seven groups of viruses classified by the structure of their genomes and their 
shared properties. The viral genome, RNA or DNA, can either be single-stranded (ss) or 
double-stranded (ds), and may or may not use reverse transcriptase (RT) to convert 
ssRNA into dsDNA. Additionally ssRNA maybe either sense (+) or antisense (–). The 
seven classes of viruses as categorized by David Baltimore are simplified in the table and 
diagram below. 
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Class of 
virus 
Type of virion genome Example of viruses 
I dsDNA viruses with double stranded DNA  Adenoviruses 
Herpesviruses 
Poxviruses 
  
II ssDNA viruses with single stranded (+) sense DNA  Parvoviruses  
III dsRNA viruses with double stranded RNA Reoviruses  
IV (+)ssRNA viruses with single stranded (+) sense RNA Picornaviruses 
Togaviruses  
 
V (–)ssRNA viruses with single stranded (–) sense RNA Orthomyxoviruses 
Rhabdoviruses 
 
VI (+)ssRNA-RT viruses with single stranded (+) sense RNA,  
with DNA intermediate in the life cycle using reverse 
transcriptase (RT)  
 
Retroviruses  
VII dsDNA-RT viruses with double stranded DNA using RT   Hepadnaviruses  
Table 4.1  Classes of virus according to type of genome in the virion (adapted from Baltimore 
Cassification of Viruses website). 
 
 
 
 
 
 
 
 
 
Figure 4.1  The Baltimore Classification of Viruses – Classes I-VII. The diagram shows relationship 
between the viral genome and its mRNA. (+) indicates sense RNA/DNA and (-) indicates antisense or 
complementary RNA/DNA. ds=double stranded, ss=single stranded, RT=reverse transcriptase.    
± dsDNA 
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+ ssDNA 
± dsDNA 
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4.1.1 Lentiviruses 
Lentiviruses are a type of retrovirus from the Class VI, the most commonly used amongst 
the seven classes of viruses in the Baltimore classification system.  
The HIV is the most clinically relevant lentivirus as it is responsible for AIDS. As 
lentivirus means a slow virus, the progression of HIV-related disease has a slow onset, 
which may take years for the symptoms to develop.      
There are various types of retroviruses which show different interactions with their 
specific hosts. Although these retroviruses have different biological properties, they share 
the same basic genomic organization and mode of replication. In the infected cells, the 
genome of the virions, the RNA, is reverse transcribed into a DNA forming a provirus.   
4.1.2 Genomic Structure of Retroviruses 
In the simplest form, the retrovirus genome contains two positive single stranded RNA. 
The retroviral RNA genome carries an m7G5’ppp5’Gm cap group at the 5’ end and a 
poly(A) tail at the 3’ end (Figure 4.2). The coding regions of the retroviral genome are 
located in between two untranslated flanking ends. The coding regions are the key 
elements for viral replication. The retroviral genome is large, consisting of 7000 – 10000 
nucleotides, including a short repeated (R) sequence at both 5’ and 3’ ends. The R region 
is involved in strand transfer during reverse transcription in which the PBS (primer 
binding site) and the PPT (polypurine tract) play the main part. The packaging signal () 
main function is to assemble the viral RNA into new virions.         
All retroviruses, with simple or complex genomic structure, contain gag, pol and env 
ORFs (open reading frames). gag (group specific antigen) encodes polyproteins such as 
the capsid protein (CA), the matrix protein (MA) and the nucleoprotein (NC), which are 
found in all retroviruses. Cleavage of these polyproteins exposes the core protein of the 
viral particle. pol encodes enzymes for viral replication, the RT (reverse transcriptase) 
and IN (integrase). In some retroviruses, the retroviral protease enzyme (PR) is either 
encoded by the 3’ of the gag ORF, the 5’ of the pol ORF or in between the gag-pol ORF. 
Proteins of the viral envelop, the surface glycoprotein (SU) and the transmembrane 
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glycoprotein (TM) are encoded by env (Coffin, Hughes et al. 1997; Pedersen and Duch 
2001). 
 
Figure 4.2  Genomic structure of a simple retrovirus. The organization of genome and gene expression 
pattern of a simple retrovirus shown the structure of an integrated provirus linked to flanking host cellular 
DNA. This is located at the terminal of the virus at the LTR sequence (U3-R-U5). The full length RNA 
serves as genomic RNA and mRNA for translation of the gag and pol ORFs into polyproteins. The splicing 
of the mRNA generated the env mRNA which encodes the Env precursor glycoprotein. CA, capsid 
(contains RNA genome); IN, integrase; LTR, long terminal repeat (U3-R-U5 for proviral DNA, derived 
from RU5 downstream of 5’ cap and U3-R upstream of 3’ poly(A) in RNA genome); MA, matrix of 
retrovirus; NC, nucleoprotein;  PBS; primer binding site; , packaging signal; PPT, polypurine tract; PR, 
protease; RT, reverse transcriptase; SD, splice donor site; SA, splice acceptor site; SU, surface binding 
glycoprotein; TM, transmembrane protein. (adopted from Pedersen and Duch 2001).   
 
An HIV-1 genome is much more complex than the simple retrovirus genome (Figure 
4.3A). The HIV-1 provirus DNA is 9.7 kb long which includes nine ORF that translate 
into nineteen proteins. The major part of the provirus DNA is protein encoding regions 
which are flanked by 5’ and 3’ long terminal repeats (LTRs). Both 5’ and 3’ LTRs termini 
contain the 3’unique element (U3), the repeat element (R), and the 5’ unique element 
(U5). The trans elements of the provirus consist of the retroviral basic ORFs, the gag-pol, 
gag, and env, which encode the structural proteins and enzymes involved in replication. 
Other additional ORFs includes tat and ref genes coding for essential regulatory proteins, 
vif, vpu, vpr and nef genes coding for accessory proteins. These are the nine ORFs 
mentioned above. The cis elements located on the 5’ and 3’ LTRs are the att repeats, 
which contain signals for provirus integration into the host genome, enhancer/promoter 
sequence, transactivation response elements (TAR) and polyadenylation signal (polyA). 
Other cis acting sequence includes those downstream of 5’ LTRs which are primer 
binding site (PBS) and viral RNA packaging and dimerization signal ( and DIS). Central 
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cis elements are the central polypurine tract (cPPT) and central termination sequence 
(CTS). Additional cis elements are on the upstream of 3’.  
LTR including rev response element (RRE) are involved in exporting viral mRNA into 
the cytosol and purine-rich region (PPT) is important for plus strand DNA synthesis 
(Pluta and Kacprzak 2009).       
 
 
Figure 4.3  Genomic structure of HIV-1. A. Provirus DNA consist of 5’ and 3’ LTRs with U3, R and U5 
regions at both ends. The ORFs gag, gag-pol and env encode for protein and enzymes for the virus. The 
PBS, cPPT, CTS and PPT are important elements for viral replication. The attL and attR involve in the 
integration into host genome. The DIS and  are elements for dimerization and packaging of virus RNA. 
TAR and polyA involved in transcription of mRNA, the SA and SD involved in slicing of RNA. The RRE 
is responsible for transporting viral mRNA from nucleus to cytosol. B. Viral DNA splicing exposed the 
three open reading frames for producing viral proteins. tat, transactivator protein; rev, regulator of viral 
protein expression; nef, negative factor; vif, viral infectivity; vpr, viral protein R; vpu, viral protein U; att, 
attachment sites; cap, terminal 7-methylguanosine.  (Adopted from Pluta and Kacprzak 2009). 
 
The three longest ORF are the gag, gag-pol and env, while the smaller central and 3’ 
ORFs are the vif, vpu, vpr, tat, rev and nef. Alternative splicing of proviral mRNA is a 
way for complex retroviruses to reduce the size of their genome, allowing for expression 
of their genetic information (Figure 4.3B). Cleavage of gag polyprotein produces 6 
structural proteins: MA (p17) responsible for transport of Gag-RNA complex to cytosol; 
CA (p24) and NC (p7) responsible for membrane binding, capsid formation, packaging 
and dimerization during viral assembly; SP1 and SP2 regulate cleavage rates, membrane 
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binding, virus budding and virion formation; p6 is involved in interaction with host 
proteins. The gag-pol polyprotein cleavage produces enzymes RT (p66, p51), PR (p11) 
and IN (p31). Cleavage of env produces two glycoproteins, SU (gp120) and TM (gp41), 
responsible for membrane fusion and virus uptake. The original regulatory proteins are 
the transactivator protein (tat; p16/p14) which initiates transcription of viral LTR and 
regulate expression of viral proteins (rev; p19). Finally, the accessory proteins are 
comprised of negative factor (nef; p27) which is crucial for down-regulating CD4 and 
other receptors, viral infectivity factor (vif; p23) which inactivates host immune response, 
viral protein R (vpr; p14) which is involved in nuclear import of viral PIC and viral 
protein U (vpu; p16) which is responsible for degrading the CD4 receptor, release of viral 
particles and apoptosis (Pluta and Kacprzak 2009).         
4.1.3 Replication of Lentivirus 
Viruses must generate mRNAs from their genomes to produce proteins and replicate 
themselves, and, depending on the host, different mechanisms are used to achieve this in 
each virus family. 
Viral replication depends on host cell factors and species-specific characteristics. 
However, anti-viral mechanisms in the host including the restriction factor can directly 
inhibit retrovirus replication. To overcome this inhibition, some viruses such as the HIV-1 
produce additional gene products that counteract host inhibitors (Valente and Goff 2009).   
The HIV replication cycle starts with the binding of envelope glycoprotein gp120 to host 
the CD4 surface receptor (Landau, Warton et al. 1988) and host the secondary receptor 
CCR5 forming gp120-coreceptor/CD4 complexes (Dobrowsky, Zhou et al. 2008). This 
formation triggers the gp41 subunit to release free energy sufficient to induce fusion of 
the virus to the cell membrane (Melikyan, Markosyan et al. 2000). The viral core content 
is then released into the host cell cytoplasm. It was proposed that HIV-1 Nef protein is 
responsible for actin rearrangements that facilitate core content to penetrate the plasma 
membrane after fusion (Campbell, Nunez et al. 2004). Viral genome is then reverse 
transcribed by reverse transcriptase within the capsid (Arhel, Souquere-Besse et al. 2007) 
and the reverse transcription complex (RTC) is transported towards the nucleus. The 
completed provirus DNA forms preintegration complex (PIC) with other viral proteins 
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such as RT, IN, NC, Vpr, MA and cellular proteins (Bukrinsky, Sharova et al. 1993). The 
PIC is then transported through the nuclear pore into the nucleus, where the provirus 
DNA is integrated into the host genome at a specific site selected by IN (Lewinski, 
Yamashita et al. 2006). Cellular RNA polymerase II (RNAP II) together with viral tat 
protein forms a stem-loop RNA (Feng and Holland 1988) and transcribes the inserted 
sequence into proviral DNA. Viral rev protein stabilizes the unspliced and partially 
spliced mRNA transcripts, promoting the transport to cytosol and synthesis of viral 
protein (Schmid and Jensen 2008). The RNA molecules, gag, gag-pol and env proteins 
assemble the new virus particles and direct the gp120 and gp 41 glycoproteins to the cell 
membrane. Virus particles are released from the cells through budding and protease 
enzyme promotes capsid formation that maturates the virus (Pluta and Kacprzak 2001).        
 
Figure 4.4  Scheme of HIV-1 lifecycle. A, HIV virus binds to CD4 cell surface receptor. B, Fusion of viral 
envelop membrane with cell membrane releases the viral content into cytosol. C, Virus genome is 
transcribed and preintegration complex (PIC) is formed. D, PIC is imported into the nucleus. E, Viral DNA 
is integrated into the cell genome. F, Genomic viral DNA is transcribed into viral RNA and exported into 
the cytocol. G, Coding viral RNA is translated into viral proteins. H, Viral proteins and the viral RNA 
assemble at cell membrane. I, Viral contents are encapsulated into membrane by budding. J, Release of 
fully encapsulated virus. (adopted from Pluta and Kacprzak 2001).     
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4.1.4 HIV-derived (based) Lentiviral Vectors 
Viral vectors including HIV-based vectors are widely used these days in basic research 
and gene therapy applications because of their high rates of gene transfer ability. 
Retroviral vectors have an ability to integrate into the host DNA. Therefore, the 
retrovirus-based systems offer long-term, stable transgene expression. 
The advantage of using lentiviral-based vectors is their ability to infect dividing and non-
dividing cells. Lentiviral vectors can transduce a wide range of quiescence cells including 
progenitors and stem cells (Ricks, Kutner et al. 2008; Santoni and Naldini 2009). 
The first recombinant retroviral vector systems, with a replication-defective virus, were 
developed in the 1980s. Following that, a system for recombinant HIV-based vector 
production was described in which a HIV-1 vector with replication defective and deleted 
sequence encoding the viral envelope (Env) glycoprotein was cotransfected with an 
expression vector encoding heterologous envelope protein to from HIV-1 pseudotypes 
(Page, Landau et al. 1990; Landau, Page et al. 1991). Along with the unique lentiviral 
vector properties that includes selection of ‘safe’ integration site in the host genome, 
efficient long term gene delivery to dividing and non-dividing cells, relatively large 
loading capacity and target specificity achieved by pseudotyping, these are key factors for 
the popular use of HIV-based lentiviral vector as a vehicle for gene transfer application 
(Pluta and Kacprzak 2009).       
To date, experiments utilizing a lentivirus as a gene delivery tool have adopted a well-
established production system. This system uses three vectors; a packaging vector, a 
transfer vector and an envelope vector, with the concept to separate trans elements 
encoding for structural, accessory and enzymatic proteins from cis elements required for 
reverse transcription, integration, RNA synthesis and packaging.  
The packaging vector encodes genes responsible for structural proteins for the formation 
of infectious particles as well as viral enzymes. In the vector, the 5’-LTR is replaced by a 
CMV promoter and the packaging signal () sequence has been deleted. The original 
polyA signal has been replaced by those from simian virus 40 (Naldini, Blomer et al. 
1996). This prevents the packaging of full-length mRNA encoding trans elements into 
viral particles. The RRE sequence was maintained unchanged in the vector. Further 
modification generated the second generation of the packaging vector. This includes the 
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removal of accessory proteins not required in virus replication. Deletion of vif, vpr, vpu 
and nef reduces the cytotoxicity and virulence, leaving only the tat and rev proteins, 
expressed together with gag, gag-pol and env glycoprotein (Gibbs, Regier et al. 1994). 
Other modifications describe additional deletions leaving only the gag-pol, tat and rev 
ORFs (Zufferey, Nagy et al. 1997; Mochizuki, Schwartz et al. 1998). 
The transfer vector usually carries the sequence for the gene to be expressed with its own 
promoter. The vector contains elements such as the PBS, gag, RRE, cPPT and modified 
LTR (Naldini, Blomer et al. 1996). The elements are needed for reverse transcription, 
nuclear import, integration and packaging. The RRE is dependent on gag to enhance gene 
transfer efficiency (Clever, Sassetti et al 1995). As a safety measure, the U3 region in the 
3’ LTR of the vector is deleted, producing the self-inactivating (SIN) vector (Dull, 
Zufferey et al. 1998). Replacement of 5’ LTR U3 by CMV promoter has been shown to 
enable tat dependent vector cassette expression (Kim, Mitrophanous et al. 1998). The SIN 
vector showed reduction in the expression of transcript and a marked reduction in 
producing viral particles in host cells (Bukovsky, Song et al. 1999). The SIN vectors are 
less harmful viruses. It was proven that the genotoxicity mainly depends on active LTRs 
(Montini, Cesana et al, 2009).  
The envelope vector provides envelope glycoprotein in the lentiviral vector system and 
enhances specificity towards target cells. This vector also improves viral particle stability 
during viral concentration and long term storage (Page, Landau et al.1990). 
4.1.5 IRES and WPRE 
As mentioned previously, during viral infection, host defence mechanisms can inhibit 
virus replication by blocking protein synthesis. To combat this intrinsic immunity, most 
viruses often use the internal ribosome entry site (IRES) to ensure that translation is 
activated. The IRES facilitates initiation of protein synthesis independent of the 5’ end. 
Over 56 viral and 80 cellular IRES sequences have been characterized and this sequence 
has been widely used in lentiviral vectors (Baird, Turcotte et al. 2006; Mokrejs, 
Vopalensky et al. 2006). It was shown that when two ORF are linked by IRES, the 
expression of the second ORF is driven by IRES by enabling and enhancing downstream 
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ORF translation. If the upstream ORF is not functional, the second ORF is still productive 
enhanced by IRES (Balvay, Soto Rifo et al. 2009). 
The woodchuck hepatitis virus (WHE) post-transcriptional regulatory element (PRE) is 
one of the cis activating elements (Zufferey, Donello et al. 1999). With the insertion of 
WPRE sequence in the 3’ untranslated region of a transcript, the overall transgene 
expression increased more than 6 fold (Oh, Bajwa et al. 2007).          
4.2 Results 
4.2.1 Cloning of lentivector harbouring luciferase reporter gene and 
fluorescent protein expressing gene 
To generate lentiviral vector expressing luciferase reporter gene coupled with fluorescent 
protein gene, the pHR’-SINcPPT-SIEW (pSIEW) lentivector was used for this purpose 
(Figure 4.5). pSIEW contains 5’LTR (long terminal repeats) and 3’LTR, an SFFV 
promoter, a linker element IRES, an enhanced green fluorescent protein (EGFP) reporter 
gene, an Ampicillin resistance gene (Amp) and several viral elements such as GaG, RRE, 
cPPT and WPRE. In the transduction of targeted cells with the lentivectors, the cassette 
between 5’LTR and 3’LTR was integrated into the genome of the cells. Therefore, the 
genes intended for expression in the transduced cells have to be inserted between the two 
LTR regions in order for the lentivector to be able to express the inserted gene.   
The generation of two lentiviral vectors is described in this chapter. The first lentivector is 
the pSLIEW, an addition of firefly luciferase (luc+) on the pSIEW lentivector backbone, 
and the second lentivector is the pSRLICW, additions of Renilla luciferase (RLuc) and 
mCherry fluorescent protein (mCherry) on a modified pSIEW. For the second lentivirus, 
utilization of other vectors was needed because of non- compatible sites for insertion of 
the reporter genes required.   
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Figure 4.5  Map of pHR-SINcPPT-SIEW Lentivector (pSIEW). This lentivector was utilized in cloning 
of luciferase-fluorescent protein genes harbouring lentivirus. The vector backbone consists of 5’ and 3’ 
LTR (long terminal repeat), GaG, RRE (Rev-responsive element), cPPT (central polypurine tract), a 
promoter SFFV (spleen focus forming virus), IRES (internal ribosome entry site), EGFP (enhanced green 
fluorescent protein) and WPRE (woodchuck posttranscriptional regulatory element).  indicates the site of 
insertion of firefly luciferase reporter gene (luc+) and  indicates the region modified and replaced by 
oligonucleotides.   
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4.2.1.1 Luc+ and EGFP expressing lentivector (pSLIEW) 
The pSLIEW lentivector harbouring the firefly luciferase (luc+) and green fluorescence 
protein (EGFP) was successfully constructed before this work was undertaken by Dr Olaf 
Heidenreich. However, the clones generated had not been tested. In brief, the pGL3-Basic 
plasmid (Figure 4.6) carrying luc+ reporter gene cassette was used in the cloning of 
pSLIEW vector. To generate a functional luc+/EGFP expressing vector, the luc+ cassette 
from the plasmid could be inserted only before the IRES and EGFP cassette in the pSIEW 
lentivector (refer to Figure 4.4). Downstream of IRES is a unique single cutting site at the 
8256 nt, the BamHI, which is also available downstream of the luc+ cassette from the 
pGL3-Basic plasmid at 2004 nt site. However, the luc+ reporter SV40 upstream of 
BamHI was not needed and had to be removed.  
All the mentioned techniques and protocols used in this section were as described in the 
Materials and Methods Section 2.2.2. 
The plasmid was double digested with XbaI and BamHI at 1742 nt and 2004 nt sites 
respectively in a 1x buffer Tango as suggested by Fermentas Double Digestion 
(Fermentas, UK). In order to be able to use the BamHI site for insertion into pSIEW, 
following digestion the Klenow fill-in technique was applied using the Klenow Fragment 
of the DNA Polymerase I enzyme (Promega, USA) to restore the BamHI sequence and 
blunt-ended the overhanging open frame. The digested and blunt-ended plasmid was 
religated, followed by DNA purification. With the BamHI cutting site directly upstream 
of luc+ cassette, the plasmid was again double digested with BglII (at the 36 nt site) and 
BamHI to remove the luc+ cassette. At the same time, the pSIEW lentivector was 
digested with BamHI for insertion of the luc+ cassette. The restriction enzyme BglII has 
the same overhang as the BamHI (as shown below), therefore the fragment cut out by 
these two enzymes can be inserted into a site which has been cut by either one of the 
enzymes. However, the disadvantage is that the intended insert could ligate to pSIEW in 
the wrong direction.  
BamHI sequence:  5’…G^GATC  C…3’  
        3’…C  CTAG^G…5’ 
 
BglII sequence: 5’…A^GATC  T…3’ 
   3’…T  CTAG^A…5’ 
  
^ indicates the cutting site 
of the enzymes 
129 
 
The digested plasmid and lentivector were run through agarose gel electrophoresis and 
the linearized open frame single band of pSIEW lentivector (10.2 kb) and the luc+ 
cassette (1.7 kb) fragment were cut out of the gel and purified for ligation, followed by 
transformation into competent cell Stbl3, agar plating, inoculation of colonies and 
extraction of plasmids (termed clones) DNA from each colony inoculated using miniprep 
kit (Qiagen).   
 
 
Figure 4.6  Map of pGL3-Basic vector. The 4818 bp plasmid contains firefly luciferase (luc+) region 
required for the generation of pSLIEW. Plasmid was double digested with BamHI (site: 2004 nt) and XbaI 
(site: 1742 nt) to remove the SV40 region from the vector. Klenow fill-in method was performed to religate 
the plasmid to retain the BamHI sequence. Modified vector without the SV40 promoter region were double 
digested with BglII (at 36 nt) and BamHI (now at 1742 nt) to get the lu+ reporter cassette (1.7 kb) to be 
inserted into pSIEW to generate the pSLIEW lentivector. Techniques used were as detailed in the Materials 
and Methods. (vector map was taken from Promega). 
 
To verify successful insertion of luc+ into the pSIEW vector and to prove that the insert 
was in the right direction, clones (plasmids) DNA were triple digested with XhoI (at 1 nt), 
AscI (at 8219 nt) and BamHI (at 8956 nt) in 2x Buffer Tango which was compatible for 
the three enzymes. To inactivate the enzymes, the digestion was incubated at 80C for 20 
minutes, and the digested plasmids were run through electrophoresis in 1% agarose gel. 
Ligated pSIEW–luc+ plasmid is expected to yield three bands of 8.2 kb, 1.9 kb and 1.7 
kb whereas non-ligated pSIEW plasmid will produce two fragments of 8.2 kb and 2.0 kb.  
Figure 4.7 shows that, out of 10 clones tested, two clones were successfully ligated with 
insertion of luc+ cassette in pSIEW vector at the right direction. Clones 2 and 5 produced 
the 3 bands described above; therefore these clones were successfully generated pSLIEW 
plasmids.  
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Figure 4.7  Digestion of the cloned plasmids DNA for verification of luc+ insert in pSIEW. Aliquots of 
1 µg of plasmids DNA were triple digested with XhoI, AscI and BamHI restriction enzymes in 2x buffer 
Tango and incubated in 37C for 1 hour before enzymes were heat inactivated at 80C for 20 minutes. 
Aliquots of 6 µl of digested plasmids were separated by on 1% agarose gel electrophoresis run for 90 
minutes. Gel was stained in 2 ng/ml ethidium bromide solution before viewing under UV-light. Clones were 
run against 1 kb DNA ladder for bands size determination. Gel showed 10 clones were tested. Clones 2 and 
5 with successful luc+ insertion yielded bands at 8.2 kb, 1.9 kb and 1.7 kb. 
 
The single colony inoculations of these pSLIEW plasmids were aliquoted into a larger 
volume of LB broth for overnight culture at 37C in orbital shaker to amplify the plasmid 
in order to get a higher concentration of the plasmid DNA for the lentiviral production 
work described later in this chapter. DNA of the plasmid from overnight incubation was 
isolated and purified using an endotoxin-free maxiprep kit (Qiagen). The concentration of 
the plasmid DNA was measured using a nanodrop spectrophotometer, and then, along 
with pSIEW DNA, the pSLIEW DNA was digested with restriction enzymes XhoI, AscI 
and BamHI for reconfirmation of the presence of the right plasmid. Figure 4.8 showed the 
digested plasmids where pSIEW without the insert yielded two bands and the pSLIEW 
with the luc+ insertion yielded three bands.       
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Figure 4.8  Digestion of the pSLIEW plasmid by XhoI, AscI and BamHI. Plasmid DNA isolated and 
purified using endotoxin-free maxiprep kit according to manufacturer’s procedures as detailed in Materials 
and Methods. Aliquots of 1 µg DNA of pSIEW and pSLIEW vector were incubated with restriction 
enzymes XhoI, AscI and BamHI in 2x Buffer Tango (Fermentas) at 37C for 1 hour as detailed in Materials 
and Methods. Enzymes were inactivated by increasing the temperature to 80C for 20 minutes. Agarose gel 
electrophoresis at 0.8% in 1x TAE was run for 1 60 minutes. Gel was stained in 2 µg/ml ethidium bromide 
for 20 minutes prior to viewing under UV light. Digested DNA was run against 1 kb DNA ladder for bands 
identification. Gel showed digested pSIEW produced 2 bands at 8.2 kb and 2.0 kb lengths (v) whereas 
digested pSLIEW yielded 3 bands at 8.2 kb, 1.9 kb and 1.7 kb lengths which confirmed the insertion of 
Luc+ at BamHI recognition site.       
 
The insertion of luc+ reporter gene cassette of 1.7 kb length into the backbone of pSIEW 
plasmid (10.2 kb) generated a pSLIEW plasmid of 11.9 kb length, as illustrated in Figure 
4.9.    
 
 
Figure 4.9  Schematic representation of generated pSLIEW. The insertion of luc+ reporter gene (1.7 kb) 
upstream of IRES and EGFP in the pSIEW lentivector (10.2 kb) backbone generating a 11.9 kb pSLIEW 
plasmid. The backbone of pSIEW contains 5’LTR, 3’LTR and all the important viral elements and 
Ampicllin resistant cassette in for selection in bacterial competent cells.   
pSIEW lentivector (10.2 kb) 
pSLIEW lentivector (11.9 kb) 
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4.2.1.2 RLuc and mCherry expressing lentivector (pSRLICW) 
The pSRLICW lentivector harbouring the Renilla luciferase (RLuc) reporter gene and 
mCherry fluorescence protein (mCherry) was generated by using pSIEW from Figure 4.5 
as a main backbone vector. To construct a functional pSRLICW lentivector, the RLuc 
reporter gene has to be inserted upstream of IRES and mCherry protein gene downstream, 
replacing EGFP in the main pSIEW backbone. The pRL-SV40 (Figure 4.10) and 
pcDNA3.1-mCherry (Zeo) (Figure 4.11) vectors were selected for this purpose for the 
RLuc and mCherry reporter genes respectively. However, as there were no compatible 
restriction enzyme sites for these reporter genes to be inserted directly into the pSIEW 
plasmid, a more complex strategy had to be planned.  
 
 
 
 
Figure 4.10  Map of pRL-SV40 vector. Renilla luciferase (RLuc) reporter gene is located in between NheI 
and XbaI recognition sites. This vector contains Ampicillin (Amp) resistant gene to enable selection of 
bacteria that contain the plasmid for amplification. (from Promega).  
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Figure 4.11  Map of pcDNA3.1-mCherry (Zeo). The intended mCherry is located between BamHI and 
EcoRI recognition sites. The vector contains Ampicillin (AMP) resistance gene for selection of bacteria that 
contain the plasmid and for amplification purposes. (provided by Christian Berens, Microbilogy Unit, 
University Erlangen-Nuernberg). 
 
The reporter genes cassettes, RLuc and mCherry, could be inserted together into another 
vector with compatible insertion sites available.  For this purpose, the pBluescript II KS+ 
vector (Figure 4.12) was selected because of the availability of the multiple cloning sites 
(MCS) to be manipulated, and a range of unique (single) restriction enzyme recognition 
sites. The sequence from SacI to XhoI was selected for manipulation as circled in red in 
the MSC of the vector.    
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Multiple cloning site (MCS) 
 
Figure 4.12  Map of pBluescript II KS+ with MCS sequence. pBluescript II KS(+) vector contains a 
multiple cloning site (MCS) with series of unique (single) restriction enzymes recognition sites which 
facilitates insertion of genes of interest. A range of 93 bp nucleotides from SacI and XhoI (circled in red) 
was replaced by a designed 79-bp polylinker oligonucleotides with series of unique restriction enzymes 
sequence. (source: Thermo Scientific).  
 
A polylinker of oligonucleotides containing a series of restriction enzymes was designed 
as illustrated in Figure 4.13. The restriction enzymes in the polylinker were assembled so 
that the inserted genes would be in the right position and order. Figure 4.13A illustrates 
the series of restriction enzymes with gaps between Csp45I and XbaI, EcoRI and NcoI, 
BglII and MunI, and SalI and XhoI, within which these gaps were filled in with at least 
four nucleotides (allocated as n). Figure 4.13B illustrates the gaps were intended in order 
for RLuc, IRES, mCherry and WPRE. The actual sequence of the polylinker (5’3’) is 
as shown in Figure 4.13C, with the gaps replaced with random nucleotide arrangements 
so as not to interfere with the functions of the downstream or upstream genes of the 
polylinker. Sequence in red showed the complementary sequence (3’5’) of the 
polylinker.  
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The idea of this polylinker is to replace SacI – XhoI sequence in the pBluescript II KS+ 
vector (approximately 93 bp nucleotides) with the polylinker of SacI – XhoI 
(approximately 76 bp nucleotides) and to insert the gene cassettes into the selected 
position in the polylinker sequence one after another. As the final event, when the 
polylinker was completely filled with the inserts, the BamHI—XhoI segment from the 
pSIEW vector will be replaced with the BamHI—XhoI sequence of the polylinker.  
   
A 
 
B 
 
 
C 
5’ – GAGCTCGGATCCTTCGAAGCTATCTAGAGAATTCAGCTCCATGGAGATCTGATCCAATTGGTCGACCGTACTCGAG – 3’ 
 
3’ – CTCGAGCCTAGGAAGCTTCGATAGATCTCTTAAGTCGAGGTACCTCTAGACTAGGTTAACCAGCTGGCATGAGCTC– 5’ 
 
 
Figure 4.13  Polylinker oligonucleotides. A, Series of restriction enzymes constructed from SacI to XhoI 
with gaps within enzymes filled in by four nucleotides (n in blue). B, The nucleotides gaps were illustrated 
to be replaced by the intended inserts RLuc, IRES, mCherry and WPRE. C, The actual sequence of the 
polylinker (5’3’; sense) with random nucleotides filling in the gap; underlined sequences are to indicated 
sequence of one restriction enzyme from the adjacent restriction enzyme sequence; nucleotides in blue are  
Red sequence indicates the complementary (3’5’; antisense) of the polylinker.    
 
The oligonucleotides were designed so that upon annealing, there is a 5’-SacI restriction 
enzyme recognition site overhang at the 3’ end and 3’-XhoI restriction enzyme 
recognition site overhang at the 5’ end.  
The sense and antisense of the polylinker oligonucleotides were hybridized as detailed in 
Materials and Methods Section 2.2.2.9. To ligate the annealed oligonucleotides with the 
pBluescript II KS+ vector, the vector was digested with SacI and XhoI enzymes to 
linearise and remove the 93 bp of SacI to XhoI segment. Figure 4.14 shows a fragment of 
2961 bp of the linearized pBluescript II KS+ vector. The band was excised under UV-
Sac I – BamHI – Csp45I – nnnn – Xba I – EcoRI – nnnn – Nco I – Bgl II – nnnn – Mun I – Sal I – nnnn – Xho I 
Sac I – BamHI – Csp45I – RLuc – Xba I – EcoRI – IRES– Nco I – Bgl II – mCherry– Mun I – Sal I – WPRE – Xho I 
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light and purified using Qiaquick gel extraction kit. The purified vector was ligated with 
76 bp polylinker oligonucleotides and transformed into JM109 competent cells for 
production of clones as described in Materials and Methods. Plasmid DNA was prepared 
from these clones.  
 
 
 
Figure 4.14  Digestion and gel purification of pBluescipt II KS+ with SacI and XhoI. Aliquot of 1.2 µg 
of pBluescript II KS+ vector was incubated with restriction enzymes SacI and XhoI in 1x Buffer SacI at 
37ºC for 1 hour. Enzymes were inactivated at 80ºC for 20 minutes following 1% agarose gel electrophoresis 
for 60 minutes. Gel was stained in 2 µg/ml ethidium bromide solution prior to viewing under UV-light. 
Digested DNA was run against 1kb ladder for identification of the band size. Gel showed linearized vector 
at 2.9 kb. Band was excised and purified as described in Materials and Methods for ligation with hybridized 
polylinker oligonucleotides.    
 
 
The clone DNA was digested with restriction enzyme Csp45I, which is a unique single 
cutting recognition site in the oligonucleotide. With the polylinker insert ligated in the 
vector, the expected band was 2944 bp. Figure 4.15 shows clones 2 and 3 to be positive 
for the oligonucleotide insert. Clones 1 and 4 were not ligated. Clones 2 and 3 were 
amplified by overnight LB broth culture to prepare a purified higher concentration of 
DNA as detailed in Materials and Methods.   
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Figure 4.15  Restriction digest of oligonucleotides–pBluescript II KS+ by Csp45I. Aliquots of 1µg 
DNA from plasmids were incubated with Csp45I in 1x Buffer Tango at 37ºC for 1 hour. Enzyme was heat 
inactivated at 80ºC for 20 minutes following by 1% agarose gel electrophoresis for 90 minutes. Gel was 
stained in 2 µg/ml ethidium bromide solution for 20 minutes before viewing under UV-light. Gel showed 
clones 2 and 3 yielded a single band at 2.9 kb. These clones indicated successful ligation of polylinker 
oligonucleotides and pBluescript II KS+ vector.          
 
 
For insertion of IRES into the modified pBluescript II KS+ vector-oligo ligated (pBsKS-
PL vector), the IRES fragment was isolated from pSIEW by digesting the vector with 
EcoRI and NcoI restriction enzymes. In parallel, the pBsKS-PL vector was also digested 
with the same enzymes. Figure 4.16 showed single band of the linearized two preparation 
of pBsKS-PL vector in lane 2 and 3. The digested pSIEW vector produced three bands of 
526 bp, 592 bp and 6000 bp. The IRES fragment isolated was further confirmed as shown 
in gel on the right to be a 592 bp fragment. The linearized pBsKS–PL and the IRES bands 
were excised under UV-light and purified using gel extraction kit.  
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Figure 4.16  Restriction digest of pBsKS-PL and pSIEW vectors with EcoRI and NcoI. Aliquots of 1 
µl vectors DNA were incubated with restriction enzymes EcoRI and NcoI in 2x Buffer Tango at 37ºC for 1 
hour. Enzymes were inactivated at 80ºC for 20 minutes followed by 1% agarose gel electrophoresis for 60 
minutes. Gel was stained in 2 µg/ml ethidium bromide solution for 20 minutes prior to viewing under UV-
light. Digested DNA was run against 1kb DNA ladder (gel on the left) and 100 bp DNA ladder (gel on the 
right) for identification of the band size. Gel on the left showed linearized pBsKS-PL giving bands sizes of 
2.9 kb in the two digestions prepared. pSIEW digestion gave 3 separated fragments sizes; expected band 
size for IRES was at 592 bp which was confirmed on the gel on the right to be the upper band. Linearized 
pBsKS-PL and IRES bands were excised and purified for ligation as described in the Materials and 
Methods.    
 
 
The purified vector and IRES DNA was ligated and transformed into competent cells 
JM109 for colony formation on LB agar plates. Plasmid DNA was prepared from these 
colonies. To verify that the vector contained the inserted IRES fragment, plasmid DNA 
was digested with Csp45I restriction enzyme. Figure 4.17 shows different plasmid DNA 
samples following digestion with Csp45I enzymes. With the IRES fragment inserted, the 
predicted band size was 3536 bp, without IRES fragment insertion the band size would be 
2944 bp. Out of nine colonies tested, eight colonies were positive for the IRES insert, one 
clone did not have the insert in. The cloned vectors from positive 3536 bp bands were 
amplified in LB broth and vector DNA was isolated and purified as described in Materials 
and Methods Section 2.2.2.7 and 2.2.2.8.              
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Figure 4.17  Restriction digest of pBsKS-PL – IRES ligation by Csp45I. Aliquots of 1µg DNA from 
plasmids were incubated with Csp45I in 1x Buffer Tango at 37ºC for 1 hour. Enzyme was heat inactivated 
at 80ºC for 20 minutes followed by 1% agarose gel electrophoresis for 60 minutes. Gel was stained in 2 
µg/ml ethidium bromide solution for 20 minutes prior to viewing under UV-light. Digested DNA was run 
against 1kb DNA ladder for identification of the band size. The numbers indicated the DNA of clones in the 
lanes. Gel showed 9 plasmid clones was digested for verification of the insert. All clones except clone 2 
linearized yielded a band size of 3.5 kb contained insertion of IRES fragment.         
 
 
To insert the WPRE fragment into the cloned pBsKS-PL-IRES vector, the WPRE 
segment was isolated from pSIEW. In the original plan, when designing the polylinker 
oligonucleotides, WPRE was supposed to be inserted between the SalI and XhoI 
restriction enzymes recognition sites. However, in the pSIEW vector (refer to Figure 4.5), 
there were two SalI recognition sites at both ends (upstream and downstream) of WPRE, 
in which the SalI recognition sites were upstream of XhoI recognition site. Therefore, the 
pSIEW lentivector was digested with restriction enzyme SalI to isolate the WPRE 
fragment. In the same manner, the cloned pBsKS-PL-IRES vector was also digested with 
the same restriction enzyme to prepare for ligation with WPRE. Gel electrophoresis as 
shown in Figure 4.18 shows digestion of the pBsKS-PL-IRES vector in which the 
restriction enzyme SalI linearized the vector into a 3536 bp band, and digestion of two 
preparations of pSIEW vector with SalI produced two bands at 614 bp and 9595 bp. The 
linearized pBsKS-PL-IRES vector and the 614 bp WPRE fragment bands were excised 
and purified for ligation. The ligated vector and WPRE were transformed into competent 
cells JM109 and plated on LB agar for colonies formation as detailed in Materials and 
Methods Section 2.2.2.5. Plasmid DNA prepared from these colonies was digested with 
EcoRI for verification of insertion.   
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Figure 4.18  Digestion of pBsKS-PL-IRES and pSIEW by SalI. Aliquots of 1 µl vectors DNA were 
incubated with restriction enzyme SalI in 1x Buffer Tango at 37ºC for 1 hour. Enzymes were inactivated at 
80ºC for 20 minutes followed by 0.8% agarose gel electrophoresis for 60 minutes. Gel was stained in 2 
µg/ml ethidium bromide solution for 20 minutes prior to viewing under UV-light. Digested DNA was run 
against 1kb DNA ladder and 100 bp DNA ladder for identification of the band size. Gel showed linearized 
pBsKS-PL-IRES giving bands sizes of 3.5 kb and pSIEW digestion yielded bands at 9.5 kb and 614 bp 
lengths. Linearized pBsKS-PL-IRES and 614 bp WPRE bands were excised and purified for ligation as 
described in the Materials and Methods.    
 
 
Figure 4.19 shows the agarose gel electrophoresis of 13 plasmid DNA digested with 
restriction enzyme EcoRI. Plasmids with WPRE insertion in pBsKS-PL-IRES were 
expected to give a single band at 4159 bp.  Without insertion of WPRE colonies would 
retain a 3545 bp band. The gel showed plasmid 1, 3, 5, 9, 11, 12 and 13 showed the 
expected band indicating positive insertion of WPRE in the vector. The other plasmids 
were negative for insertion.  
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Figure 4.19  Restriction analysis of pBsKS-PL-IRES–WPRE ligation. Aliquots of 1µg DNA from 
plasmids were incubated with EcoRI in 1x Buffer Tango at 37ºC for 1 hour. Enzyme was heat inactivated at 
80ºC for 20 minutes followed by 1% agarose gel electrophoresis for 90 minutes. Gel was stained in 2 µg/ml 
ethidium bromide solution for 20 minutes prior to viewing under UV-light as described in Materials and 
Methods. Digested DNA was run against 1kb DNA ladder for identification of the band size. Gel showed 13 
clones were digested for verification of insert. Positive WPRE inserted in pBsKS-PL-IRES plasmid yielded 
band at size of 4159 bp. Clones 1, 3, 5, 9, 11, 12 and 13 were positive generation of pBsKS-PL-IRES-
WPRE plasmids.          
 
 
To confirm the insertion was in the right direction, plasmids DNA positive for insertion of 
WPRE were randomly selected and digested with restriction enzymes PstI and XhoI 
followed by gel electrophoresis of the digested DNA. In the correct direction of the 
inserted WPRE, the expected bands will be at 608 bp and 3551 bp lengths. Of seven DNA 
samples tested, four plasmids were inserted with the right direction of WPRE as shown in 
Figure 4.20. The positive correct direction of WPRE plasmid, pBsKS-PL-IRES-WPRE, 
was further amplified in large volumes of LB broth to prepare a higher endotoxin-free 
DNA as detailed in Materials and Methods Section 2.2.2.7 and 2.2.2.8.       
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Figure 4.20  Digestion of pBsKS-PL-IRES-WPRE with NcoI. To confirm insertion of WPRE was in the 
correct direction, aliquot of 1µg DNA from plasmids were incubated with restriction enzymes PstI and 
XhoI in 1x Buffer R at 37ºC for 1 hour as detailed in Materials and Methods. Enzyme was heat inactivated 
at 80ºC for 20 minutes. Agarose gel electrophoresis was run in 0.8% agarose gel for 60 minutes. Gel was 
stained in 2 µg/ml ethidium bromide solution for 20 minutes before viewing under UV light. Digested DNA 
was run against 1kb DNA ladder for identification of the band size. The numbers indicate the DNA of clone 
in the lanes. Gel showed 7 plasmid clones was tested. Clones 1,3,4,5 and 6 contained insertion of WPRE 
fragment in correct direction.         
 
The next step was insertion of the RLuc reporter gene into the pBKS-PL-IRES-WPRE 
vector.  To insert the RLuc reporter gene, the RLuc segment was digested out from pRL-
SV40 vector (refer to Figure 4.10). In designing the polylinker, the RLuc gene was 
supposed to be inserted between the Csp45I and XbaI restriction sites. In the pRL-SV40 
vector, the Csp45I recognition site was located upstream of the RLuc gene and the XbaI 
recognition site was downstream of the gene. However, on looking at the sequence of the 
gene, the Csp45I site was located at the beginning of the ATG reporter RLuc gene. If the 
vector was cut with the mentioned restriction enzyme, this would render the RLuc gene 
non-funtional. Therefore, the NheI restriction enzyme in the upstream of the RLuc gene 
was used instead. However, some modification was made in the preparation of the genes 
for ligation. 
The pBsKS-IRES-WPRE vector was digested with restriction enzyme Csp45I whereas 
the pRL-SV40 vector was digested with restriction enzyme NheI. After incubation with 
the restriction enzymes, the T4 DNA Polymerase was added to blunt-ended sticky ends of 
the linearized vectors, as detailed in Materials and Methods Section 2.2.2.10. The 
digested and blunt-ended DNAs of both vectors were purified with Qiaquick PCR 
Purification Kit. Next, the purified blunt-ended DNAs of the pBsKS-IRES-WPRE and 
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pRL-SV40 vectors were digested with restriction enzyme XbaI and agarose gel 
electrophoresis was performed. Figure 4.21 shows that the XbaI digested pPR-SV40 
produced two bands of 2768 bp and 947 bp lengths. The RLuc reporter gene was the 
latter. The pBsKS-IRES-WPRE vector yielded a single 4.1 kb. The vector and the RLuc 
bands were excised and gel purified before ligation followed by transformation into Stbl3 
competent cells for colony formation. Plasmid DNA was prepared from these colonies.      
 
 
 
Figure 4.21  Digestion of pRL-SV40 and pBsKS-PL-IRES-WPRE vectors for ligation. To prepare the 
vectors for ligation, aliquot of 1µg DNA from pRL-SV40 and pBsKS-PL-IRES-WPRE was incubated with 
restriction enzymes NheI and Csp45I respectively in 1x Buffer Tango at 37ºC for 1 hour. Enzyme was heat 
inactivated at 80ºC for 20 minutes. For blunt-ending the overhang ends of digested vectors, T4 DNA 
Polymerase was added with 1x T4 DNA Polymerase Buffer and 100 µM dNTPs in final volume of 30 µl, 
and incubated at 11ºC for 20 minutes. Enzyme was inactivated at 75ºC for 10 minutes. The blunt-ended 
vectors were purified using Qiaquick PCR Purification kit. Aliquots of 25 µl of purified vectors were 
incubated at 37ºC for 1 hour with restriction enzyme XbaI separately. Enzyme was inactivated at 80ºC for 
20 minutes. Protocols used were as detailed in Materials and Methods. Agarose gel electrophoresis was run 
on 0.8% agarose gel in 1x TAE buffer for 70 minutes. Gel was stained in 2 µg/ml ethidium bromide for 20 
minutes before viewing under UV light. Digested DNA was run against 1kb ladder for identification of the 
band size. 
 
Plasmid DNA was digested with XbaI for confirmation of the insert. Gel electrophoresis 
of the digested plasmids was shown in Figure 4.22. Successful ligation was expected to 
yield a band of 5106 bp length. The gel showed that out of 15 plasmids isolated, only one 
clone (clone 8) was positive for the RLuc insertion into the pBsKS-IRES-WPRE plasmid. 
The other clones had no insert. The clone inoculation of the positive pBsKS-IRES-
WPRE-RLuc plasmid was cultured in higher volume of LB broth to achieve higher 
concentration of purified endotoxin-free DNA as detailed in Materials and Methods. The 
following step was insertion of mCherry into the pBsKS-PL-IRES-WPRE-RLuc plasmid.  
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Figure 4.22  Digestion of pBsKS-PL-IRES-WPRE-RLuc with XbaI. To confirm insertion of RLuc in the 
pBsKS-PL-IRES-WPRE vector, aliquot of 1µg DNA from plasmids were incubated with restriction enzyme 
XbaI in 1x Buffer Tango at 37ºC for 1 hour as detailed in Materials and Methods. Enzyme was heat 
inactivated at 80ºC for 20 minutes. Agarose gel electrophoresis was run in 0.8% agarose gel for 60 minutes. 
Gel was stained in 2 µg/ml ethidium bromide for 20 minutes before viewing under UV light. Digested DNA 
was run against 1kb ladder for identification of the band size. The numbers indicated the DNA of clone in 
the lanes. Gel showed 15 clones were tested. Clone 8 was positive for producing a 5.1 kb pKS-PL-IRES-
WPRE-RLuc vector.  
 
For insertion of mCherry protein gene into the plasmid, the mCherry gene as taken out of 
the 5732 bp pcDNA3.1-mCherry (Zeo) vector (refer to Figure 4.11). In the polylinker 
oligonucleotide sequence (refer to Figure 4.9), the mCherry was designed to be inserted in 
between BglII and MunI recognition sites. To isolate the mCherry fragment from the 
vector, however, the BamHI and EcoRI recognition sites were used instead. It was 
possible to use these restriction enzymes because of the presence of the same overhang 
sequences exposed following digestion. The restriction enzyme BamHI has the same 
overhang sequence as the BglII enzyme while the EcoRI restriction enzyme has the same 
sequence as the MunI enzyme as stated below.     
 
BamHI sequence:  5’…G^GATC  C…3’  
        3’…C  CTAG^G…5’ 
 
BglII sequence: 5’…A^GATC  T…3’ 
   3’…T  CTAG^A…5’ 
 
EcoRI sequence: 5’…G^AATT  C…3’ 
   3’…C  TTAA^G…5’ 
 
MunI sequence: 5’…C^AATT  G…3’ 
   3’…G  TTAA^C …5’ 
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Therefore, for the ligation to take place, the pcDNA3.1-mCherry (Zeo) vector was 
digested with restriction enzymes BamHI and EcoRI to isolate the mCherry whereas the 
pBsKS-IRES-WPRE-RLuc plasmid was digested with restriction enzymes BglII and 
MunI. Figure 4.23 showed gel results of two preparations of digestion for each vector and 
plasmid. The digestion produced a single band of linearized pBsKS-IRES-WPRE-RLuc 
plasmid at 5.1 kb and digestion of pmCherry vector yielded two bands at 5.0 kb and 724 
bp. The mCherry fragment was the smaller band size. The linearized plasmids and the 
mCherry fragments were excised under UV-light and were purified for ligation followed 
by transformation into Stbl3 competent cells and colony formation on agar plates. 
Purified DNA was prepared from these colonies as detailed in Materials and Methods.  
 
 
 
Figure 4.23  Restiction digest of pBsKS-PL-IRES-WPRE-RLuc and pcDNA3.1-mCherry vectors for 
ligation. To prepare the vectors for ligation, aliquot of 1.5 µg DNA from pcDNA3.1-mCherry was 
incubated with restriction enzymes BamHI and EcoRI in 2x Buffer Tango for 1 hour whereas aliquot of 1 
µg pBsKS-PL-IRES-WPRE-RLuc was incubated with restriction enzymes BglII and MunI in 1x Buffer 
Tango at 37ºC for 1 hour. Enzyme was heat inactivated at 80ºC for 20 minutes. Protocols were as detailed 
in Materials and Methods. Agarose gel electrophoresis was run on 0.8% agarose gel in 1x TAE buffer for 
60 minutes. Gel was stained in 2 µg/ml ethidium bromide for 20 minutes before viewing under UV light. 
Digested DNA was run against 1kb DNA ladder for identification of the band size. Gel showed two 
restriction digests prepared for each vectors. Linearized pBsKS-PL-IRES-WPRE-RLuc vector bands were 
at 5.1 kb. Digestion of pcDNA3.1-mCherry yielded 2 bands at size of 5.0 kb and 724 bp. Bands of 
linearized plasmid and 724 mCherry fragment were excised and purified for ligation as detailed in 
Materials and Methods.  
 
The cloned plasmid DNA was digested with restriction enzyme Csp45I for confirmation 
of the insert. Figure 4.24 showed bands produced on gel following electrophoresis. 
Insertion of mCherry in pBsKS-IRES-WPRE-RLuc plasmid was expected to yield a 5.8 
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kb clones. Five clones tested were positive for the insertion with bands at almost 6 kb. 
These clones generated the pBsKS-IRES-WPRE-RLuc-mCherry plasmids.  
 
 
 
Figure 4.24  Digestion of pBsKS-PL-IRES-WPRE-RLuc-mCherry by Csp45I. To confirm insertion of 
mCherry in the pBsKS-PL-IRES-WPRE-RLuc vector, aliquots of 1µg DNA from plasmids were incubated 
with restriction enzyme Csp45I in 1x Buffer Tango at 37ºC for 1 hour as detailed in Materials and Methods. 
Enzyme was heat inactivated at 80ºC for 20 minutes. Agarose gel electrophoresis was run in 0.8% agarose 
gel for 60 minutes. Gel was prepared with ethidium bromide at a concentration of 1 µg/ml gel. The gel was 
viewed directly under UV light following electrophoresis. Digested DNA was run against 1kb ladder for 
identification of the band size. The numbers indicated the DNA of clone in the lanes. Gel showed all 5 
clones tested were positive for insertion of mCherry with expected band at 5.8 kb which indicated clones of 
pKS-PL-IRES-WPRE-RLuc-mCherry vector was generated.   
 
The completely filled polylinker on the pBsKS-IRES-WPRE-RLuc-mCherry plasmids 
were ready to be removed and inserted into the pSIEW vector. As usual, the cloned 
plasmid was produced into higher copies for higher purified DNA concentrations.  
To insert the polylinker nucleotide into pSIEW vector, the 1.9 kb fragment from BamHI 
to XhoI recognition sites containing IRES, EGFP and WPRE in the vector had to be 
removed. This removal was to be replaced by insertion of a 2.9 kb fragment from the 
filled oligonucleotides.  For this purpose, the pSIEW vector was digested with restriction 
enzymes BamHI and XhoI. The cloned pBsKS-IRES-WPRE-RLuc-mCherry plasmid was 
digested with restriction enzymes GsuI followed by BamHI and XhoI. This additional 
cutting was required to avoid producing two bands at similar size if digested by BamHI 
and XhoI only. The digested vector and plasmid was run in gel electrophoresis and the 
bands produced were shown in Figure 4.25. Two preparations of digestion for both vector 
and cloned plasmid were shown. Digestion of the pSIEW vector produced two bands, the 
removed 1.9 kb band, and the 8.3 kb band size. The cloned plasmid was digested into 
three segments producing bands at 2.9 kb, 1.5 kb and 1.4 kb lengths. The vector 8.3 kb 
band and the cloned plasmid 2.9 kb band were excised and gel purified as described in 
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Materials and Methods Sections 2.2.2.3 to 2.2.2.5. The purified DNA of both fragments 
were ligated and transformed into competent cells Stbl3 for colony formation and 
plasmids DNA isolation.      
 
 
 
Figure 4.25  Digestion of pSIEW and pBsKS-PL-IRES-WPRE-RLuc-mCherry. Aliquots of 0.3µg 
DNA from pSIEW vector were incubated with restriction enzymes BamHI and XhoI in 1x Buffer Tango at 
37ºC for 1 hour as detailed in Materials and Methods. Aliquots of 0.3µg DNA from pBsKS-PL-IRES-
WPRE-RLuc-mCherry plasmid were incubated with restriction enzymes GsuI in 1x Buffer Tango at 30ºC 
for 1 hour followed by addition of restriction enzymes BamHI and XhoI in 2x Buffer Tango at 37ºC for 1 
hour as detailed in Materials and Methods. Enzymes were heat inactivated at 80ºC for 20 minutes. Gel was 
prepared with ethidium bromide at a concentration of 1 µg/ml gel. The gel was viewed directly under UV 
light following electrophoresis. Digested DNA was run against 1kb ladder for identification of the band 
size. Gel showed two preparations of digestions for each vector and plasmid. pSIEW digestion yielded band 
at 8255 bp and 1954 bp, pBsKS digestion yielded bands at 2913 bp, 1507 bp and 1465 bp.    
 
DNA exracted form the clone was digested with restriction enzymes BamHI and PvuI for 
confirmation of the ligation and inserts. Successful ligations were expected to produce a 
11169 bp vector. The expected bands size from the digested clone DNA were 6576 bp 
and 4593 bp. Figure 4.26 showed gel electrophoresis results from the digestion. DNA 
from 10 clones was digested; all clones except clone 8 produced bands at the expected 
size, proving that in these 9 clones polylinker was successfully inserted into the pSIEW 
vector. pSRLICW lentivector was successfully cloned. 
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Figure 4.26  Restriction digestion of pSRLICW by BamHI and PvuI for insert confirmation. To 
confirm insertion of polylinker in the pSIEW vector, aliquot of 1µg DNA from plasmids were incubated 
with restriction enzymes BamHI and PVuI in 2x Buffer Tango at 37ºC for 1 hour as detailed in Materials 
and Methods. Enzyme was heat inactivated at 80ºC for 20 minutes. Agarose gel electrophoresis was run in 
0.8% agarose gel for 80 minutes. Gel was prepared with ethidium bromide at a concentration of 1 µg/ml 
gel. The gel was viewed directly under UV light following electrophoresis. Digested DNA was run against 
1kb ladder for identification of the band size. The numbers indicated the clone in the lanes. Gel showed 10 
clones were tested. Except clone 8, all clones were positive for insertion producing expected bands at 6576 
bp and 4593 bp length. The pSRLICW vector was generated with a length of 11169 bp.   
 
Schematic representation of the constructed pSRLICW lentivector is as shown below. 
The RLuc reporter gene is located upstream of mCherry fluorescent protein gene 
connected by IRES. The expressions of RLuc and mCherry are driven by the SFFV 
promoter upstream of RLuc.   
 
 
 
Figure 4.27  Schematic representation of generated pSRLICW vector. The new constructed lentivector 
contained RLuc reporter gene upstream of IRES and mCherry fluorescent protein gene. The SFFV promoter 
in the vector backbone promotes the expression of RLuc and mCherry. Lentivector also contains Ampicillin 
(Amp) resistance gene for a selection of plasmid in bacterial culture.    
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4.2.2 Production of lentivirus 
To be able to use the newly constructed pSLIEW and pSRLICW lentivectors for the 
intended in vivo experiment, the functionalities of the lentivectors were first determined in 
in vitro experiments. To do this, lentivirus was produced by transfecting 293T cells with 
the lentivirus particles as described in Materials and Methods Sections 2.2.2.11 to 
2.2.2.13. Briefly, to produce lentivirus particles, the lentivectors were prepared with 
packaging and envelope vectors, the pCMV-dR8.91 and the pMD2.G respectively (Figure 
4.28). The peudovirus particles were in form of calcium phosphate precipitates.  
  
 
 
 
 
 
 
 
 
Figure 4.28  Maps of pCMVdR8.91 and pMD2.G vectors. Packaging and envelop vectors used in 
production of pseudovirus particles with the newly constructed lentivectors. (Vector maps source from 
LentiWeb.com)    
 
These precipitates were added into 293T cells cultured at the confluency of 30% to 40% 
plated the day before. Figure 4.29 shows transfection of lentivirus in 293T cells as viewed 
under a fluorescent microscope. With the presence of EGFP gene in the back bone of 
pSLIEW and the mCherry gene in the backbone of the pSRLICW the transfected 293T 
cells expressed the fluorescent protein as expected. Transfection with pSLIEW produced 
green 293T cells and pSRLICW transfection produced red cells. Viruses were left to 
replicate and reproduce themselves in the 293T cells for 3 days after removal of 
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unengulfted particles. The lentivirus produced in the medium was concentrated after 4 
days in culture.   
 
 
Figure 4.29 Transfection of 293T cells with pSLIEW and pSRLICW. 293T cell were seeded at a 
concentration of 2 x 10
5
 cells/ml in plates a day prior to transfection with the lentivirus. Aliquots of 20 µg 
DNA of pSLIEW or pSRLICW lentivectors were prepared with 15 µg DNA of pCMVd8.91 and 5 µg DNA 
of pMD2.G vectors for production of calcium phosphate (CaPO4) as detailed in the Materials and Methods. 
Precipitates were left to develop for 30 minutes. The viral particles precipitates were dropped into the 30% -
40% confluent 293T cells. Figures showed pSLIEW transfected 293T cells expressing green fluorescence 
and pSRLICW transfected 293T cells expressing red fluorescence when view under fluorescence 
microscope a day after transfection. Imaged were taken at two separate experiments. 400x magnification.       
 
The pSRLICW was newly generated just shortly before the end of this project. Therefore, 
the utilization of the lentiviral in the following steps were only based on the use of 
pSLIEW.  
4.2.3 Transduction of cell lines with pSLIEW 
pSLIEW lentivirus produced and concentrated as described above were used to transduce 
the leukaemic cell lines. Four cell lines were used for transduction with the lentivirus; two 
ALL cell lines, SEM and RS4;11, and two AML cell lines, Kasumi-1 and SKNO-1. Cells 
were transduced by spin inoculation as detailed in the Materials and Methods Section 
2.2.2.15. Cells were left for 4 days for stable transduction and proliferation before 
viewing under a fluorescence microscope. Flow cytometric analysis was performed on the 
cell lines using a FACScan machine as detailed in Materials and Methods Section 
2.2.2.15. Fluorescence photographs of the green fluorescence cells together with the flow 
cytometric histogram are shown in Figure 4.30. The histogram from FACS analysis 
showed that, from the same preparations of virus, SKNO-1 cells were easily transduced 
with a high intensity of green fluorescence cells measured. The RS4;11 cells were the 
pSLIEW transfected 293T cells pSRLICW transfected 293T cells 
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least infected with high populations of non-infected cells. As measured by FACS, the 
transduction efficiency for SEM cells was 45%, whereas in RS4;11cells the efficiency 
was only 5%. In Kasumi-1 cells, 72% cells were efficiently transduced and transduction 
in SKNO-1 cells was highly efficient with 98% of cells transduced. The flow results were 
run against non-infected controls. Fluorescent cells in photographs showed large 
populations of cells with a high intensity of green SKNO-1 cells compared to Kasumi-1 
and SEM cells while in RS4;11 there were only a few cells and these had low 
fluorescence intensity. The photographs of fluorescent cells were consistent with the 
histogram of transduced cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30  Analysis of transduced cell lines by flow cytometry and fluorescent microscopy. 
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With the exception of RS4;11, all the other transduced cells were kept according to the 
standard culture regime. RS4;11 was only kept in culture for a short period for analysis, 
the cells were discarded after when several passages no green fluorescent cells were 
detected under fluorescent microscopy and by luciferase assay.    
4.2.3.1 Luciferase Assay 
The luciferase assay was also performed on the transduced cell lines to determine the 
functionality of the luciferase reporter gene in the lentivirus. The luminescence count was 
measured using a Scintillation and Luminescence counter. 1 x 10
5
 cells were processed 
for the analysis as detailed in Materials and Methods Section 2.2.2.17. Figure 4.31 
showed the results of the analysis. The luminescence count detected in the transduced 
SEM cells was 15.3 x 10
4
 and for the transduced RS4;11 cells was 0.44 x 10
4
. Transduced 
Kasumi-1 was measured as 32.9 x 10
4 
for luminescence count and transduced SKNO-1 
cells was 134.8 x 10
4
. These results complement the flow analysis on the transduced cells 
suggested that the efficiency of infection in ALL cell lines is much lower than AML lines.  
The efficiency of Kasumi-1 and SKNO-1 cells infection were 2.2-fold and 8.8-fold higher 
respectively than the SEM cells.   
 
 
Figure 4.31  Luciferase assay of transduced cell lines. 1 x 10
5
 of transduced cells line were washed in 
PBS and lysed with 1x lysis buffer using Luciferase Assay System (Promega) as described in Materials and 
Methods. 10 µl lysates were aliquoted into luminescence plate-reader. 50 µl Luciferase Assay Reagent was 
added prior to luminescence count by Scintillation and Luminescence Counter (Perkin Elmer).   
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4.2.3.2 Sorting of transduced cell populations 
From the results of flow cytometric analysis of the transduced cells, it was shown that 
SEM and Kasumi-1 cells in culture consisted of a mixture of non-transduced and 
transduced cells. To establish a high percentage of transduced cells in culture, the 
Kasumi-1 and SEM cells were sorted for green (gfp) positivity using fluorescence-
assisted cell sorting (FACS) as described in Materials and Methods Section 2.2.2.16. 
SKNO-1 cells were not sorted for gfp positivity as the transduction efficiency was very 
high. 
Figure 4.32 shows a dot plot graph and the gating of gfp positive cells. Non-transduced 
cells were run as controls. Two distinguishable populations were detected as shown in 
pre-sort dot plots. Cells gated in green were populations of gfp positive cells (in the pre-
sort column). For Kasumi-1, 28% of green fluorescence cells were gated as pre-sort and 
these cells were sorted for gfp positive population whereas for SEM, 39% gfp positive 
cells were gated in pre-sort and sorted out for gfp positive population. The purity of 
positive green fluorescence cells sorted (in the post-sort column) were 92% for Kasumi-1 
and 95% for SEM. Approximately 1.5-2.0 x 10
6
 gfp positive cells were sorted for both 
cells. Sorted cells were maintained in culture for the xenotransplant experiments 
described in Chapter 5.  
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Figure 4.32  FACS sorted green positive (gfp+) cells. Aliquots of 10
7
 Kasumi-1 and SEM cells were 
washed and resuspended with PBS. Cells were sorted into culture medium with addition of 2% Penicillin-
Streptomycin as detailed in Materials and Methods. Dot plot graphs showed transduced Kasumi-1 and SEM 
cells were gated on the gfp+ cells in the pre-sort column by comparing to control negative cells. Sorted cells 
were analysed by FACS to determine the purity of cells as shown in the post-sort column.  
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4.2.3.3 Gfp/luc+ cells culture 
Sorted SEM and Kasumi-1 gfp positive cells were maintained for stable and normal 
proliferation rates in culture. Cells were then checked by FACS analysis to determine 
populations of green positive cells. Figure 4.33 shows the FACS analysis and 
fluorescence images of sorted gfp+ SEM and Kasumi-1 cells. Histograms of the gfp+ 
sorted cells showed both SEM and Kasumi-1 cells have 89% green cells populations in 
culture. Approximately 10% of non-transduced cells were contaminating the sorted gfp+ 
cultures. Images of fluorescence cells confirmed the high populations of green cells in 
culture.  
 
 
 
 
Figure 4.33  Flow cytometry analysis and image of stable sorted cells in culture. Aliquots of 10
6
 cells 
were washed and suspended in 2 ml PBS. Cells were analysed using FACScan. Control cells are non-
tranduced cells growing in culture, gated at M2 in histogram. Gfp+ sorted cells are sorted cells in stable 
condition in culture. Images of sorted cells growing in culture are shown on the right panel. 
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4.3 Discussion 
The experiments described in this chapter aimed to generate lentiviral vectors expressing 
different luciferase reporter genes and fluorescent protein genes, which could serve as 
labelling markers for tracking cells in vivo.  In order to be able to track a random mixture 
of two different cell populations in vivo mentioned in chapter 3, these cells will have to be 
labelled with different markers. Lentivirus was used to carry the inserted gene of interest 
into the DNA of infected cells. These genes are incorporated into the genome of the cells 
and are expressed upon induction. 
The cloning of pSLIEW and pSRLICW used a pSIEW lenitival SIN vector backbone. 
Cloning of pSLIEW was successfully done just before the start of this project. The 
pSLIEW clone was amplified in broth and was aliquoted and kept in glycerol stocks after 
confirmation by restriction digest. pSLIEW was used in transfection and transduction of 
cells as discussed later.   
The cloning of pSRLICW was very challenging. Firstly, there were no compatible 
resctriction sites for the insertion of RLuc and mCherry into the pSIEW vector backbone. 
An oligonucleotide polylinker was designed to overcome this. Then, there were many 
failed attempts to get inserts in the polylinker sites. Extensive efforts with various 
modifications were tried before the inserts were finally integrated into the polylinker. 
Each cassette inserted into the polylinker used a different approach. IRES was the easiest 
to be cloned into the linker. Various strategies were used to insert the polylinker into 
pSIEW. Due to the time taken to successfully clone the pSRLICW, the production of 
lentivirus was only done once. This second lentivector was still being tested to prove the 
functionality sequence for the vector to be utilized in future experiments when the 
fellowship finished. The limitation of the work carried out in this part was the slow 
progression of successful cloning of relevant inserts into the specific sites in the 
oligonucleotides. 
In producing the lentivirus, this work employed the three vector system, the packaging 
vector, the transfer vector and the envelop vector. This is to avoid the production of 
functional provirus. Although the lentivector backbone used was already a self-
inactivating vector which cannot produce viral particles, nonetheless, using this system 
serve as a safety measure. 
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Lentivirus was produced in the 293T cells. The conventional method for lentiviral vector 
production relies on efficient cotransfection of the producer cells 293T, with packaging 
plasmid, helper envelope and vector. The 293T cells are normally used for producing 
lentivirus because they are highly transfectable and they express the SV40 T-large antigen 
which enables replication of plasmids containing SV40 ori of replication (Soneoka, 
Cannon et al. 1995). 
As seen in the images of the highly transfected 293T cells in this chapter, transfection of 
the two constructed lentivirus produced green (pSLIEW) and red (pSRLICW) cells. This 
showed the fluorescent proteins EGFP and the mCherry inserted into pSIEW were 
working and could be used in cell transduction. However, fluorescence images of the 
293T cells transfected with pSRLICW lentivirus showed the 293T cells were not 
transfected as high as the previously prepared pSLIEW lentivirus production. The most 
likely reason is that a high passage of 293T cells was used. Two studies have stated that it 
is critical the 293T cells are not passaged more than 18-20 times before transfection to 
produce the viral vectors (Reiser 2000; Mitta, Rimann et al. 2005). Therefore, 293T cells 
lower than 18 passages have a higher efficiency of cotransfection.  The transfected 293T 
cells were left for 4 days for high virus production. Medium with lentivirus was 
ultracentrifuged to concentrate the virus. However, it was reported that vectors carrying 
large inserts above 7kb in their backbones were particularly fragile; they need a careful 
preparation specifically during ultracentrifugation in concentrating the virus (al Yacoub, 
Romanowska et al. 2007). Since both of the generated lentivirus, the pSLIEW and the 
pSRLICW were large, 11.1 kb and 11.9 kb, this information was taken into consideration 
when preparing the concentrated lentivirus produced by the 293T cells.  
By using the same suspension of concentrated pSLIEW virus, transduction of ALL and 
AML cell lines was done using spinnoculation method. FACS analysis showed that AML 
cells have higher rates of transduction with the lentivirus. By taking SEM cells as the 
reference, Kasumi-1 cells was 1.6-fold and SKNO-1 was 2.2-fold higher rates of 
transduction than SEM and rates of transduction for RS4;11 was 9-fold lower than SEM. 
Higher transduction rates mean that the virus genome can easily integrate into the DNA 
of the cells. RS4;11 cells were the most resistant to infection. Low transduction rates may 
occur because the cells have a defence mechanism against infection. Alternatively the 
cells may have low expression of surface receptor for binding the virus. 
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The transduced cells were also tested for functionality of luciferase gene inserted into the 
backbone of the lentivirus. From transduced cells, we know that the EGFP was 
functional. However, this does not mean that luciferase is also functional. As previously 
mentioned, IRES is located upstream of EGFP and luciferase is upstream to IRES. Even 
if the first gene is not functional IRES can drive the expression of the second gene. A 
luciferase assay was performed on transduced cells to test the functionality of the reporter 
gene luciferase. From the bar chart (in figure 4.30) SKNO-1 has very high intensity of 
luminescence counts while RS4;11 luminescence activity detected was negligible. A 
similar pattern was seen with the FACS analysis for fluorescence, suggesting that the 
luminescence results complement the EGFP data. This means that both the reporter genes 
were functional. 
The transduced cells were kept in culture for stable and normal growth rate and to have a 
high population of cells to work with. Since Kasumi-1 and SEM cultures have a high 
percentage of nontranduced cells mixed with the transduced cells, transduced green cells 
(gfp/luc+) were sorted to get high populations of green cells. RS4;11 was not sorted as the 
green cells were untraceable. Although the FACScan analysis showed transduced 
Kasumi-1 cells were higher than SEM cells, however, in FACS sorting percentage of 
green cells gated were lower for Kasumi-1 cells. Cells were sorted into a 2% penicillin 
and streptomycin treated culture medium since the first attempt of sorting, the cells were 
sorted in a non-treated medium and as a consequence the sorted cells were highly infected 
with bacterial contamination. Approximately 10
6 
gfp+ cells were sorted. To verify the 
purity of the gfp+ cells sorted cells were re-analysed on the FACS machine. Post-sorted 
cells contained a high population of gfp+ cells with more than 90% purity. Sorted cells 
were kept in dense culture in a 24-well plate to keep the cells in close contact. The sorted 
cells were dormant for three weeks in culture with an increasing population of apoptotic 
and necrotic cells. This is thought to be because the cells were exposed to multiple 
assaults. First, for sorting purpose the cells were suspended in phosphate buffered 
solution. Sorting of cells took hours to complete using the FACSVantage cell sorter, 
meaning the cells had been in buffered solution for a  long period of time. The sorting 
itself was also a pressure for the cells. Additionally, cells were kept in 
penicillin/streptomycin treated medium. Medium was partially removed to replace with a 
fresh media to initiate cell proliferation. Finally, when the sorted cells started to 
proliferate at the bottom of well, cells were transferred into a 48-well plate to expand the 
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cells and to remove if not all, but most of the debris and necrotic cells from culture. The 
sorted cells were finally stable in culture eight weeks after sorting. Cells were then 
aliquoted to analyse the percentage of gfp+ cells in culture. FACScan analysis showed 
high percentage with 83% of gfp+ cells. This is supported by fluorescent image proving 
the high populations of gfp+ cells in both Kasumi-1 and SEM. However, this percentage 
of gfp+ cells were approximately 10% lower than the purity checked post sorting. It is 
likely that most of the necrotic cells were the gfp+ cells. Alternatively the non-transduced 
cells could have grown more rapidly. Unfortunately, this was not determined for. 
In conclusion, the generated lentiviral vector expressing luciferase reporter gene and 
green fluorescent protein gene are functional for both genes. This lentiviral vector can be 
used as a marker to track any cells intended for in vivo experimentations. The transduced 
gfp+ sorted cells may be utilized as a primary or secondary marker for studies utilizing 
other markers as therapeutic or drug testing studies. The generated second lentiviral 
vector harbouring Renilla luciferase reporter gene and mCherry protein gene may serve 
the same purpose. These two lentiviral vectors may be used as dual markers in in vitro or 
in vivo experiments.    
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CHAPTER 5  
MOUSE MODEL FOR LEUKAEMIA – BIOLUMINESCENCE 
IMAGING 
5.1 Introduction 
5.1.1 Humanized Mouse Models  
Generating mouse models that can accommodate human haematopoietic cells was started 
over 30 years ago when severe combined immunodeficiency (SCID) mice were 
discovered. Engraftments of fetal hematopoietic tissues and HSCs into this model were 
very low and failed to generate a human immune system, the presence of mouse T, B and 
NK cells were the reasons for the engraftment failure (McCune, Namikawa et al 1988; 
Lapidot, Pflumio et al. 1992). Following this, non-obese diabetic (NOD)/SCID mice were 
generated to have no B and T cells and depleted NK cells. This model allowed higher 
levels of human PBMCs and HSCs to engraft (Hesselton, Greiner et al. 1995; Lowry, 
Shultz et al. 1996), but the residual activity of NK cells impeded engraftment of the 
human lymphoid compartment. The humanized mice were modified to become 
homozygous for targeted mutations at the interleukin-2 receptor -chain locus (Il2rg). The 
absence of IL-2R -chain caused severe impairment by preventing development of B, T 
and NK compartments. These NOD/SCID/Il2rg, also known as NSG mice, support 
greatly increased engraftment of human HSCs and PBMCs compared to all previously 
developed immunodeficient mouse models (Shultz, Ishikawa et al. 2007). The route of 
xenotranplanting human hematopoietic cells into mice varied from subcutaneous, 
intravenous and intrafemoral injections. The most preferable route of xenotransplantation 
is intrafemoral injection directly into bone marrow, the niche for haematological tissue. 
Xenotransplating leukaemic cells in these develop humanized mice are detailed in 
Chapter 1 (Section 1.6) and Chapter 3 (Section 3.1.3). 
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5.1.2 Bioluminescence In Vivo Imaging 
Bioluminescence refers to the biochemical generation of light in living organisms. This 
enzymatic generation of visible light emission is a naturally occurring phenomenon in 
some non-mammalian species (Contag and Ross 2002). A variety of different 
bioluminescent systems have been identified in nature, with each requiring a specific 
enzyme and substrate. The bioluminescent reporters include luciferases from firefly 
(Photinus pyralis), sea pansy (Renilla), jellyfish (Aequorea), corals (Tenilla), beetles 
(Pyrophorus plagiophthalamus and Lampyris), and several bacterial species (Vibrio 
fischeri and Vibrio harveyi) (Hastings 1996; Sala-Newby, Thomson et al. 1996). 
Luciferases in general generate light by catalysing the corresponding substrates in the 
presence of ATP, Mg
2+
 and oxygen.     
In vivo bioluminescence imaging is a technique that is based on detection of light 
emission from cells or tissue utilizing the bioluminescent reporter genes, a tool for non-
invasive in vivo monitoring of human biology, diseases and molecular processes in small, 
intact living subjects. Importantly, repetitively imaging using this modality does not have 
any deleterious effects on the experimental animals as there is no evidence of 
toxicological or immune effects of the substance used has been reported. 
A number of studies have reported the successful application of bioluminescence imaging 
modalities in monitoring diseases in mice or rats. These include the study on growth of 
tumours and lung cancer metastases (Sadikot and Blackwell 2005; Zinn, Chaudhuri et al. 
2008), effect of treatment on intracerebral tumour (Rehemtulla, Stegman et al. 2000), 
activation of transcription on a specific gene and bacterial infections (Benaron, Contag et 
al. 1997), progression of melanoma (Klerk, Overmeer et al. 2007) and various other 
experiments in validating the bioluminescence measurements of tumour loads and 
reporter gene expressions (Bhaumik and Gambhir 2002; Contag and Ross 2002) 
(reviewed in (Klerk, Overmeer et al. 2007)). These studies demonstrate that 
bioluminescence imaging is rapid, easy to perform and sensitive. This method can detect 
tumour shortly after inoculation, even in cases when limited and relatively few cancer 
cells are available. 
This chapter utilizes the bioluminescence imaging technique to monitor progression of 
green fluorescent/luciferase-expressing leukaemic cells in xenografts of NSG mice.   
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5.2 Results 
5.2.1 Growth curve study 
In order to understand the expansion of different cell lines engrafted in mice, growth 
curves of the cell lines used in this chapter were generated to determine the growth 
characteristics of the cells in vitro. SEM, Kasumi-1 and SKNO-1 cell lines were cultured 
as described in Section 2.1.1.1, without change of medium throughout the experiment. 
Cell growth was counted daily for 7 consecutive days using the trypan blue exclusion 
method as described in Section 2.2.1.2. Figure 5.1 shows the characteristic growth curves 
obtained for the cell lines, each showing a lag, exponential and plateau phases. The 
lengths of the lag phase of the growth curves in each cell line were similar but the 
exponential phase differed in all cells. SEM lines showed a longer exponential phase and 
reach plateau phase after 120 hours (5 days) in culture whereas SKNO-1 showed a shorter 
exponential phase and reach plateau after 4 days (96 hours) in culture. Kasumi-1 cells has 
a low and prolonged exponential phase and plateau after 6 days in culture.   
 
 
Figure 5.1  Growth curves of SEM, Kasumi-1 and SKNO-1 cell lines. SEM and Kasumi-1 cells were 
grown in RPMI with Hepes modification medium supplemented with 10% FBS (v/v) and 2 mM L-
glutamine (v/v). SKNO-1 cells was grown in RPMI with Hepes modification medium supplemented with 
20% FBS (v/v), 2 mM L-glutamine (v/v) and 7 ng/ml GM-CSF (v/v). Cells were seeded at 0.5 x 10
6
 
cells/ml at the start of experiment and cell growth was counted daily for 7 consecutive days using a 
Neubauer hematocytometer counting chamber with the trypan blue exclusion method as describe in 
Materials and Methods. The data presented are the mean ± s.e.m of three independent experiments. 
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5.2.2 Bioluminescence Imaging of Engrafted Mice 
To evaluate the expansion and progression of leukaemic cells in vivo and to be able to 
track the cells, lentiviral transduced and green fluorescent positive (gfp+)-sorted SEM and 
Kasumi-1 cells and unsorted SKNO-1 cells (from Chapter 4 Section 4.3.3) were 
transplanted intra femorally (i.f) into female NSG mice. Animals were prepared for 
transplantation and the protocol used in this procedure is described in Materials and 
Methods Section 2.2.1.15. Briefly, three animals were used in each group and for each 
animal, 20 μl of 106 cells were transplanted separately with each cell line. Immediately 
after implantation, while still anaesthetised, animals were injected intraperitoneally (i.p) 
with XenoLight Rediject D-Luciferin (Caliper) and were immediately subjected to 
bioluminescence imaging in a dark chamber using an IVIS Spectrum Imager (Caliper). D-
Luciferin is the substrate for luciferase. Therefore, Luciferase (luc+) from the transduced 
leukaemic lines (gfp+luc+ cells) in the animals reacted with the administered luciferin and 
produced luminescence light, which was detected by the imager. Images were captured 
after 10 sec exposure to luminescence channel and images from the emission filter at 620-
640 nm were selected for display (see Section 2.2.3.2 for detailed explanation). 
Luminescence imaging was carried out weekly to track the expansion of the cell 
population in the mice. In images from each different cell lines, each mouse was allocated 
as mouse 1 (m1), mouse 2 (m2) and mouse 3 (m3). If mice showed severe manifestation 
of leukaemia or signs of distress they were humanely killed by cervical dislocation.  
5.2.2.1 SEM(gfp+luc+) engraftment  
Images showing the progression of the infected cells in vivo are shown in Figure 5.2. On 
day 0, luminescence light was detected at the site of injection (right leg) in all mice. On 
day 7, images of mouse taken individually showed the intensity of luminescence light on 
the right leg had increased showing expansion of the implanted SEM(gfp+luc+) cells in vivo. 
On day 15 mice were imaged simultaneously rather than individually the week before. 
The images showed a high intensity of luminescence light was detected in m2 indicating 
presence of a high number of the transduced cells whereas no luminescence light was 
detected in m1 and m3. Luminescence detection was automatically set at a high intensity 
range resulting low luminescence emitting cells were not displayed. On day 21, 
luminescence light emitted in all mice, showed accumulation of the transduced cells in 
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right leg of m1, wide expansion of the cells in m2, particularly in the midriff section, and 
dissemination of the cells to left midriff of m3. Mouse 2 had difficulty moving at this 
point while mouse 1 and mouse 3 were showing effects of the disease. Four days later, at 
day 25, m2 was physically very weak and had loss mobility of the hind limb, and was 
dragging the limb when moving about. Images on day 25 showed luminescence light was 
detected in throughout m2, with high intensity on the midriff and part of the head. When 
the animal was imaged from the side, it was shown that the spleen and probably the liver 
and bone marrow of both legs were infiltrated. Mouse 2 was culled at this point and the 
peripheral blood, bone marrow and organs were collected for flow cytometry analysis. On 
day 28 post-transplantation, m1 images showed accumulation of the transduced SEM 
cells on right leg and m3 images showed systemic spread of the cells. Mouse 3 was also 
culled due to lost mobility of hind limb. Mouse 1 was culled after imaging on day 35 with 
the similar condition. Bone marrow and spleen of the culled mice were collected for flow 
cytometry analysis.     
 
 
 
 
 
 
 
 
 
 
 
 
 
166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2  Bioluminescence images of SEM(gfp+luc+) engrafted mice. Rediject D-Luciferin (30 mg/ml) 
was injected intraperitoneally (i.p) at 150 µl/mouse prior to imaging on sedated mice. Images were 
photographed in dark chamber condition under bioluminescence channel to capture luminescence light 
emitted from cells in vivo. Pseudocolour panels on the right of each image indicate intensity of 
luminescence measured. Series of weekly images are depicted. Animals were humanely culled due to 
severe condition following engraftment. d=day; m=mouse.
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5.2.2.1.1 Flow cytometry analysis 
Flow cytometry analysis was performed by labelling SEM cells with anti-mouse CD45 
and TER119 antibodies conjugated with PE-Cy7 and a specific SEM marker anti-human 
CD133 conjugated with APC, as detailed in the Materials and Methods Section 2.2.1.16.  
Figure 5.3A depicts an example of gating of human lymphocytes population from debris 
in dot plot graph, following gating of human cells from mouse cells contamination on a 
histogram plot. Figure 5.3B and 5.3C showed histogram and dot plot graphs of non-
transduced SEM as negative control and transduced SEM (SEM(gfp+luc+)) cells used in 
xenograft model as a positive control respectively. The dot plot populations in control 
cells were at the lower quadrant of the PE-Cy7 channel showing the populations were 
human cells. For this control and peripheral blood part, results are presented below, cells 
were mistakenly labelled with CD38, which is not specific for SEM cells. Therefore 
experimental dot plot data was presented comparable with the controls. In the 
SEM(gfp+luc+) positive control dot plot graph there were two populations measured. As 
explained in Chapter 4, sorted gfp+ SEM were contaminated with a low percentage of 
gfp-negative cells and these cells expanded over time in culture.    
Peripheral blood of mouse 2 at the end point was collected and processed using 
lymphoprep reagent according to manufacturer’s protocol as detailed in Materials and 
Methods Section 2.2.3.7 to isolate lymphocytes from whole blood. Flow cytometry 
analysis on the isolated lymphocytes of mouse 2 showed 15.4% of the lymphocytes were 
human SEM cells with 51.2% of these cells were positive for gfp (Figure 5.3D), which 
explained the overall luminescence light detected in the animal terminated on day 25. For 
mouse 1 and mouse 3, peripheral blood was not collected for analysis. 
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Figure 5.3  Flow cytometry analysis of peripheral blood isolated at terminal point of mouse (m2) 
engrafted with SEM(g+luc+) cells. Lymphocytes or leukaemic cells were isolated from peripheral blood 
using lymphoprep technique as detailed in Materials and Methods. Isolated cells were labelled with mouse 
antibody anti-CD45 and anti-TER119 conjugated with PE-Cy7.  (A) Dot plot showing population of human 
leukaemic cells gated out in the analysis. Dot plot data was the result of population gated out from 
histogram graph. (B) Histogram and dot plot graphs of non-transduced SEM cells as negative control and 
(C) Histogram and dot plot graphs of SEM(g+luc+) cells from sorted culture. (D) Histogram and dot plot 
graphs of lymphocytes isolated from peripheral blood showing presence of SEM(g+luc+) cells in the blood 
circulation of the mouse.     
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The bone marrow and spleen of all 3 mice were also collected and analysed by flow 
cytometry.  Figure 5.4 shows examples of gating the SEM cell populations in control 
cells, which was done in a similar manner to the sample analysis. Human cells were gated 
towards the right from mouse cells in the mmPE-Cy7/Count histogram (Figure 5.4A), 
followed by purification of the SEM cells by isolating the cell population in a gate in a 
dot plot graph (Figure 5.4B). Figure 5.4C(i) and 5.4C(ii) depicted unstained SEM cells as 
a negative control and stained SEMgfp+luc+ cells as a positive control respectively.  
 
 
 
 
 
Figure 5.4  Gating of SEM cells in flow cytometric analysis.  Non-transduced SEM cells and gfp-positive 
SEM cells from stable ongoing culture were suspended in PBS as detailed in Materials and Methods. Cells 
were labelled with anti-human CD133-APC antibody in combination with anti-mouse CD45- and TER119-
PE-Cy7 antibodies. (A) Histogram showed the gating of human cells towards the right of the graph (marked 
as MM negative) on the mouse (mm) PE-Cy7 channel. (B) Dot plot graph indicates further gating from MM 
negative to purify human cells from debris. (C) Dot plot of unstained control negative SEM (i) and positive 
gfp SEM (ii) showed the cells are CD133 positive. The positive control cells are a mixture of negative and 
positive green fluorescence cells in FITC channel.          
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Analysis of bone marrow and spleen from engrafted mice are as shown in Figure 5.5. In 
mouse 1, 94% of retrieved cells from bone marrow were human leukaemic cells and 71% 
of these cells were gfp-positive. 53% of the mouse spleen was populated with human cells 
where 67% of the cells were positive for gfp (Figure 5.5A). These results corresponded 
with the high luminescence intensity at the site of right leg and the left abdominal part on 
day 35 when the animal was killed. Analysis of the bone marrow and spleen of mouse 2 
showed the sites contained SEM cells with 62.1% gfp-positive of 65.6% human cells and 
60.1% gfp-positive from 45.4% gated human cells respectively (Figure 5.5B). In mouse 3 
samples analysis, the bone marrow cells population contained 46.6% human leukaemic 
cells with 64.5% gfp-positive SEM cells and the spleen was infiltrated with 11.6% human 
leukaemic cells with 69.2% gfp-positive SEM cells (Figure 5.5C).  For mouse 1, 50,000 
cells was counted for both bone marrow and spleen samples whereas 30,000 cells was 
counted from spleen samples of mouse 2 and mouse 3, and 12,000 cells and 10,000 cells 
from bone marrows of mouse 2 and 3 respectively. Liver samples were excluded in the 
analysis due to the difficulty of gating human cells from mouse cells.         
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Figure 5.5  Flow cytometric analysis of cells retrieved from bone marrow and spleen at the end-point 
of mice engrafted with SEM(g+luc+) cells. (A), (B) and (C) represent dot plot data from mouse 1 (m1), 
mouse 2 (m2) and mouse 3 (m3) respectively, engrafted with the implanted cells. Retrieved cells were 
processed as describe in Materials and Methods and labelled with CD133-APC antibody to identify SEM 
cells and combining with mouse anti-CD45- and anti-TER119-PE-Cy7 antibodies. Fluorescent gfp cells 
were measured by FITC channel. Dot plot data on left panel show analysis of cells retrieved from bone 
marrow and dot plot data on right panel show analysis from spleen of mice. Percentage of SEM(gfp+luc+) cells 
in dot plot populations were as depicted in the graphs.  
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5.2.2.2 Kasumi-1(gfp+luc+) engraftment  
Images showing progression of post implanted Kasumi-1(gfp+luc+) cells in mice are shown 
in Figure 5.6. On the day of implantation (d0), luminescence light was detected at the site 
of implantation on right leg in all three mice, m1, m2 and m3, which continued to 
increase the following week (d7). However, imaging on day 15, 21, 28, 35 and 41 
displayed only that m2 showed increasing intensity on the region of the right leg. No 
visible luminescent emission was seen on imaging of m1 and m3 on the same days. On 
day 49, m2 had visibly developed a large lump on the right leg, which was luminescent 
on imaging. The mouse was having difficulty in movement and the flexibility of the leg 
was limited. m2 was culled following imaging on day 49 and bone marrow and spleen, as 
well as the tumour on the right leg were collected. On the same day, m1 did not show any 
light detected at the same luminescent intensity used, whereas m3 started to show 
luminescent light emerging on the left abdominal compartment suggesting the expansion 
of the engrafted cells in vivo. The following imaging on day 55 showed the luminescence 
light noted in m2 a week before had grown bigger with higher luminescent intensity, m1 
remained negative. However,  8 days later (on day 63), luminescence imaging showed a 
sudden widespread expansion of engrafted cells in m1 on the right lower abdominal 
region while the luminescent intensity on m3 increased slightly indicating growth 
expansion of the engrafted Kasumi-1gfp+luc+ cells. Luminescent images on day 70, 78 and 
84 demonstrated further growing of the human cells in the animals. On day 78, a ventral 
view of m2 was also imaged showing extension of the engrafted cells proliferated with 
possible high infiltration of the spleen. Images on day 84 and 91 post transplantation 
showed the dorsal view and ventral view of both m1 and m3 mice with luminescent light 
emission covering wider regions, most notably in m3. This mouse was culled on day 91 
due to an enlarged abdomen. Bone marrow, spleen and emerging abdominal tumours 
were collected for analysis. The final image of m1 14 days later (day 135) showed 
luminescent light from the enlarged abdominal region as seen in the ventral view. The 
dorsal view of the mouse also showed emergence of human cells in the left abdominal 
region, which was thought to be the continuation of the region detected on the ventral 
view. The mouse was killed after the final imaging and bone marrow, spleen and 
abdominal tumours were collected for analysis. On daily observation until the day the 
animals were culled, all 3 mice did not show any physical sign of illness from the disease 
at the time of termination.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6  Bioluminescence images of Kasumi-1gfp+luc+ engrafted mice. Luciferin was injected intraperitoneally (i.p) into mice prior to imaging. Bioluminescence 
imaging was taken on weekly basis to track progression of the leukaemic cells in vivo. Animals were humanely culled due to physical conditions following engraftment.  
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5.2.2.2.1 Flow cytometry analysis 
Flow cytometry analysis was performed by labelling cells with Kasumi-1 cell specific 
marker CD34 conjugated with APC, and with anti-mouse CD45 and TER119 antibodies 
conjugated with PE-Cy7 to exclude contamination with mouse cells, as detailed in 
Materials and Methods Section 2.2.1.16.  
Figure 5.7 shows examples of gating of human cells in histogram (A) followed by gating 
of the cells in dot plot (B) to purify the Kasumi-1 cells population from debris. Figure 
5.7C showed dot plot populations of stained non-transduced Kasumi-1 cells and 
transduced Kasumi-1(gfp+luc+) cells as negative and positive controls respectively. The 
control cells are totally CD34-positive human Kasumi-1 lines. As explained in Chapter 4, 
sorted Kasumi-1(gfp+luc+) culture were not totally pure green cells but still a mixture of 
small percentage of non-transduced gfp-negative cells in culture. This resulted in two 
populations of gfp-positive and gfp-negative cells measured on FITC channel in the dot 
plot.     
Figure 5.8 shows flow analysis of samples collected after culling of mouse 2 on day 49. 
Bone marrow, spleen and tumour from the right leg of the mouse were isolated and 
processed as described in Materials and Methods Section 2.2.3.4. Histogram of the flow 
analysis on bone marrow (top) and spleen (middle) showed negligible human cells in the 
samples. No or negligible human cells were seen in the corresponding dot plot graphs on 
the right panel. However analysis from the leg tumour (bottom) showed high percentage 
of human cells gated (72.6%) in the histogram. The corresponding dot plot graph showed 
80% of the cells were of Kasumi-1 gfp-positive cells which give the light intensity in the 
images.   
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Figure 5.7  Gating of Kasumi-1 cells in flow cytometric analysis. Cultured non-transduced Kasumi-1 
cells and gfp-positive sorted culture of transduced Kasumi-1 cells in PBS were labelled with anti-human 
CD34-APC antibody in combination with anti-mouse CD45- and TER119-PE-Cy7 antibodies. (A) 
Histogram showed the gating of human cells towards the right of the graph (marked as MM negative) on 
the mouse (mm) PE-Cy7 channel. (B) Dot plot graph indicates further gating from MM negative to purify 
human cells from debris. (C) Dot plot stained control negative (left) and positive gfp (right) from ongoing 
culture showed the Kasumi-1 cells are CD34 positive. Negative control cells are negative for green 
fluorescence in FITC channel and positive control cells are a mixture of negative and positive green 
fluorescence cells.        
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Figure 5.8  Flow cytometry analysis of samples collected from Kasumi-1(gfp+luc+) engrafted mouse 2 at 
the end-point on day 49. Bone marrow, spleen and leg tumour collected from the mouse were processed as 
described in the Materials and Methods. Cells were labelled with human antibody anti-CD34-APC 
combined with mouse antibodies anti-CD45- and anti-TER119-PE-Cy7. Top: histogram and dot plot graphs 
from bone marrow; Middle: histogram and dot plot graphs from spleen; Bottom: histogram and dot plot 
graphs from leg tumour. Figures on the graphs indicate percentage of Kasumi-1 (human) cells in the gates. 
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Analyses of cells collected from mouse 3 at terminal-point, three months post-
transplantation, are shown in Figure 5.9. Although it was a long-term engraftment, the 
mouse spleen was at normal size measuring 1 cm in length. However the abdominal 
cavity was filled with two separate solid encapsulated tumours, a large tumour measuring 
2 cm in diameter and a smaller tumour measuring 1 cm in diameter (Figure 5.9A). The 
spleen and tumours were processed as described in Materials and Methods Section 
2.2.3.4. Flow cytometric analyses of the samples were as shown in Figure 5.9C. Although 
the spleen was a normal size, it was infiltrated with 29.4% of Kasumi-1 cells of which 
86.4% were gfp-positive. However, in the bone marrow of the mouse there were only 6% 
of Kasumi-1 cells measured. The small abdominal tumour were consisted almost entirley 
of Kasumi-1gfp+luc+ cells, 94% of the 95.3% positive Kasumi-1 cells were positive for gfp. 
Although only 66.3% cells in the large abdominal tumour were of Kasumi-1, 98.5% of 
these cells were gfp-positive. Therefore, these tumours corresponded with the two distinct 
luminescent masses seen in m3 at day 91. 
For mouse 1, at terminal-point after 4.5 months post-implantation of Kasumi-1gfp+luc+ , the 
abdominal cavity of the mouse was found to be filled with fat-like, solid encapsulated, 
spongy spleen-attached and stomach-attached tumours as shown in photograph (A) in 
Figure 5.10. Flow analysis of the cells retrieved from bone marrow, spleen and the 
tumours were as shown in Figure 5.10B. As it was gated for human cells in the histogram, 
Kasumi-1gfp+luc+ cells measured in the bone marrow and spleen were 11.8% and 18.2% 
respectively and 81% to 90% of those cells were positive for gfp. The tumours analyses 
isolated Kasumi-1 cells in fat-like, solid, spleen-attached and stomach-attached tumours 
as much as 70.8%, 93.3%, 89.7% and 79.6% respectively. All cells from these isolated 
populations were more than 99% gfp-positive. These results corresponded with the 
luminescent band on the abdomen of m1 seen on day 135 at the time the mouse was 
culled.       
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Figure 5.9  Flow cytometric analysis of Kasumi-1gfp+luc+ engrafted mouse 3. Cells suspensions from 
bone marrow, spleen and two solid abdominal tumours (small and large) collected from mouse 3 at terminal 
day 91 post xenograft were labelled with human specific antibody anti-CD34-APC combined with mouse 
specific antibodies, anti-CD45 and anti-TER119 conjugated with PE-Cy7. The photograph on top, A, 
showed the normal spleen size of 1 cm length, with large solid tumour measuring 2 cm diameter and small 
solid tumour measuring 1 cm diameter. Analysis of the samples, B, showed dot plot data of spleen, bone 
marrow, small abdominal tumour and large abdominal tumour (as labelled on the graphs. Dot plot data was 
on channels FITC/CD34-APC. Abs=abdominal.        
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Figure 5.10  Flow cytometric analysis of Kasumi-1gfp+luc+ engrafted mouse 1. Samples collected from 
mouse 1 at the terminal day 135 were processed and antibodies labelled were as described in Materials and 
Methods. Bone marrow, spleen and tumours suspension cells were labelled with human antibody anti-
CD34-APC in combination with mouse antibodies anti-CD45- and anti-TER119-PE-cy7 to exclude mouse 
cells. A, Photograph showing various types of tumours isolated from the mouse abdominal cavity. B, Dot 
plot graphs showing analysis of samples collected from the mouse. FITC channel measured green 
fluorescent cells, CD34-APC channel measured human cells in samples.   
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5.2.2.3 SKNO-1(gfp+luc+) engraftment  
Images showing progression of implanted SKNO-1gfp+luc+ cells in mice were as shown 
in Figure 5.11. On day 0, all three mice showed luminescent light emission from cells at 
the site of implantation. However, after one week of implantation, m1 showed a high 
intensity of luminescence light from the engrafted leg, which was low in m2. No visible 
light was detected in m3 even when the luminescence detection sensitivity was increased. 
On day 15, luminescent light was only detected in mouse 1. After three weeks post-
implantation (d21), mouse 1 maintained the emission of luminescent light intensity, 
mouse 2 started to show emission of luminescence light suggesting the implanted cells in 
this mouse had started to expand, however, mouse 3 still did not show any sign of 
luminescent emission. Although the images from this week were ‘contaminated’ with 
false luminescent signal on the surface, the luminescence light emitted from the cells in 
vivo was still distinguishable. For the following two weeks at day 28 and day 35, images 
showed luminescent light detected in m1 and m2 but not m3. Unfortunately, all three 
mice did not regain consciousness and died after imaging on day 35. There was no sign of 
illness seen in animal up to the last day of luminescence imaging. Bone marrow and 
spleen from the mice were collected for flow cytometry analysis. 
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Figure 5.11  Bioluminescence imaging of mice engrafted with SKNO-1gfp+luc+ cells. Sedated mice 
were injected with 150 mg/kg body weight of Rediject D-Luciferin solution prior to luminescence imaging 
in dark chamber. Mice images were photographed and superimposed with the luminescence light emitted by 
the cells in vivo as detected by luminometer. Pseudocolor bars on the left of images indicate luminescence 
intensity measured.   d=day; m=mouse   
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5.2.2.3.1 Flow cytometry analysis 
Flow cytometry analysis of the cells retrieved from mice engrafted with SKNO-1gfp+luc+  
were performed as detailed in Materials and Methods Section 2.2.1.16 by labelling the 
cells with SKNO-1 markers anti-human CD38 conjugated with APC and exclusion of 
mouse cells by anti-mouse CD45 and TER119 conjugated with PE-Cy7.  
Figure 5.12 shows the example of gating SKNO-1 cells in histogram (A) which shows the 
gated cells were of human cells. The gated SKNO-1 cells were purified from debris in dot 
plot (B). Figure 5.12C showed dot plot graphs for the negative control of non-transduced 
SKNO-1 cells on the left and the positive control of transduced SKNO-1gfp+luc+ cells on 
the right.  
For the bone marrow and spleen samples collected post mortum from all three mice 
engrafted with SKNO-1gfp+luc+ cells, flow analyses of antibody labelled samples failed to 
demonstrate the presence of any luminescent SKNO-1 cell. All the dot plot results gave 
the same pattern as shown in Figure 5.13A for the analysis of the bone marrow (left) and 
spleen (right) samples from mouse 1. This is despite the presence of high SKNO-1 cells 
measured and gated in the histogram of the spleen and much lower percentage in bone 
marrow samples (Figure 5.13C). In all three mice, bone marrow samples were mouse 
cells in majority with less than 10% SKNO-1 cells detected. In the spleen samples 
analysis, histogram graphs distinguished two peaks, which were gated accordingly. 
Spleen in mouse 1 contained at least 39.4% SKNO-1 cells whereas 53.6% and 51.1% 
mouse 2 and mouse 3 spleens respectively were populated with SKNO-1 cells. 
Unfortunately peripheral blood of the mice was not collected for analysis.   
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Figure 5.12  Gating of SKNO-1 cells in flow cytometric analysis. Single cell suspensions of cultured 
non-transduced SKNO-1 cells and unsorted gfp-positive transduced SKNO-1 cells in PBS were labelled 
with anti-human CD38-APC antibody in combination with anti-mouse CD45- and TER119-PE-Cy7 
antibodies. A, Histogram showed the gating of human cells towards the right of the graph (marked as MM 
negative) on the mouse (mm) PE-Cy7 channel. B, Dot plot graph indicates further gating from MM 
negative to purify human cells from debris. C, Dot plot stained control negative (left) and control positive 
gfp (right) from ongoing culture showed SKNO-1 cells are CD38 positive. Negative control cells are 
negative for green fluorescence in FITC channel and positive control cells are positive green fluorescence 
cells.        
 
 
 
 
A B 
C 
184 
 
 
 
 
 
 
 
Figure 5.13  Flow cytometric analysis of SKNO-1g+luc+ engrafted mice. Bone marrow and spleens were 
collected from all 3 dead mice and processed as described in Materials and Methods. Cells from bone 
marrow and spleen suspensions washed in PBS were labelled with human antibody CD38-APC in 
combination with mouse antibodies anti-CD45- and anti-TER119-PE-Cy7. A, Examples of dot plot results 
from bone marrow (left) and spleen (right) in FITC/CD38-APC channels. B, Histograms of bone marrow 
analysis (left panel) and spleen analysis (right panel) of mouse 1 (top), mouse 2 (middle) and mouse 3 
(bottom). Histograms are in mmPE-Cy7/Count channel.  
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5.3 Discussion 
The main aim of this chapter was to evaluate and track in vivo engraftment of different 
leukaemic cell lines transduced with lentivirus harbouring firefly (Photinus sp.) luciferase 
reporter gene (luc+) and green fluorescent protein (gfp+) sequence. Luc+ was utilized in 
the luminescence imaging whereas the gfp+ was used in the identification of the cells in 
flow cytometry analysis. In order to follow the expansion of the implanted cells and 
progression of the disease, a time course for bioluminescence imaging was performed. 
Following implantation of the cells, all images of the engrafted mice showed 
luminescence at the site of implantation indicating the cells were successfully implanted 
into the femur cavity of the mice. This was based on the roughness felt during 
intrafemoral transplantation. However, the 26G needle used to ‘drill’ a hole on the tip of 
femur for insertion of the cells could possibly have minutely punctured the side wall of 
femur which could result in cells diffusing from the hole and accumulate in the 
surrounding muscle tissues, although this was never scientifically proven.    
In the SEM implanted animals, dissemination of the cells was rapid. All mice presented 
with severe leukaemia conditions within 3-5 weeks post transplantation and mice were 
killed to prevent unnecessary suffering. Mice had loss of mobility of the hind limb, more 
severe in the first mouse to be affected, suggesting the cells had infiltrated the central 
nervous system of the animal. The engrafted mice seemed lethargic, which could be 
assumed due to heavy burden of the leukaemia. This was seen in the pattern of 
luminescence covering the entire body in one mouse and most body parts of the other 
two.  
Isolated lymphocytes of mouse 2 however, were mistakenly labelled with CD38, which is 
not a surface marker for SEM cells. Thus, the SEM population could only be displayed as 
mouse negative cells; low in PE-Cy7 in the dot plot graphs. Nevertheless, the flow-
analysis graphs confirmed the presence of SEM cells in the peripheral blood which 
proved the leukaemic cells were present in the circulation. It could be assumed, since all 
the mice had lost mobility of the hind leg towards the end-point, that the other two mice 
could have the same circulating leukaemic cells in the system, although the percentage of 
cells could be less. The bone marrow analysis showed the presence of the leukaemic cells 
indicating the leukaemic SEM cells were being generated in the compartment and the 
slightly enlarged spleens, measuring 1.2-1.5 cm in all mice, showed infiltration of 
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leukaemic cells as spleen also acts as a target for homing for lymphoid cells as well as the 
bone marrow.       
In Kasumi-1(gfp+luc+) engraftment, none of the mice showed any effect of the disease on 
daily physical monitoring until the day the mice had to be terminated due to discomfort of 
the growing tumours. The luminescence images monitored throughout the study clearly 
indicated that the pattern of localized luminescence differed from those seen in SEM. The 
mice also survived longer despite the growing tumours. Compared to SEM engraftment, 
there was lower percentage of human cells populating the bone marrow cavity of Kasumi-
1 engrafted mice. 
There was a negligible percentage of cells measured by flow analysis of bone marrow and 
spleen in mice with leg tumours in the region of the initial site of implantation, which 
could probably mean that the implantation had missed the femoral compartment and 
implanted cells accumulated in the surrounding quadricep muscles. Hence, the Kasumi-
1(gfp+luc+) cells implanted were trapped within the tissue and proliferated to form localized 
leg tumours. This phenomenon was occasionally seen in other xenograft studies in our 
group and may be because of fine, 27 or 30G, needle of the 0.5 ml insulin syringe used in 
intrafemoral injection is easily bent and could fail to penetrate the femoral cavity.  
However, in the other two mice implanted with gfp+luc+ Kasumi-1 cells, localized 
tumours had also formed as seen in luminescence imaging. Flow analysis of bone marrow 
of these mice showed the bone marrow compartment contained only 6% to 11% human 
cells indicating the engrafted cells had migrated and expanded in different sites in vivo.   
All Kasumi-1 transplanted mice develop localized tumours, although in different forms as 
shown by the photographs of the tumours. Interestingly, in all the tumours, more than 
95% of the human cells gated out from mouse cells were gfp-positive cells. This 
phenomenon indicated that there was a possibility that the tumours retained the gfp+luc+ 
cells and the non-gfp+ cells spread elsewhere or did not survive in the engraftment.   
The same behaviour of Kasumi-1(gfp+luc+) cells producing localized tumours and high 
percentage of these cells in the tumours were also seen in other experiments on 
intrahepatic transplantation of these cells into newborn Rag2 mice, not reported here. The 
Rag2 mice developed localized tumours in various sites, including the neck and 
abdominal cavity with no infiltration of the spleen or bone marrow after 8-9 weeks 
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engraftment (Elda Latif, Lars Buechler and Mike Batey). This indicates the Kasumi-
1(gfp+luc+) cells tend to accumulate and form localized tumours.     
Experiments using SKNO-1 engrafted mice failed to give conclusive results regarding the 
pattern of disease progression. The mice did not regain consciousness after the week 5 
imaging procedure due to incorrect mixing oxygen and isoflurane in the anaesthesia. This 
experiment has not yet been repeated due to limitations in the numbers of NSG mice 
available for experimentation. In addition, the flow analysis of samples in the SKNO-1 
mice did not show any gfp positive SKNO-1 cells although high percentages of gfp 
negative SKNO-1 cells were gated off from mice cells. The analysis was repeated twice at 
two separate times and the results were the same albeit the control positive SKNO-1gfp+luc+ 
cells run at the same time gave high positive gfp cells population. The reasons for this are 
unclear. 
In the growth curve study, all the cell lines used grew in suspension, but unlike the 
Kasumi-1 and SKNO-1 lines, the SEM cells tend to stick to flask surface and required a 
slight forced flushed with medium to detach the cells. This cell behaviour was a normal 
condition for SEM cells, as reported by other collaborating laboratories that used the 
same cell line (unpublished), although they were from different sources.  The forced 
flushed was the reason causing the SEM cells to show a slower growth within 48 hours, a 
slightly longer lag phase time for the cells to recover before growing in its normal 
exponential phase, in which the doubling time of the SEM in the experiment is prolonged 
to between 48-72 hours instead of 30 hours as stated by the DSMZ database, the cell lines 
supplier. The growth curves for Kasumi-1 and SKNO-1 cells were as stated by the 
supplier. The growth curves study could explain the growth and expansion of the 
engrafted cell lines in vivo as mice transplanted with SEM cells developed leukaemic 
conditions earlier than SKNO-1 and Kasumi-1 engrafted mice. 
In the luminescent imaging described in this chapter, SEM and Kasumi-1 images did not 
indicate the exact luminescent intensity. As the flow analysis indicated, there was also 
presence of gfp-negative cells in the culture which was used in the initial transplantation. 
This could give false negative images. For SKNO-1 it could be assumed that the 
luminescent light detected was totally from the cells since the SKNO-1 initially 
transplanted were from highly transduced cells (>98% cells transduced).   
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Several techniques have been improved since we first used IVIS System for 
bioluminescent imaging. Because luciferin can penetrate the cell membrane, luciferase in 
transduced cells in mice immediately reacted on the substrate producing luminescent 
light. In the beginning we measured the luminescent emission directly after injection of 
luciferin intraperitoneally, concomitant with anaesthesia. However, it has been reported 
that luminescent intensity produced is the highest 10 minutes after exogenous luciferin is 
administered.      
After completion of the experiment in this chapter, it was decided that it was best to 
image mice individually rather than placing all three mice together in the chamber. This is 
due to different luminescence light intensity emitted by different mice depending on the 
expansion of the leukaemic cells in the individual mice. If a mouse with high engraftment 
of the lentiviral infected cells was viewed together with mouse with lower engraftment of 
the cells, the high luminescence intensity of the first mouse will obscure the luminescence 
intensity emitted by second mouse. Thus, the second mouse will appear to show no 
engraftment at the particular day of luminescence imaging.    
It has been suggested that a comparison of luminescence intensity could be performed by 
serial dilution of transduced cells in plates viewed under the same conditions as the 
animal imaging to give an indication of cell expansion in transplanted mouse. A few 
studies of this type have been reported using the IVIS system. However, this method does 
not take into consideration diffraction of the light emitted by surrounding tissues. 
 
In conclusion, mice engrafted with SEM cells succumbed to disease much earlier than 
Kasumi-1 and SKNO-1 engrafted mice, reflecting the rapid growth of this ALL cell line 
from a patient on relapse. The bioluminescence imaging was shown to provide a means of 
tracking progression of engrafted cells in vivo. Rapidly proliferating cells were shown to 
disseminate rapidly whereas slow proliferating cells were more likely to develop localize 
tumours in mice.   
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CHAPTER 6  
GENERAL DISCUSSION 
6.1 Overall Summary 
Despite the many advances in understanding the development of acute lymphoblastic 
leukaemia, the ability to develop clinically effective therapies based on this knowledge is 
still of limited success. Although conventional therapies provide an overall favourable 
outcome for children with acute lymphoblastic leukaemia, up to 20% patients who 
include certain cytogenetic subgroups, suffer from a poor survival due to relapse. Re-
treatment responses in these patients remain poor. There is therefore an urgent need for 
better targeted chemotherapy to improve event-free survival of these patients. Many 
advances have been made to understand the mechanisms which affect chemosensitivity. 
Various ALL cell lines or blasts from some ALL patients grown in specialized medium 
have been extensively used in drug response studies to relate the changes in drug uptake, 
metabolism or efflux on chemosensitivity. However, this does not reflect the clinical 
situation of the patients for several reasons. The majority of the cell lines are derived from 
relapse patients which are already chemoresistant. In addition, in most cell-line studies 
only a single therapeutic drug or one or two combinations of drugs are used while 
clinically patients are given more than 5 drugs in combination therapy for prolonged 
periods. Moreover, primary blast cells from patients do not divide in culture and the 
samples are time limited to work on extensively.  
In order to overcome those limitations of in vitro work, this thesis have proposed an in 
vivo study utilizing humanized mice as a model for leukaemic blasts xenograft. The 
NOD-SCID IL2Rnull (NSG) mouse model was chosen as this model more accurately 
reflects the clinical situation. The NSG model is also suitable for highly efficient 
engraftment of malignant or normal hematopoietic cells as supported by other workers 
(Ishikawa, Yasukawa et al. 2005; Shultz, Ishikawa et al. 2007; Le Viseur, Hotfilder et al. 
2008; Notta, Doulatov et al. 2008; Schmitz, Breithaupt et al 2011). 
In Chapter 3, the xenografted match paired L707 presentation and relapse blast cells both 
were able to repopulate mouse bone marrow, disseminate in peripheral blood and 
infiltrate organs, particularly the spleen and ovaries, and occasionally at random, liver, 
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kidneys and gastric lining. The accumulation, distribution and localization of engrafted 
blasts were proven by the high percentage of human blasts measured in mouse bone 
marrow, spleens and ovaries, which is in agreement with other reported studies (Yan, 
Wieman et al. 2009; Cheung, Fung et al. 2010). Blast cells harvested from engrafted 
spleen of mice from primary and secondary transplantation of both L707 presentation and 
relapse showed similar morphology to that of the original patient biopsies, indicating high 
infiltration of human leukaemic cells, confirmed by the presence of ALL leukaemic 
markers. Importantly, the morphology and the immunophenotypes of xenografts were 
essentially unaltered from the original patient samples.  
In primary transplantation of L707 blast cells and in the subsequent secondary 
transplantation, the ovaries of the mice were persistently infiltrated by engrafted relapse 
blasts but not the presentation blasts, marked by the high percentage of human leukaemic 
cells retrieved from the ovaries. Up to 99% of relapse blast cells were measured in the 
ovaries which is an interesting finding, although no similar findings have been reported. 
There were several studies reported on ovary infiltration in ALL patients who relapsed 
(Reid and Marsden 1980; Chu, Craddock et al. 1981; Kim, Cho et al. 2008) although the 
incidence is rare, and no indication of presentation cells localizing in the ovaries have 
been reported. However, Dolmans et al. in their study had reported that, although the 
histology of cryopreserved ovarian tissue from ALL patients did not show presence of 
leukaemic cells, 7 of 12 patients showed positive leukaemic markers in their ovarian 
tissues. In addition, 4 of the reimplanted ovarian tissues produced abdominal leukaemic 
masses in grafted mice (Dolmans, Marinescu et al. 2010). The claim from this paper 
indicates that there is a possibility of very minimal percentage of presentation cells 
residing in the ovary of engrafted mice without changing the morphology of the tissue. 
Unfortunately, this possibility was not taken into consideration in the L707 xenografts. 
Perhaps this parameter could be included in future experiments. Although the actual 
condition of the deceased L707 patient was not known, there is a high possiblility the 
disease could have affected the ovaries of the patient in similar manner after relapse. 
Infiltration of leukaemic blasts into other organs is an indicatation of widespread disease.  
A study reported on an invasive pre-B-ALL relapse cell line and patient relapse cells that 
produced CNS leukaemia in engrafted NOD/SCID mice. The pre-B cell line uniquely 
expressed asparaginyl endopeptidase (AEP), intracellular adhesion molecule-1 (ICAM-1) 
and ras-related C3 botulinum toxin substrate 2 (RAC2), in which the latter was also 
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identified in the bone marrow aspirate obtained from the relapsed patient. These findings 
suggest that these proteins supported the engraftment of ALL blasts and the occurrence of 
CNS disease in the mice (Holland, Castro et al. 2011). Although the condition of the mice 
was not reported in their study, this evidence may perhaps explain the loss of hind leg 
mobility seen in the L707 presentation cell but not relapse cell engrafted mice (without 
treatment), which was persistently experienced by all primary and secondary xenografted 
mice. Flow cytometry analysis of the spinal cord (together with brain stem) of a few mice 
in this presentation group indicated the presence of human leukaemic blasts in the sample, 
which strongly supports the evidence for CNS infiltration of the presentation cells. 
Besides, the fundamental and essential mechanisms that control postural muscle tone and 
locomotion are located in the brain stem and spinal cord (Jahn, Deutschländer et al. 2008; 
Takakusaki and Matsuyama 2010). Thus, infiltration of leukaemic blasts in the brain stem 
and spinal cord could have caused the partial immobility condition, which was confirmed 
by the presence of blasts cells in these regions in flow cytometry analysis. Moreover, as 
mentioned in Chapter 3, the L707 presentation and relapse cells were positive for CD10 
and CD19 fraction. These surface markers were also mentioned by Holland et al. as the 
fraction which contributed to infiltration of the relapse cells into the CNS (Holland, 
Castro et al. 2011). Contrary to the reported evidence, in the L707 case, there was no 
possible explanation for why the relapse cells did not invade the CNS compartment in the 
same way as presentation cells.  
In the competitive repopulation of L707 discussed in Chapter 3, NSG mice were 
xenotransplanted with various proportions of presentation and relapse cells to investigate 
which clone has a greater advantage of repopulating and disseminating in the absence or 
presence of dexamethasone treatment. In the absence of treatment, following engraftment, 
mice engrafted with a higher proportion of presentation cells (90%-P+10%-R and 70%-
P+30%-R) showed severe manifestation of the disease with loss of locomotion in the hind 
region, which was not observed in mice engrafted with lower presentation cell 
proportions (10%-P+90%-R, 30%-P+70%-R and 50%-P+50%-R). This condition shows 
that although in the presence of a small percentage of relapse cells, a higher percentage of 
presentation cells in the engrafted population manifested the disease. However, a higher 
proportion of relapse cells in the engrafted populations may combat the ability of 
presentation cells to manifest the disease by ‘crowding’ the in vivo environment, 
marginally lowering the presentation efficiency to manifest the disease condition. As a 
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lymphocytotoxic drug, dexamethasone presumedly killed most of the presentation cells, 
given that glucocorticoid receptors in this cell population are intact (unlike the affected 
GC-receptor in relapse cells).  
Initially, it was thought that following relapse, leukaemic cells would divide more rapidly 
than presentation given the notion that in subpopulations of poor prognosis ALL, patients 
did not survive post relapse. However, this hypothesis proved to be wrong in the L707 
case. The survival curve of the engrafted mice showed mice xenografted with L707 
presentation cells had a shorter life span than those of relapse, indicating the presentation 
cells were more ‘aggressive’, proliferating rapidly, producing rapid fatality of engrafted 
mice. Mice engrafted with various proportions of presentation and relapse blasts had an 
intermediate level of survival. Meyer et al. in their study implied that the shorter the time 
that the diagnosis cells transplanted into NOD/SCID mice took to manifest leukaemia, the 
higher the risk that these patients would relapse (Meyer, Eckhoff et al. 2011). In the L707 
case, mice engrafted with presentation cells succumbed to leukaemia in less than 8 weeks 
post transplantation, within the 10 weeks threshold of rapid time to leukemia. This result 
reflected the clinical condition where the L707 patient suffered from relapse 5 months 
after remission.  
Introduction of dexamethasone prolonged the survival of mice engrafted with 
presentation blasts, and survival of mice engrafted with various proportions of the 
presentation blasts reached similarity to those of relapse. Relapse survival curves were not 
affected in the absence or presence of treatment. To date similar findings have not be 
reported elsewhere. One closely related study was reported by Kang et al., although in 
their study a combination of vincristine-dexamethasone-L-asparaginase (VXL) was used 
as treatment for engrafted mice. Event free survival (EFS) was quantified as the time 
taken from initiation of treatment until the mice were killed due to treatment-related 
toxicity during and 4 week post treatment. There was no difference in the EFS of vehicle-
treated controls of both diagnostic and relapse engrafted mice. VXL treatment 
significantly delayed progression of diagnostic cells by 7-fold and relapse cells by 3.5-
fold (Kang, Kang et al. 2007). It could be hypothesized that the treated presentation mice 
could have survived longer than relapse mice, due to elimination of presentation cells by 
dexamethasone. However, taking into consideration that not all presentation cells were 
killed during treatment, the remaining presentation cells would rapidly proliferate. With 
increasing tumour burden, the engrafted mice only survived 2 weeks longer than the non-
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treated presentation mice. A study by Yan et al. derived pre-B ALL leukaemic blasts from 
the same patient at diagnosis and relapse, and subcutaneously inoculated the blasts into 
SCID mice. Based on the size of tumour growth subcutaneously, they reported that the 
diagnosis and first relapse blasts either did not grow or grew very slowly, while blasts at 
second relapse grew in an indolent manner, and blasts at third relapse displayed an 
aggressive growth pattern. They concluded that patients whose leukaemic cells grew 
aggressively either at diagnosis or relapsed had a worse clinical outcome than those with 
no tumour or indolent growth pattern (Yan, Wieman et al. 2009). This study is the closest 
possible comparison that showed a contrast of aggressiveness of leukaemic blasts to the 
findings from the L707 case. The prognosis of the patient is in agreement with their study. 
Interestingly, the duration of survival of mice engrafted with L707 relapse blasts 
correlated directly to the survival of the patient following relapse.  
Further analysis was done in competitive repopulation with various proportions (mixed 
populations) of presentation and relapse blast cells to determine the proportion of cells 
populated in the engrafted mice. It was shown by FISH, in agreement with molecular 
analysis that without treatment, the percentages of presentation cells engrafted were 
higher than the initial proportions of the cells transplanted into mice, indicating the 
presentation cells outnumbered the relapse cells because of the aggressiveness and rapid 
proliferation of the cells. Dexamethasone administration successfully reduced the 
percentages of these presentation cells, allowing an advantage for relapse cells to populate 
more. Interestingly, in dexamethasone treated mice engrafted with presentation blasts, one 
of the mice had 16% of cells showing a single signal for the NR3C1 gene which indicates 
a deletion of the NR3C1 gene occurred in these cells. This heterozygous deletion is likely 
induced by dexamethasone treatment. In the whole population of leukaemia, leukaemic 
stem cells (LSCs) or leukaemic-initiating cells exist within the tumour and sustain the 
growth of the tumour by clonal proliferation. Perhaps following transplantation of the 
leukaemia cells intrafemorally into mice, the LSCs could have homed within the niche in 
the bone marrow. It has been mentioned elsewhere (Yamazaki, Iwama et al. 2009; van der 
Wath, Wilson et al 2009; Trumpp, Essers et al. 2010) that similar to hematopoietic stem 
cells, the leukaemic stem cells (LSCs) exist individually in their niches in the bone 
marrow in dormancy and quiescence stage. The dormant LSCs are awakened in response 
to hematopoietic stress to replenish hematopoietic system with a malignant clone 
(Trumpp, Essers et al. 2010). Dexamethasone treatment caused depletion in blood supply 
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when presentation cells (or other mice normal blood supply) were killed and in turn 
reduced the tumour burden. During the awakening from dormancy stage, LSCs could be 
targeted by continuous dexamethasone treatment which could have caused the 
heterozygous deletion. Following cessation of treatment, the affected LSCs would then 
proliferate to replenish the hematopoietic system with the new malignant clone. The 
proliferation capacity could be slower as the LSCs now are similar to the relapse cells. At 
the same time, probably the remaining presentation cell clones propagate to repopulate 
the system. Thus, a small percentage of heterozygous one allele deletion of NR3C1 
leukaemic cells and homozygous unaffected NR3C1leukaemic cells could have circulated 
in the engrafted mice, repopulate in the bone marrow, disseminate and infiltrate the 
spleen. This could be the possible explanation for the presence of heterozygous 
NR3C1allele.    
Assessment of the repopulation of presentation and relapse blasts would be greatly 
facilitated if these cell populations could be physically tracked utilizing a real-time 
bioluminescence detector. For this purpose, lentiviruses carrying different reporter genes 
have been developed as a tool for transferring these genes into target cells. In Chapter 4, 
the generated lentiviruses pSLIEW and pSRLICW were proven fuctional. pSLIEW 
efficiently transduced AML (SKNO-1 and Kasumi-1), compared to ALL cells (SEM and 
RS4;11). By comparison to RS4;11 which yielded negligible transduction capacity, 
transduction efficiencies in SEM was 9-fold higher, Kasumi-1 was 15-fold higher and 
almost 20-fold higher in SKNO-1 cells. Several attemps were made to transduce L707 
cells but patient primary cells were proven difficult to successfully tranduce. This work 
had to be abandoned due to limited supply of primary materials. 
In Chapter 5, the transduced and sorted SEM and Kasumi-1 cells were engrafted into 
NSG mice and progression of disease was successfully monitored by luminescent 
imaging. Images from engrafted SEM cells showed a rapid progression of leukaemic 
disease in which the engrafted mice were short-lived; they succumbed to the disease after 
three to five weeks post xenotransplantation. These mice showed loss of locomotion in 
the hind region as seen in the L707 studies. Although SEM cells are cells from relapse, 
nonetheless, the imaging results and the physical condition may be the best way to 
correlate with the aggressiveness of the L707 presentation cells discussed in Chapter 3. It 
could be possible that similar images of disease progression were seen if the L707 were 
able to be transduced. The peripheral blood confirmed the presence of SEM cells which 
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explained the overall widespread luminescence detected. The luminescence image 
showed engraftment of the SEM cells through the blood system including the cranial 
region. This observation is in agreement with Xie et al. who demonstrated the first real 
time imaging on migration of HSC cells from bone marrow to the cranial region of mice 
(Xie, Yin et al. 2009). Moderate engraftments of blast cells were measured in the bone 
marrow and spleen of engrafted mice possibly because the cells were rapidly 
disseminating in the blood, without depositing to a great extent in the solid organs.   
Contrasting observations were made in the Kasumi-1 engrafted mice. Kasumi-1 cells are 
slowly progressing cells which tend to produced solid tumours in xenografted mice. 
Luminescence images showed progression of tumour mass but not widespread disease. 
Mice were killed because of tumour mass burden, with no symptoms or signs of physical 
illness. At post mortem various types and sizes of tumours were discovered, particularly 
in the abdominal cavities of 2 of the engrafted mice. All tumours showed high 
percentages of Kasumi-1 cells. Low engraftment of Kasumi-1 cells was measured in the 
bone marrow and spleen of xenografted mice due to the accumulation of the cells in the 
tumours. Maris et al., in their anti-tumour drug testing study, used Kasumi-1 for the 
reason that the cell line produced solid tumours which was a suitable model for their 
experiment (Maris, Courtright et al. 2008). 
6.2 Overview 
L707 presentation and relapse cells repopulated and engrafted NSG mice and 
recapitulated human disease. Presentation cells persistently infiltrated the CNS whereas 
relapse cells persistently infiltrated the ovary. The presentation cells were more 
aggressive leading to rapid fatality; this proliferation was affected by dexamethasone.  
The lentiviral-transduced cell lines SEM and Kasumi-1 xenografts have proved the in 
vivo monitoring capability by luminescence imaging. SEM lines showed rapid 
widespread disease whereas Kasumi-1 lines produced localized tumour masses. 
6.3 Future Investigations 
In future experiments, additional drug approaches such as treating mice with vincristine 
or methotrexate alone or in combination could be used to more closely mimic the clinical 
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situation and determine if the effect on therapy of GR deletion is restricted to 
dexamethasone.  
In future work, a prospective study could be included to evaluate the molecular 
mechanism that may contribute to the different growth characteristics of the leukaemic 
blasts. Genes involved in proliferation and survival of the cells such as β-catenin could be 
of interest in future knockdown studies. β-catenin has been implicated as an integral 
component in Wnt signalling pathway which controls self-renewal of hematopoietic stem 
cells. Dysregulation of this pathway occurs in various malignancies including leukaemia. 
High expression and accumulation of β-catenin was detected in ALL blasts, which 
provide proliferation and survival advantage to leukaemic B-cell progenitors (Khan, 
Bradstock et al. 2007). It has been reported that by down-regulating β-catenin levels in 
AML cell lines and patient samples, engraftment in the bone marrow of xenografted mice 
was affected due to reduced adhesion to the endosteum. It was concluded that β-catenin 
plays a major role in proliferation, cell cycle progression, adhesion and influences disease 
establishment in vivo (Gandillet, Park et al. 2011; Siapati, Papadaki et al. 2011). In this 
way, targeting the Wnt signalling pathway might be a useful therapeutic strategy in 
treating pro-B ALL. 
Very recently, Uchida et al. had perfected an optimized protocol by Millington et al. to 
improve the transduction efficiency of CD34+ cells by stimulating the cells for 24 hours 
in a serum-free media supplemented with SCF, FLT3 and thrombopoietin, and followed 
by 24 hours lentiviral transduction in the media (Millington, Arndt et al. 2009; Uchida, 
Hsieh et al. 2011). As a result, high transduction efficiency was achieved and the 
engraftment of cells in humanized xenograft mice was improved (Uchida, Hsieh et al. 
2011). In future work, this technique could be adopted for improving transduction 
efficiency of cell lines. Importantly, the aim is to achieve high transduction efficiency for 
L707 blast cells for xenograft, and for tracking the cells as planned for the competitive 
repopulation study.  
The disadvantage of the clonal evolution and competitive repopulation studies in this 
thesis is that the study is based only on a single case of matched paired presentation and 
relapsed t(17;19) cells. For comparison studies perhaps other matched paired patient 
primary materials of the same or different translocations could be obtained for the studies. 
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APPENDIX 1 
Percentage of leukaemic cells engrafted determined by immunophenotyping 
Flow cytometry analysis - % of blasts in bm, spleen and ovaries 
      
  
  
not tested or negligible 
value 
  
ttd time to death 
 
      
  % of cells tpln ttd (days) bm spleen ovaries 
Primary transplant        
m1 
100P  
44 80.1 86.5   
m2 51 88.2 92.1   
m3 43 86.4 91.9   
m1 
100R  
59 90.3 94.8 97.4 
m2 59 94.2 85.1 98.9 
m3 59 89.7 79.2 97.0 
Secondary transplant 1       
m1 
100P 
33 86.2 93.3   
m2 70 90.6 98.3   
m3 51 80.8 86.0   
m1 
100R  
56 90.7 92.9 87.0 
m2 56 82.9 89.1 96.3 
m3 56 89.5 84.8 91.5 
Secondary transplant 2 - Untreated       
m1 
100P 
38 82.8 89.8   
m2 31 92.8 94.5   
m3 38       
m4 35 88.9 67.8   
m5 38 72.9 81.4   
m1 
90P+10R 
34 62.4 86.9   
m2 35 87.9 90.5   
m3 31   84.6   
m4 45 92.5 79.6   
m5 31 89.5 89.3   
m1 
70P+30R 
48 65.4 89.7 71.6 
m2 45 89.5 86.5   
m3 36 89.0 79.1 89.2 
m4 35       
m5 42 73.4 95.8 78.0 
m1 
50P+50R  
49 91.2 89.7 90.1 
m2 45 89.6 93.8   
m3 41 88.2 91.9 95.4 
m4 45       
m5 48 90.5 95.4 82.1 
m1 
30P+70R 
38 89.1 87.7 48.2 
m2 31 65.0 62.2 85.0 
m3 44       
m4 45 89.9 90.7   
m5 62 82.1 93.2   
m1 
10P+90R 
41       
m2 35 79.2     
m3 34 82.7 84.5 86.2 
m4 41 89.6 94.8 97.5 
m5 49 97.6 86.4 87.9 
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m1 
100R 
48       
m2 62 88.1 92.8 99.2 
m3 43 90.3 89.9 92.5 
m4 58 79.8 94.3 95.9 
m5 58 89.0 95.1 98.2 
Secondary transplant 3 - 
Dexamethasone treated       
m1 
100P+dex 
42       
m2 64 55.0 53.6   
m3 64 87.6 41.2   
m4 59 69.5 61.2   
m5 55 71.5 24.6   
m1 
70P+30R+dex 
51 75.2 45.8 79.8 
m2 55 57.5 59.4 66.1 
m3 57       
m4 53 77.7 55.9 67.5 
m5 48       
m1 
50P+50R+dex 
60       
m2 62 78.8 78.9 80.2 
m3 64 87.5 63.1   
m4 62 90.7 83.8   
m5 51 88.8 87.0 94.7 
m1 
30P+70R+dex 
60 88.0 74.2 95.4 
m2 55 94.1 98.8 89.4 
m3 51 80.6 93.2   
m4 62       
m5 51 74.1 89.2 75.3 
m1 
100R+dex 
64 94.7 85.3   
m2 64 87.4 91.0 99.8 
m3 55       
m4 62 79.5 62.7 99.3 
m5 57 94.5 86.3 98.8 
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APPENDIX 2 
Cells scored in cytogenetic analysis by FISH technique 
m# 
Ratios of 
cells   2R2G 2R0G 2R1G 
Non-treated 
  
  
m1 10P:0R 100 0 0 
m2 10P:0R 100 0 0 
m3 10P:0R nc nc nc 
m4 10P:0R 100 0 0 
m5 10P:0R 100 0 0 
m1 9P:1R nc nc nc 
m2 9P:1R 100 0 0 
m3 9P:1R 99 1 0 
m4 9P:1R 100 0 0 
m5 9P:1R 97 3 0 
m1 7P:3R 88 12 0 
m2 7P:3R 82 18 0 
m3 7P:3R 54 46 0 
m4 7P:3R nc nc nc 
m5 7P:3R 89 11 0 
m1 5P:5R 65 35 0 
m2 5P:5R 81 19 0 
m3 5P:5R 18 82 0 
m4 5P:5R nc nc nc 
m5 5P:5R 100 0 0 
m1 3P:7R 79 21 0 
m2 3P:7R 96 4 0 
m3 3P:7R 
  
  
m4 3P:7R 97 3 0 
m5 3P:7R 15 85 0 
m1 1P:9R nc nc nc 
m2 1P:9R 32 68 0 
m3 1P:9R 66 34 0 
m4 1P:9R 60 40 0 
m5 1P:9R 35 65 0 
m1 0P:10R nc nc nc 
m2 0P:10R 0 100 0 
m3 0P:10R 0 100 0 
m4 0P:10R 0 100 0 
m5 0P:10R 0 100 0 
 
Dexamethasone treated  
m1 10P:0R+ dex nc nc nc 
m2 10P:0R+ dex 177 1 35 
m3 10P:0R+ dex 100 0 0 
m4 10P:0R+ dex 100 0 0 
m5 10P:0R+ dex 100 0 0 
m1 7P:3R + dex 11 89 0 
m2 7P:3R + dex 91 9 0 
m3 7P:3R + dex nc nc nc 
m4 7P:3R + dex 45 55 0 
m5 7P:3R + dex nc nc nc 
m1 5P:5R + dex 11 89 0 
m2 5P:5R + dex 9 91 0 
m3 5P:5R + dex 94 6 0 
m4 5P:5R + dex 82 18 0 
m5 5P:5R + dex 32 68 0 
m1 3P:7R + dex 10 90 0 
m2 3P:7R + dex 12 88 0 
m3 3P:7R + dex 5 95 0 
m4 3P:7R + dex 3 97 0 
m5 3P:7R + dex 9 91 0 
m1 0P:10R + dex 0 99 1 
m2 0P:10R + dex 0 100 0 
m3 0P:10R + dex 0 100 0 
m4 0P:10R + dex 0 100 0 
m5 0P:10R + dex 0 100 0 
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FITNESS OF t(17;19) CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA 
IN IMMUNODEFICIENT MICE 
Elda Latif, Klaus Rehe, Mike Batey, Christine J. Harrison, Josef Vormoor, Andy Hall, 
Olaf Heidenreich 
Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, 
Newcastle University and Sir James Spence Institute, Royal Victoria Infirmary, 
Newcastle upon Tyne. 
 
Background  
Survival rates in childhood ALL are now in the region of 90%, however treatment 
outcomes in certain cytogenetic subgroups remain poor. The translocation, 
t(17;19)(q22;p13), is a rare  cytogenetic abnormality, which occurs in less than 1% of 
childhood acute lymphoblastic leukaemia (ALL) and is associated with a very poor 
prognosis and chemotherapy resistance. Understanding the mechanisms of resistance in 
these patients is therefore a priority.  
Aims  
It has been assumed that following relapse, ALL cells will divide more rapidly than at 
presentation. In order to test this hypothesis, we have developed an animal model of 
competitive repopulation using paired samples from presentation and relapse from a case 
of t(17;19) positive ALL.  
Methods 
Leukemic cells from a child with t(17;19) positive ALL obtained at presentation and at 
relapse were analysed for copy number variations using the Affymetrix Genome-Wide 
Human SNP Array 6.0 (SNP6.0) platform. Deletion of the NR3C1 gene (glucocorticoid 
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receptor) on chromosome 5 was detected at relapse but not at presentation. This was 
confirmed by fluorescence in situ hybridisation (FISH). Cells were separately 
transplanted via intrafemoral injection into immunocompromised NOD/scid IL2Rnull 
(NSG) female mice. Human blasts recovered from primary transplantations were 
subsequently used for secondary transplantation in mixed populations with ratios of 
presentation to relapse cells of 10:0, 9:1, 7:3, 5:5, 3:7, 1:9 and 0:10. Engraftment and 
progression of disease were assessed by flow cytometry at the terminal time-point. The 
percentages of presentation and relapse cells which engrafted in these mice were 
determined using FISH for NR3C1 deletion. The expression levels of glucocorticoid 
receptor (NR3C1) in the harvested leukemic cells were determined by real-time 
quantitative PCR. 
Results  
Microarray analysis identified a deleted region of chromosome 5 involving the NR3C1 
gene in cells obtained at relapse but not at presentation. Without treatment, those mice 
transplanted with relapse cells survived significantly longer than those transplanted with 
presentation cells (p=0.005), while the survival rates of mixed cells fell between the two 
curves. All engrafted mice presented with an enlarged spleen indicating leukaemic 
infiltration. This was confirmed by flow cytometry, which identified t(17;19) cells with 
CD19+/CD10+/CD34- immunophenotype among those isolated from bone marrow (85-
92%) and spleen (64-90%). FISH analysis showed that the percentages of presentation 
cells which engrafted in the mice with mixed populations were always higher than the 
ratios initially transplanted. Real-time PCR analysis confirmed that the levels of NR3C1 
from all ratios of mixed cells represented the level of the presentation cells only. 
Repopulation experiments are currently being repeated with mice treated with 
Dexamethasone. 
Conclusions  
In this study we observed that in t(17;19) positive ALL, without treatment, presentation 
cells outgrew cells obtained at relapse regardless of the ratio of cells initially transplanted. 
It is anticipated that, on treatment, relapse cells will outgrow those obtained at 
presentation, due to deletion of the glucocorticoid receptor, which would render cells 
insensitive to steroid treatment.  
